Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level

Combined therapy for the treatment of diabetes and related conditions and for the treatment of conditions improved by the increase in the level of GLP-1 in blood.

Field of the Invention

The present invention relates to compositions and methods to treat or prevent diabetes and conditions related to it. The present invention also relates to compositions and methods to increase the level of GLP-1 in blood in a mammal.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Background of the invention

The following discussion aims to facilitate the understanding of the invention, but it is not intended or admitted that be prior art to the invention.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

A. Diabetes

Type 2 diabetes is one of the diseases most common chronicles Type 2 diabetes is characterized by basal and postprandial hyperglycemia and due to relative insufficiency of insulin Hyperglycemia can cause complications. long-term microvascular and macrovascular, such as nephropathy, neuropathy, retinopathy and vascular disease peripheral In addition, Type 2 diabetes is a comorbid disease which frequently combines hyperlipidemia, atherosclerosis and hypertension. Hyperlipidemia is a primary risk factor for cardiovascular disease due to atherosclerosis. The obesity it is a common risk factor well known for the development of atherosclerosis, stroke, hypertension and type 2 diabetes. Type 2 diabetes causes significant morbidity and mortality at a considerable cost for patients, their families and society. The incidence of Type 2 diabetes in the United States is approximately 7% and represents as much as 10% of all Health care dollars. In addition, the incidence of diabetes Type 2 worldwide is increasing, so that currently believes that Type 2 diabetes is a worldwide epidemic.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

B. Glucagon-like Peptide 1 (GLP-1)

The glucagon-like peptide 1 (GLP-1) is an incretin hormone obtained from the post-translational modification of proglucagon and secreted by cells Endocrine of the intestine. GLP-1 mediates its actions through a specific G protein coupled receptor (GPCR), specifically GLP-1 R. GLP-1 It is best characterized as a hormone that regulates homeostasis of glucose GLP-1 has been shown stimulates glucose dependent insulin secretion and increases the mass of pancreatic beta cells. It has also been shown that GLP-1 reduces the rate of gastric emptying and Promote satiety. The efficacy of peptide agonists GLP-1 in the control of blood glucose in Type 2 diabetics have been shown in several clinical studies [see, for example, Nauck <i>et al</i>., Drug News Perspect (2003) 16: 413-422], as well as its effectiveness in body mass reduction [Zander <i>et al</i>., Lancet (2002) 359: 824-830].

The agonists of the receptor of GLP-1 are additionally useful in protection against myocardial infarction and against cognitive disorders and neurodegenerative GLP-1 has been shown to be cardioprotective in a rat myocardial infarction model [Bose<i>et al</i>., Diabetes (2005) 54: 146-151] and it has demonstrated in rodent models that GLP-IR is involved in learning and neuroprotection [During <i>et to the</i>., Nat Med (2003) 9: 1173-1179; and Greig<i>et to the</i>., Ann NY Acad Sci (2004) 1035: 290-315].

Certain disorders, such as Type diabetes 2, are characterized by a deficiency in GLP-1 [see, for example, Nauck <i>et al</i>., Diabetes (2004) 53 Suppl 3: S190-196].

GLP-1 peptide agonists current experience an absence of oral bioavailability, which negatively affects patient compliance. The efforts to develop GLP-1R agonists of molecules Small, non-peptidergic and bioavailable orally have not succeeded so far [Mentlein, Expert Opin Investig Drugs (2005) 14: 57-64]. An attractive alternative approach is to develop an active composition orally to increase the endogenous level of GLP-1 in the blood.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

C. GPR119

The GPR119 G protein coupled receptor (GPR119; for example, human GPR119, GenBank® Accession No. AAP72125 and alleles thereof; for example, mouse GPCR119, No. GenBank® access AY288423 and alleles thereof) is expressed selectively in pancreatic beta cells. GPR119 activation leads to an elevation of the level of intracellular cAMP, which agrees that GPR119 is coupled to Gs. The agonists for GPR119 stimulate glucose dependent insulin secretion <i>in vitro</i> and lower a high blood glucose level <i>in alive</i>. See, for example, WO International Applications 04/065380, WO 04/076413 and EP 1338651. In the bibliography of patents, reference has been made to GPR119 as RUP3 (see, for example, International Application WO 00/31259).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

D. Dipeptidyl Peptidase IV (DPP-IV)

Dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) shows catalytic activity against a large number of peptide substrates that include peptide hormones, neuropeptides and chemokines. The incretins glucagon-like peptide 1 (GLP-1) and polypeptide glucose-dependent insulinotropic (GIP), which stimulate the glucose dependent insulin secretion and promote other homeostasis mode of blood glucose, are cleaved quickly by DPP-IV in the alanine in position 2, leading to the inactivation of its biological activity. The both pharmacological and genetic attenuation of the activity of DPP-IV is associated with an increased action of the Incretin, increased insulin and decreased blood glucose<i>in vivo</i> It has been shown that the genetic attenuation of DPP-IV activity provides resistance to Obesity and increases insulin sensitivity. An inhibitor of Second generation DPP-IV, LAF237 (Ahren <i>et to the</i>., J Clin Endocrinol Metab (2004) 89: 2078-2084; and Villhauer<i>et al</i>., J Med Chem (2003) 46: 2774-2789) is currently in Phase 3 clinical trials for Type 2 diabetes and others DPP-IV inhibitors are in clinical development, including MK-0431, BMS-477118, PSN-9301 and SYR-322.

Since incretin hormones are not the only substrates for DPP-IV, worries that the inhibition of cleavage of other endogenous substrates of DPP-IV may lead to side effects undesirable [see, for example, Chen <i>et al</i>, J Biol Regul Homeost Agents (2004) 18: 47-54]. Thus, it would be advantageous to identify a promoter activity of the blood glucose homeostasis that was associated with substantially lower concentrations of inhibitor DPP-IV

Yasuda N, <i>et al</i> evaluated the effects of subchronic treatment with metformin and a DPPIV inhibitor in a model of obesity and altered glucose tolerance in rat. He combination treatment caused a significant increase in GLP-1 levels (J. Pharm. Exp. Theva. Vol. 310, No. 2, 2004 pp. 614-619).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

E. G protein coupled receptors

GPCRs share a common structural motive which has seven sequences of between 22 and 24 hydrophobic amino acids that form seven alpha helices, each of which crosses the membrane (each transmembrane region is identified by a number, it is that is, transmembrane-1 (TM-1), transmembrane-2 (TM-2), etc.). The transmembrane helices are linked by chains of amino acids between the transmembrane-2 and the transmembrane-3, transmembrane-4 and transmembrane-5 and the transmembrane-6 and transmembrane-7 on the outside, or "extracellular" side of the cell membrane (these are called "extracellular" regions 1, 2 and 3 (EC-1, EC-2 and EC-3), respectively). Transmembrane propellers they are also linked by chains of amino acids between the transmembrane-1 and the transmembrane-2, transmembrane-3 and transmembrane-4 and the transmembrane-5 and the transmembrane-6 inside, or side "intracellular", of the cell membrane (these are called "intracellular" regions 1, 2 and 3 (IC-1, IC-2 and IC-3), respectively). He "carboxy" ("C") terminal end of the receiver will found in the intracellular space inside the cell and the "amino" ("N") terminal end of the receptor is found in the extracellular space outside the cell.

Generally, when an agonist joins a G-protein coupled receptor (often referred to as "activation" of the receiver) there is a change in the conformation of the receiver that facilitates the coupling between the intracellular region and an intracellular "G protein." It has been described that GPCRs are "promiscuous" with respect to the G protein, that is, a GPCR can interact with more than one protein G. See, Kenakin, T., 43 Life Sciences 1095 (1988). Although other G proteins may exist, they are currently G proteins that have been identified Gq, Gs, Gi, `Gz and Go. The coupling of a GPCR activated by ligand with the G protein initiates a process of signaling cascade (called "signal transduction"). Under normal conditions, signal transduction gives as result, ultimately, cell activation or cell inhibition

Gs stimulates the enzyme adenylyl cyclase. The Gi (and Gz and Go), on the other hand, inhibit adenylyl cyclase. The adenylyl cyclase catalyzes the conversion of ATP into cAMP; for the therefore, activated GPCRs that couple to the Gs protein are associated with increased cellular levels of cAMP. On the other hand, the Activated GPCRs that are coupled to the Gi (or Gz, Go) protein, are associated with decreased cell levels of cAMP. See in general, "Indirect Mechanisms' of Synaptic Transmission", Cap. 8, From Neuron To Brain (3rd Ed.) Nichols, JG <i>et al</i> eds. Sinauer Associates, Inc. (1992). Therefore, they can be used assays that detect cAMP to determine if a compound candidate is, for example, an agonist for the recipient (i.e. such a compound would increase cAMP levels). Gq and Go are associated with the activation of the enzyme phospholipase C, which at its once it hydrolyzes the phospholipid PIP2, releasing two messengers intracellular: diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). The increased accumulation of IP3 is associated with the activation of receptors associated with Gq and Go. See, in general, "Indirect Mechanisms of Synaptic Transmission ", Chapter 8, From Neuron To Brain (3rd Ed.) Nichols, J. G. <i>et al</i> eds. Sinauer Associates, Inc. (1992). They can used tests that detect the accumulation of IP3 to determine if a candidate compound is, for example, an agonist for a receptor associated with Gq or Go (i.e. a compound of this type would increase the levels of IP3). You can also use a assay that detects the level of intracellular free calcium to determine if a candidate compound is, for example, an agonist for a receptor associated with Gq or Go (i.e. a compound of this type would increase intracellular free calcium levels). See for example, Table A ("N / A": "no applicable").

TABLE A

<figref>1</figref>

There are also promiscuous G proteins that they seem to couple several GPCR classes with the route of the phospholipase C, such as Gal5 or Gα6 [Offermanns and Simon, J Biol Chem (1995) 270: 15175-80], or G proteins chimerics designed to couple a large number of GPCRs different with the same route, for example, phospholipase C [Milligan and Rees, Trends in Pharmaceutical Sciences (1999) 20: 118-24].

Under physiological conditions, there are GPCRs in the Cellular membrane in equilibrium between two different conformations: an "inactive" state and an "active" state. A receiver in an inactive state is unable to connect to the path of intracellular signaling transduction to initiate the signal transduction that leads to a biological response. He changing the conformation of the receptor to the active state allows the connection with the transduction path (using G protein) and It produces a biological response.

A receiver can stabilize in a state active by a ligand or a compound such as a drug. The recent discoveries, including, but not limited to exclusively to modifications in the amino acid sequence of the receptor, provide means other than ligands or drugs for promote and stabilize the receptor in the conformation of state active. These means effectively stabilize the receptor in a active state, simulating the effect of a ligand binding to receiver. Stabilization by said independent means of ligand is called "constitutive receptor activation". A endogenous receptor that exhibits activity in the absence of ligand se denominated constitutively active endogenous receptor.

Summary of the Invention

The present invention relates to the combination of an amount of a GPR119 agonist with a amount of a dipeptidyl peptidase IV inhibitor (DPP-IV), so that the combination provides a effect of lowering blood glucose level in a subject above that provided by the amount of the agonist of GPR119 or the amount of DPP-IV inhibitor alone, and the use of said combination to treat or prevent diabetes and Conditions related to it. The present invention also refers to the combination of an amount of an agonist of GPR119 with an amount of a dipeptidyl peptidase inhibitor IV (DPP-IV), so that the combination provides an effect of increasing the level of GLP-1 in blood in a subject above that provided by the amount of OPR119 agonist or the amount of the inhibitor of DPP-IV alone and the use of such combination to treat or prevent a condition that is improved by increased GLP-1 level in blood or to increase the level of GLP-1 in blood in a subject deficient in GLP-1

This document describes methods of treatment or prevention of diabetes or a condition related to it that include administering to a subject that a therapeutically effective amount of a composition needs it which comprises or consists essentially of a GPR119 agonist and a DPP-IV inhibitor. Preferably, the agonist of GPR119 and the DPP-IV inhibitor are administered in sufficient amounts to lower blood glucose level in the subject Preferably, the blood glucose level is a high blood glucose level

This document also describes methods of treatment or prevention of a condition that is improved by increased level of GLP-1 in blood, which includes administer to a subject that needs an amount therapeutically effective of a composition comprising or consisting essentially in a GPR119 agonist and an inhibitor of DPP-IV Preferably, the GPR119 agonist and the DPP-IV inhibitor are administered in amounts enough to increase the level of GLP-1 in blood in the subject

This document also describes methods to increase the level of GLP-1 in blood, which include administering to a subject deficient in GLP-1 a therapeutically effective amount of a composition that comprises or consists essentially of an agonist of GPR119 and a DPP-IV inhibitor. Preferably, the GPR119 agonist and DPP-IV inhibitor are administered in sufficient quantities to increase the level of GLP-1 in blood in the subject.

Preferably, diabetes is type diabetes. two.

Preferably, the condition related to the diabetes is selected from the group consisting of hyperglycemia, impaired glucose tolerance, insulin resistance, insufficiency of pancreatic beta cells, insufficiency of enteroendocrine cells, glycosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, retinopathy diabetic, diabetic coronary artery disease, disease diabetic cerebrovascular, peripheral vascular disease diabetic, metabolic syndrome, hyperlipidemia, atherosclerosis, stroke, hypertension and obesity.

Preferably, the condition that is improved by increased blood GLP-1 level is selected among the group consisting of diabetes, a related condition with diabetes, myocardial infarction, learning disorder, memory impairment and a neurodegenerative disorder.

Preferably, the condition that is improved by Increased level of GLP-1 in blood is a disorder neurodegenerative selected from the group consisting of injury excitotoxic brain caused by severe epileptic seizures, Alzheimer's disease, Parkinson's disease, Huntington, prion-associated disease, stroke, disease of motor neuron, impaired learning or memory, injury traumatic brain, spinal cord injury and neuropathy peripheral

Preferably, the subject is a human being.

In a first aspect, the present invention has a composition that comprises or consists essentially of a GPR119 agonist and a DPP-IV inhibitor, in which said DPP-IV inhibitor is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention refers to a dosage form of the composition in which the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to decrease the level of blood glucose in a subject. In certain embodiments, the blood glucose level is a glucose level in high blood. In certain embodiments, the present invention refers to a dosage form of the composition in which the GPR119 agonist and DPP-IV inhibitor are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

In certain embodiments, the subject is a being human.

In a second <i>appearance</i> appearance, the The present invention has a composition comprising or consisting of essentially in a GPR119 agonist and an inhibitor of DPP-IV for use in a method of treatment of human or animal body by therapy, wherein said inhibitor of DPP-IV is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention refers to a dosage form of the composition in which the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to decrease the level of blood glucose in a subject. In certain embodiments, the blood glucose level is a glucose level in high blood. In certain embodiments, the present invention refers to a dosage form of the composition in which the GPR119 agonist and DPP-IV inhibitor are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

The present invention also presents a composition that comprises or consists essentially of an agonist of GPR119 and a DPP-IV inhibitor for use in a method of treatment or prevention of diabetes, or a condition related to it, of the human or animal body by therapy, in which said DPP-IV inhibitor is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention relates to a dosage form of the composition in which the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to decrease the level of blood glucose in a subject. In certain embodiments, the blood glucose level is a glucose level in high blood.

The present invention also presents a composition that comprises or consists essentially of an agonist of GPR119 and a DPP-IV inhibitor for use in a method of treatment or prevention of a condition that is improved by increased level of GLP-1 in the body's blood human or animal by therapy, wherein said inhibitor of DPP-IV is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention refers to a dosage form of the composition in which the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

The present invention also presents a composition that comprises or consists essentially of an agonist of GPR119 and a DPP-IV inhibitor for use in a method of treatment or prevention of a deficiency of GLP-1 of the human or animal body by therapy. In certain embodiments, the present invention relates to a dosage form of the composition in which the agonist of GPR119 and DPP-IV inhibitor are in amounts enough to increase the level of GLP-1 in blood in a subject

In certain embodiments, the subject is a being human.

In a third <i>appearance,</i> the present invention presents a method for preparing a composition pharmaceutical, comprising or consisting essentially said method of mixing a GPR119 agonist and an inhibitor of DPP-IV, along with at least one vehicle pharmaceutically acceptable, wherein said inhibitor of DPP-IV is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the method it also comprises the step of preparing a dosage form of the pharmaceutical composition, in which the GPR119 agonist and the DPP-IV inhibitor are in sufficient quantities to lower the level of blood glucose in a subject. In certain embodiments, the blood glucose level is a level of high blood glucose In certain embodiments, the method it also comprises the step of preparing a dosage form of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

In certain embodiments, the subject is a being human.

In a room <i>appearance</i> aspect, the present The invention has a pharmaceutical composition comprising or It consists essentially of a GRR119 agonist and an inhibitor of DPP-IV, along with at least one vehicle pharmaceutically acceptable, wherein said inhibitor of DPP-IV is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention refers to a dosage form of the composition pharmaceutical in which the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to decrease the level of blood glucose in a subject. In certain embodiments, the blood glucose level is a glucose level in high blood. In certain embodiments, the present invention refers to a dosage form of the composition pharmaceutical in which the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

In certain embodiments, the subject is a being human.

In certain embodiments, the subject is a being human.

In a fifth <i>appearance,</i> the present invention presents the use of a composition comprising or It consists essentially of a GPR119 agonist and an inhibitor of DPP-IV for the manufacture of a medicament for the treatment or prevention of diabetes or a condition related thereto, wherein said inhibitor of DPP-IV is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention relates to a dosage form of the medicament in the one that the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to decrease the level of blood glucose in a subject. In certain embodiments, the blood glucose level is a glucose level in high blood.

The present invention further presents the use of a composition that comprises or consists essentially of a GPR119 agonist and a DPP-IV inhibitor for manufacture of a medicine for treatment or prevention of a condition that is improved by increasing the level of GLP-1 in blood, wherein said inhibitor of DPP-IV is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention relates to a dosage form of the medicament in the one that the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

The present invention further presents the use of a composition that comprises or consists essentially of a GPR119 agonist and a DPP-IV inhibitor for manufacture of a medicine for treatment or prevention of a deficiency of GLP-1, in which said DPP-IV inhibitor is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (5) -pyrrolidine (NVP-DPP728). In certain embodiments, the present invention relates to a dosage form of the medicament in the one that the GPR119 agonist and the inhibitor of DPP-IV are in sufficient quantities to increase the level of GLP-1 in blood in a subject.

In certain embodiments, the subject is a being human.

Brief description of the drawings

The invention is illustrated in relation to the figures attached to it, in which:

Fig. 1 shows a synergistic effect of a GPR119 agonist and a DPP-IV inhibitor in the decreased high blood glucose level in one trial of oral glucose tolerance (oGTT) in mice. See example 1.

Fig. 2 shows a synergistic effect of a GPRI19 agonist and a DPP-IV inhibitor in the increased level of GLP-1 in blood after a glucose exposure in mice. See Example 3.

Fig. 3 shows the expression of GPR119 in intestine. See Example 10.

Fig. 4 shows the expression of GPR119 in a enteroendocrine cell line GLUTag. See Example 11.

Fig. 5 shows an elevation of the level of Intracellular cAMP in GLUTag enteroendocrine cells by agonists from GPR119. See Example 12.

Fig. 6 shows the stimulation of the GLP-1 secretion in enteroendocrine cells GLUTag by an agonist of GPR119. See Example 13.

Fig. 7 shows an effect of the agonist of GPR119 AR244061 and DPP-IV inhibitor MK-0431 in decreasing glucose level in blood in an oral glucose tolerance test (oGTT) in mice. See Example 14.

Fig. 8 shows an effect of the agonist of GPR119 A244061 and the DPP-IV LAF237 inhibitor in the decrease in blood glucose level in a trial of oral glucose tolerance (oGTT) in mice. See example 14.

Fig. 9 shows an effect of the agonist of GPR119 AR244061 and DPP-IV inhibitor FE107542 in the decrease in blood glucose level in a trial of oral glucose tolerance (oGTT) in mice. See example 14.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Detailed description of the invention

This invention relates to the combination of certain compounds, or pharmaceutically acceptable salts of the themselves, for the treatment or prevention of diabetes and Conditions related to it. This invention relates in addition to the combination of certain compounds, or salts pharmaceutically acceptable thereof, for the treatment or the prevention of a condition that is improved by increasing the level of GLP-1 in blood. The applicant has discovered that an amount of a GPR119 agonist in combination with a amount of a DPP-IV inhibitor can provide an unexpected synergistic effect of decreased blood glucose level in a subject above that provided for the amount of GPR119 agonist alone or for the amount of DPP-IV inhibitor alone. He applicant has also discovered that a quantity of an agonist of GPR119 in combination with an amount of an inhibitor of DPP-IV can provide a synergistic effect unexpected increase in blood GLP-1 level in a subject above that provided by the amount of GPR119 agonist alone or by the amount of inhibitor DPP-IV alone. The applicant has discovered in addition that GPR119 is a receptor of secretagogues of GLP-1

By using a combination of a GPR119 agonist and a DPP-IV inhibitor of According to the present invention, it is possible to treat or prevent diabetes and related conditions with a dose of one DPP-IV inhibitor substantially lower than currently contemplated for use in diabetes therapy and conditions related to it, thereby reducing the probability of unwanted side effects associated with the DPP-IV activity inhibition. Through the use of a combination of a GPR119 agonist and an inhibitor of DPP-IV according to the present invention, is possible to treat or prevent a condition that is improved by augmentation of the level of GLP-1 in blood with a dose of one DPP-IV inhibitor substantially lower than currently contemplated for use in therapy for said condition, thereby reducing the likelihood of side effects not desired associated with the inhibition of the activity of DPP-IV In addition, by using a combination of a GPR119 agonist and a DPP-IV inhibitor According to the present invention, it is possible to treat or prevent diabetes and related conditions with a dose of an agonist of GPR119 substantially lower than contemplated currently for use in therapy for diabetes and conditions related to it, thereby reducing the probability of unwanted side effects of being associated with the activation of the GPR119 receiver. The present invention provides a new, unexpected and advantageous strategy for decrease the level of blood glucose in a subject. The present invention also provides a new, unexpected and advantageous to increase the level of GLP-1 in blood in a subject

The term "ligand", as used in this document, will mean a molecule that specifically binds to a GPCR A ligand can be, for example, a polypeptide, a lipid, A small molecule, an antibody. An endogenous ligand is a ligand that is an endogenous natural ligand for a native GPCR. A ligand can be an "antagonist", "agonist", "partial agonist" or "reverse agonist" of GPCR or Similary.

The term "agonist", as used in this document, will mean an agent (for example, ligand, compound candidate) that by virtue of joining a GPCR activate the GPCR, of so that it provokes an intracellular response mediated by the GPCR

The expression "partial agonist", as used in this document, will mean an agent (for example, ligand, candidate compound) that by virtue of the GPCR binding activates the GPCR, so as to cause an intracellular response mediated by the GPCR, although to a lesser extent or degree than an agonist full.

The term "antagonist" will mean a agent (e.g., ligand, candidate compound) that binds, and preferably joins competitively, to a GPCR in approximately the same site as an agonist or partial agonist, but that does not activate an intracellular response initiated by the form GPCR active, and therefore, can inhibit the response intracellular by an agonist or partial agonist. Typically, a antagonist does not decrease the baseline intracellular response in absence of an agonist or partial agonist.

The expression "inverse agonist" will mean an agent (e.g., ligand, candidate compound) that binds to a GPCR and that inhibits the basal intracellular response initiated by the active form of the receiver below the level activity normal base that is observed in the absence of an agonist or agonist partial.

The expression "agonist of GPR119", as used herein, refers to a compound that binds to a GPR119 receptor and acts as an agonist.

The expression "selective agonist of GPR119 ", as used herein, refers to an agonist of GPR119 that has selectivity for the GPR119 receiver over one or more closely related receptors, such as the receptor of corticotropin releasing factor 1 (CRF-1).

The expression "inhibitor of DPP-N ", as used herein, refers to to a compound that binds to DPP-N and inhibits the DPP-N dipeptidyl peptidase activity.

The expression "selective inhibitor of DPP-IV ", as used herein, is refers to a DPP-IV inhibitor that has DPP-IV selectivity on peptidases closely related, such as one or more of the enzyme cleavage after proline (PPCE), dipeptidyl peptidase II (DPP-II), dipeptidyl peptidase 8 (DPP-8) and dipeptidyl peptidase 9 (DPP-9).

The expressions "glucose level in blood "or" blood GLP-1 level "is refer to the average blood glucose concentration or the average concentration of GLP-1 in blood, respectively. In certain embodiments, the level of GLP-1 in blood is the blood level of Biologically active GLP-1, in which the GLP-1 that has agonist activity in GLP-1R is biologically active. In certain embodiments, a blood glucose level or level of GLP-L in blood is a plasma glucose level or a level of plasma GLP-1.

The expression "blood glucose level elevated "will mean a high blood glucose level, such like the one in a subject that demonstrates a clinically inappropriate basal and postprandial hyperglycemia, or such like the one found in a subject in a tolerance test oral glucose (oGTT).

The term "subject", as used in this document, will refer to a mammal, including, but not limitation, a mouse, a rat, a rabbit, a pig, a dog, a cat, a non-human primate and a human being, more preferably to a mouse or rat, more preferably a human being.

The expression "that needs prevention or treatment ", as used herein, refers to a judgment made by a healthcare professional (for example, doctor, nurse, nurse practitioner in the case of human beings; veterinarian in the case of non-human mammals) that a subject requires or will benefit from a treatment.

The expression "amount therapeutically effective "or" therapeutically effective dose "is intended mean that amount of drug that will cause the response Desired biological or medical. In certain embodiments, a quantity Therapeutically effective is that amount of drug that will generate a AUC inhibition above 30% in an oGTT assay in mouse.

The expression "amount therapeutically ineffective "or" therapeutically ineffective dose "is intended refer to a quantity of drug less than the quantity Therapeutically effective drug. In certain embodiments, a therapeutically ineffective amount is a quantity of drug that will generate an inhibition of AUC less than or equal to 30% in a oGTT assay in mouse.

The expression "amount that is effective for prevent "refers to that amount of drug that will prevent or reduce the risk of occurrence of the biological event or Doctor who seeks to prevent. In many cases, the amount that is effective for prevention is the same as the amount therapeutically effective.

The term "composition" shall mean a material comprising at least one component.

The term "active ingredient" shall mean any component that provides a pharmacological activity or other direct effect on diagnosis, cure, mitigation, treatment or disease prevention.

The expression "pharmaceutical composition" mean a composition comprising at least one ingredient active, so the composition is susceptible to investigation and Treatment in a mammal.

The expression "dosage form" it will mean the physical form in which it is produced and dispensed a drug, such as a tablet, capsule or an injectable.

As used in this document, the term "diabetes" encompasses both insulin dependent diabetes mellitus (also known as Type 1 diabetes) as diabetes mellitus no insulin dependent (also known as Type 2 diabetes).

The expression "condition related to diabetes "aims to include, but not limited to, hyperglycemia, impaired glucose tolerance, insulin resistance, insufficiency of pancreatic beta cells, insufficiency of enteroendocrine cells, glycosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, retinopathy diabetic, diabetic coronary artery disease, disease diabetic cerebrovascular, peripheral vascular disease diabetic, metabolic syndrome, hyperlipidemia, atherosclerosis, stroke, hypertension and obesity, where it is understood that conditions related to diabetes can be included in realizations individually or in any combination.

The expression "condition that is improved by increased level of GLP-1 in blood "purports to include, but not limited to, diabetes, a related condition with diabetes, myocardial infarction, learning disorder, memory impairment and a neurodegenerative disorder, where understands that conditions that are improved by increasing the level of GLP-1 in blood can be included in embodiments of individually or in any combination.

The term "atherosclerosis", as used in This document refers to a form of vascular disease characterized by deposition of atheromatous plaques containing cholesterol and lipids in the innermost layer of the walls of arteries of large and medium size.

The expression "metabolic syndrome", as defined in this document, and in accordance with the Treatment Panel of Adults III (ATP III; National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Executive Summary; Bethesda, Md., National Institutes of Health, National Heart, Lung and Blood Institute, 2001 (Pub. NIH No. 01-3670), appears when a person meets three or more than five related criteria with obesity, hypertriglyceridemia, low HDL cholesterol, pressure high blood pressure and high baseline glucose.

The expression "neurodegenerative disorder" purports to include, but not be limited to brain injuries excitotoxic caused by severe epileptic seizures, disease of Alzheimer's, Parkinson's disease, Huntington's disease, disease associated with prions, stroke, disease motor neuron, learning or memory impairment, injury traumatic brain, spinal cord injury and neuropathy peripheral

The term "obesity", as used in this document, is defined as a body mass index (BMI) of 30.0 or higher, according to WHO weight classifications [Kopelman, Nature (2000) 404: 635-643: whose description is incorporated into this document as a reference in your whole].

The expression "<i>acyl C_ {1-5}</i>"represents an alkyl radical C_ {1-5} attached to a carbonyl, where the definition alkyl has the same definition as described in this document; some examples include, but are not limited to, acetyl, propionyl, n-butanoyl,<i>iso-</i>butanoyl, sec-butanoyl, t-butanoyl (i.e., pivaloyl), pentanoyl and Similar.

The expression "<i>acyloxy C_ {1-5}</i>"represents an attached acyl radical to an oxygen atom where acyl has the same definition as has been described in this document; some examples include but without limitation, acetyloxy, propionyloxy, butanoyloxy,<i>iso-</i>butanoyloxy, sec-butanoyloxy, t-butanoyloxy and Similar.

The expression "<i>acyl C 1-6 sulfonamide</i>" he refers to a C 1-6 acyl attached directly to the sulfonamide nitrogen, where definitions for acyl C 1-6 and sulfonamide have the same meaning which has been described in this document, and an acyl C 1-6 -sulfonamide can represented by the following formula:

<figref>2</figref>

Some embodiments of the present invention are when ecylsulfonamide is an acyl C_ {1-5} -sulfonamide, some realizations are acyl C 1-4 -sulfonamide, some realizations are acyl C_ {1-3} -sulfonamide and some realizations are acyl C 1-2 Sulfonamide. The examples of an acylsulfonamide include, but are not limited to, acetylsulfamoyl [-S (O) 2 NHC (= O) Me], propionylsulfamoyl [-S (= O) 2 NHC (= O) Et], isobutyrylsulfamoyl, butyrylsulfamoyl, 2-methyl-butyrylsulfamoyl, 3-methyl-butyrylsulfamoyl, 2,2-dimethyl-propionylsulfamoyl, pentanoylsulfamoyl, 2-methyl-pentanoylsulfamoyl, 3-methyl-pentanoylsulfamoyl, 4-methyl-pentanoylsulfamoyl and Similar.

The expression "<i>alkenyl C_ {2-6}</i>"represents a radical that contains from 2 to 6 carbons, in which at least one double bond is present carbon-carbon, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons and some Embodiments have 2 carbons. Isomers both<i>AND</i> as <i>Z</i> are included by the term "<i>alkenyl</i>". Further, the term "<i>alkenyl</i>"includes di- and tri-alkenyls. Therefore, if present more than one double link, then the links can all be<i>AND</i> or <i>Z</i> or a mixture of <i>AND</i> and Z. The examples of an alkenyl include vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexanyl, 2,4-hexadienyl and the like.

The expression "<i>alkoxy C_ {1-4}</i>", as used in this document, represents an alkyl radical, as defined herein document, directly attached to an oxygen atom. The examples include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, t-butoxy, iso-butoxy, sec-butoxy and the like.

The expression "<i>I rent C_ {1-8}</i>"represents a carbon radical linear or branched, containing 1 to 8 carbons, some embodiments are 1 to 6 carbons, some embodiments are 1 at 3 carbons and some embodiments are 1 or 2 carbons. The Examples of an alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, t-butyl, pentyl, iso-pentyl, t-pentyl, neo-pentyl, 1-methylbutyl [es say, -CH (CH 3) CH 2 CH 2 CH 3], 2-methylbutyl [that is, -CH 2 CH (CH 3) CH 2 CH 3], n-hexyl and the like.

The expression "<i>rent C 1-4 -carboxamido</i>"or "<i>rent C 1-4 -carboxamide</i>" represents a single C 1-4 alkyl group attached to the nitrogen of an amide group, where the alkyl has the same definition found in this document. The rent C_ {1-5} -carboxamido can represented by the following:

<figref>3</figref>

Examples include, but are not limited to,<i>N-</i>methylcarboxamide,<i>N-</i>ethylcarboxamide,<i>N-</i>n-propylcarboxamide, <i>N-</i>iso-propylcarboxamide,<i>N-</i>n-butylcarboxamide,<i>N-</i>sec-butylcarboxamide,<i>N-</i>iso-butylcarboxamide, <i>N-</i>t-butylcarboxamide and Similar.

The expression "<i>alkylene C_ {1-3}</i>"represents a carbon group linear divalent C_ {1-3}. In some embodiments, C 1-3 alkylene refers, by example, a -CH_ {2} -, -CH_ {CH2} -, -CH 2 CHCH 2 - and the like. In some embodiments, C 1-3 alkylene refers to -CH-, -CHCH_2 -, -CHCH_ {CH2} - and similar, where these examples generally refer to "TO".

The expression "<i>rent C 1-4 -sulfinyl</i>" represents a C1-4 alkyl radical attached to a sulfoxide radical of the formula: -S (O) -, where the radical alkyl has the same definition as described in this document. Examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, iso-propylsulfinyl, n-butylsulfinyl, sec-butylsulfinyl, iso-butylsulfinyl, t-butyl, and Similar.

The expression "<i>rent C 1-4 -sulfonamide</i>" represents the groups

<figref>4</figref>

in which the alkyl C_ {1-4} has the same definition as described in this document.

The expression "<i>rent C 1-4 -sulfonyl</i>" represents a C1-4 alkyl radical attached to a sulfone radical of the formula: -S (O) 2 -, where the alkyl radical has the same definition as described in this document. Examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, iso-propylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, iso-butylsulfonyl, t-butyl, and Similar.

The expression "<i>rent C_ {1-4} -thio</i>"represents a C 1-4 alkyl radical attached to a sulfide of the formula: -S- where the alkyl radical has the same definition described in this document. The examples include, but not limited to, methylsulfanyl (i.e. CH 3 S-), ethylsulfanyl, n-propylsulfanyl, iso-propylsulfanyl, n-butylsulfanyl, sec-butylsulfanyl, iso-butylsulfanyl, t-butyl and Similar.

The expression "<i>rent C 1-4 -thiocarboxamide</i>" represents a thioamide of the following formulas:

<figref>5</figref>

in which I rent C_ {1-4} has the same definition as described in this document.

The expression "<i>rent C_ {1-4} -tioureílo</i>" represents the group of the formula:

-NC (S) N-

where one or both nitrogen are substituted with the same or different alkyl groups C 1-4 and the alkyl has the same definition which has been described in this document. The examples of a alkylthioureil include, but is not limited to, CH 3 NHC (S) NH-, NH 2 C (S) NCH 3 -, (CH 3) 2 N (S) NH-, (CH 3) 2 N (S) NH-, (CH 3) 2 N (S) NCH 3 -, CH 3 CH 2 NHCC (S) NH-, CH 3 CH 2 NHC (S) NCH 3 - y Similar.

The expression "<i>rent C_ {1-4} -ureyl</i>" It represents the group of the formula: NC (O) N- where one or the two nitrogens are substituted with the same or different C 1-4 alkyl groups, where the alkyl has the Same definition as described in this document. The examples of an alkylureyl include, but not limited to, CH 3 NHC (O) NH-, NH 2 C (O) NCH 3 -, (CH 3) 2 N (O) NH-, (CH 3) 2 N (O) NH-, (CH 3) 2 N (O) NCH 3 -, CH 3 CH 2 NHC (O) NH-, CH 3 CH 2 NHC (O) NCH 3 - y Similar.

The expression "<i>alkynyl C_ {2-6}</i>"represents a radical that contains 2 to 6 carbons and at least one triple bond carbon-carbon, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons and some Embodiments have 2 carbons. Examples of an alkynyl include, but not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentinyl, 2-pentinyl, 3-pentinyl, 4-pentinyl, 1-hexinyl, 2-hexinyl, 3-hexinyl, 4-hexinyl, 5-hexinyl and the like. The term "alkynyl" includes di- and tri-inos

The term "<i>Not me</i>" It refers to NH2 group.

The expression "<i>rent C_ {1-4} -amino</i>" It represents an alkyl radical attached to an amino radical where the radical alkyl has the same meaning as described in this document. Some examples include, but are not limited to, methylamino, ethylamino, n-propylamino, iso-propylamino, n-butylamino, sec-butylamino, iso-butylamino, t-butylamino and the like. Some realizations are "<i>rent C_ {1-2} -amino</i>".

The term "<i>aryl</i>"represents a aromatic ring radical containing 6 to 10 carbons in the ring. Examples include phenyl and naphthyl.

The term "<i>arylalkyl</i>"define a C 1 -C 4 alkylene, such as -CH 2 -, -CH 2 CH 2 - and the like, which is further substituted with an aryl group. The examples of an "arylalkyl" include benzyl, phenethylene and Similar.

The term "<i>arylcarboxamido</i>" represents a single aryl group attached to the nitrogen of an amide group, where the aryl has the same definition found in this document. The example is<i>N-</i>phenylcarboxamide.

The term "<i>arylureyl</i>" It represents the group -NC (O) N- in which one of the nitrogen is substituted with an aryl.

The term "<i>benzyl</i>"represents the group -CH 2 C 6 H 5.

The expression "<i>carbo-alkoxy C_ {1-6}</i>"refers to an alkyl ester C 1-6 of a carboxylic acid, in which the alkyl group is as defined herein. In some embodiments, the carbo-alkoxy group C 1-6 is attached to a nitrogen atom and together they form a carbamate group (for example, N-COO-alkyl C_ {1-6}). In some embodiments, the group C 1-6 carbo-alkoxy is an ester (for example, -COO-alkyl C_ {1-6}). Examples include, but without limitation, carbomethoxy, carboethoxy, carbopropoxy, carboisopropoxy, carbobutoxy, carbo-sec-butoxy, carbo-iso-butoxy, carbo-t-butoxy, carbo-n-pentoxy, carbo-iso-pentoxy, carbo-t-pentoxy, carbo-neo-pentoxy, carbo-n-hexyloxy and Similar.

The term "<i>carboxamide</i>" it means to the group -CONH_ {2}.

The term "<i>carboxy</i>"or "<i>carboxyl</i>"represents the group -CO2H; also called a carboxylic acid group.

The term "<i>cyano</i>"represents the -CN group.

The expression "<i>cycloalkenyl C_ {3-7}</i>"represents a ring radical not aromatic containing 3 to 6 carbons in the ring and at least one double bond; some embodiments contain 3 to 5 carbons; Some embodiments contain 3 to 4 carbons. The examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentenyl, cyclohexenyl and the like.

The expression "<i>cycloalkyl C_ {3-7}</i>"represents a ring radical saturated containing 3 to 6 carbons; some realizations they contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopenyl, cyclohexyl, cycloheptyl and Similar.

<pre listing-type="other">\ newpage</pre>

The expression "diacil C_ {4-8} -amino "represents a amino group linked with two acyl groups defined herein, where acyl groups may be the same or different, such as:

<figref>6</figref>

Examples of diacil groups C_ {4-8} -amino include, but without limitation, diacetylamino, dipropionylamino, acetylpropionylamino and Similar.

The expression "<i>dialquil C_ {2-6} -amino</i>" It represents an amino substituted with two of the same or different radicals alkyl, where the alkyl radical has the same definition as described in this document. Some examples include, but without limitation, dimethylamino, methylethylamino, diethylamino, methylpropylamino, methylisopropylamino, ethylpropylamino, ethylisopropylamino, dipropylamino, propylisopropylamino and the like. Some realizations are "<i>dialquil C_ {2} ._ {4} -amino</i>".

The expression "<i>dialquil C 1-4 -carboxamido</i>"or "<i>dialquil C 1-4 -carboxamide</i>" represents two alkyl radicals, which are the same or different, attached to an amide group, where the alkyl has the same definition which has been described in this document. A dialkyl C 1-4 -carboxamido can represented by the following groups:

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>7</figref>

where C_ {1-4} It has the same definition as described in this document. The Examples of a dialkylcarbonamide include, but are not limited to,<i>N, N-</i>dimethylcarboxamide,<i>N-</i>methyl-<i>N-</i>ethylcarboxamide,<i>N, N-</i>diethylcarboxamide, <i>N-</i>methyl-<i>N-</i>isopropylcarboxamide and Similar.

The expression "<i>dialquil C 2-6 sulfonamide</i>" he refers to one of the following groups shown to continuation:

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>8</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

where C_ {1-3} It has the same definition as described in this document, by example, but not limited to, methyl, ethyl, n-propyl, isopropyl and Similar.

The expression "<i>dialquil C 1-6 -thiocarboxamido</i>"or "<i>dialquil C 2-6 -thiocarboxamide</i>" represents two alkyl radicals, which are the same or different, attached to a thioamide group, where the alkyl has the same definition described in this document. A dialkyl C 1-4 -thiocarboxamido can represented by the following groups:

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>9</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Examples of a dialkylthiocarboxamide include, but not limited to,<i>N, N-</i>dimethylthiocarboxamide,<i>N-</i>methyl-<i>N-</i>ethylthiocarboxamide and the like

The expression "<i>dialquil C 1-6 -sulfonylamino</i>" he refers to an amino group linked with two alkyl groups C_ {1-3} -sulfonyl as has been defined in this document.

The term "<i>ethylene</i>" It refers to group with triple carbon-carbon bond that Represents below:

<figref>10</figref>

The term "<i>formyl</i>" It refers to -CHO group.

The term "<i>haloalkoxy C_ {1-4}</i>"represents a haloalkyl, as defined in this document, which is directly linked to a oxygen atom Examples include, but are not limited to,<i>difluoromethoxy</i>, trifluoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy and Similar.

The expression "<i>haloalkyl C_ {1-4}</i>"represents an alkyl group C_ {1-4}, defined in this document, where the alkyl is substituted with a halogen until completely substituted and a C 1-4 haloalkyl completely substituted may be represented by the formula C_ {n} L 2n + 1} in which L is a halogen and "n" is 1, 2, 3 or 4; when is present more than one halogen, then they can be the same or different and are selected from the group consisting of F, Cl, Br and I, preferably F. Examples of haloalkyl groups C_ {1-4} include, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl and Similar.

The expression "<i>haloalkyl C 1-4 -carboxamide</i>" he refers to an alkylcarboxamide group, defined herein, where the alkyl is substituted with a halogen until it is completely substituted, represented by the formula C_ {n} L_ {2n + 1} in which L is a halogen and "n" is 1, 2, 3 or 4. When more than one halogen is present, they may be the same or different and are selected from the group consisting of F, Cl, Br and I, preferably F.

The expression "<i>haloalkyl C_ {1-4} -sulfinoyl</i>" represents a haloalkyl radical attached to a sulfoxide group of the formula: -S (O) - where the haloalkyl radical has the same definition as described in this document. The Examples include, but are not limited to, trifluoromethylsulfinyl, 2,2,2-trifluoroethylsulfinyl, 2,2-difluoroethylsulfinyl and the like.

The expression "<i>haloalkyl C 1-4 -sulfonyl</i>" represents a haloalkyl radical attached to a sulfone group of the formula: -S (O) 2 - where the haloalkyl It has the same definition as described in this document. The Examples include, but are not limited to, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2-difluoroethylsulfonyl and the like.

The expression "<i>haloalkyl C_ {1-4} -thio</i>"represents a haloalkyl radical attached directly to a sulfur, where the haloalkyl has the same meaning as described in this document. Examples include, but are not limited to, trifluoromethylthio (i.e. CF 3 S-), 1,1-difluoroethylthio, 2,2,2-trifluoroethylthio and the like.

The term "<i>halogen</i>"or "<i>halo</i>"represents a fluorine, chlorine, bromine or iodo.

The expression "<i>heteroalkylene C_ {1-2}</i>"refers to an alkylene C_ {1-2} attached to a heteroatom selected from O, S, S (O), S (O) 2 and NH. Some examples represented include, but are not limited to, the groups of following formulas:

<figref>11</figref>

and Similar.

The term "<i>heteroaryl</i>" It represents a system of aromatic rings that can be a single ring, two condensed rings or three condensed rings, in which at least a carbon of the ring is replaced by a selected heteroatom, but without limitation, of the group consisting of O, S and N, where the N may be optionally substituted with H, acyl C 1-4 or C 1-4 alkyl. The Examples of heteroaryl groups include, but are not limited to, pyridyl, benzofuranyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinoline, benzoxazole, benzothiazole, 1<i>H</i>-benzimidazole, isoquinoline, quinazoline, Quinoxaline and the like. In some embodiments, the atom of heteroaryl is O, S or NH, and examples include, but without limitation, pyrrole, indole and the like.

The term "<i>heterocyclic</i>" represents a non-aromatic carbon ring (i.e. cycloalkyl or cycloalkenyl, as defined herein) where one, two or three ring carbons are replaced by a heteroatom selected, but not limited to, among the group consisting of O, S, N, where N can be optionally substituted with H, acyl C 1-4 or C 1-4 alkyl, and the ring carbon atoms are optionally substituted with oxo or a thiooxo, thus forming a carbonyl group or thiocarbonyl The heterocyclic group is a ring containing 3, 4, 5, 6 or 7 members. Examples of a heterocyclic group include, but not limited to, aziridin-1-yl, aziridin-2-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, piperidin-1-yl, piperidin-4-yl, morpholin-4-yl, piperazin-1-yl, piperazin-4-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, [1,3] -dioxolan-2-yl and the like

The term "<i>heterocyclic carbonyl</i>"represents a heterocyclic group, as defined herein, attached directly to the carbon of a carbonyl group (i.e., C = O). In some embodiments, a group ring nitrogen heterocyclic binds to the carbonyl group forming an amide. The Examples include, but are not limited to,

<figref>12</figref>

and Similar.

In some embodiments, a ring carbon binds to the carbonyl group forming a ketone group. The examples include, but not limited to,

<figref>13</figref>

and Similar.

The expression "heterocyclic-oxy" refers to a group heterocyclic, as defined in this document, which is directly attached to an oxygen atom. Examples include the following:

<figref>14</figref>

and Similar.

The expression "<i>carboxamido heterocyclic</i>"represents a heterocyclic group, as has been defined in this document, with a nitrogen in the ring, where the ring nitrogen is attached directly to the carbonyl forming an amide. Examples include, but are not limited to,

<figref>15</figref>

and Similar.

The expression "<i>sulfonyl heterocyclic</i>"represents a heterocyclic group, as has been defined in this document, with a nitrogen in the ring, where the ring nitrogen is directly linked to a SO2 group forming a sulfonamide. Examples include, but without limitation,

<figref>16</figref>

and Similar.

The term "<i>hydroxyl</i>" It refers to -OH group.

The term "<i>hydroxylamino</i>" he refers to the group -NHOH.

The term "<i>nitro</i>" It refers to group -NO_ {2}.

The expression "<i>oxo-cycloalkyl C_ {4-7}</i>"refers to a cycloalkyl C_ {4-7}, as defined in this document, where one of the carbons in the ring is replaced by a carbonyl Examples of oxo-cycloalkyl C_ {4-7} include, but is not limited to, 2-oxo-cyclobutyl, 3-oxo-cyclobutyl, 3-oxo-cyclopentyl, 4-oxo-cyclohexyl and the like, and it they represent by the following structures, respectively:

<figref>17</figref>

The term "<i>perfluoroalkyl</i>" represents the group of the formula-C_ {n} F 2n + 1}; indicated differently, a perfluoroalkyl is <i>a I rent</i> as defined in this document where the alkyl it is completely substituted with fluorine atoms and therefore it consider a subset of haloalkyl. The examples of perfluoroalkyls include CF 3, CF 2 CF 3, CF 2 CF 2 CF 3, CF (CF 3) 2, CF 2 CF 2 CF 2 CF 3, CF 2 CF (CF 3) 2, CF (CF 3) CF 2 CF 3 and the like.

The term "<i>phenoxy</i>" It refers to group C 6 H 5 O-.

The term "<i>phenyl</i>" It refers to group C 6 H 5 -.

The term "<i>phosphonoxy</i>" refers to a group with the following chemical structure:

<figref>18</figref>

The term "<i>sulfonamide</i>" it means to the group -SO2 NH2.

The expression "<i>sulfonic acid</i>" he refers to the group -SO3H.

The term "<i>tetrazolyl</i>" it means to the five-member heteroaryl of the following formulas:

<figref>19</figref>

In some embodiments, the tetrazolyl group is additionally substituted in position 1 or 5, respectively, with a group selected from the group that consists of C 1-3 alkyl, haloalkyl C 1-3 and C 1-3 alkoxy.

The term "<i>thiol</i>"represents the -SH group.

The expression "secretagogue of GLP-1 "means an agent (for example, a compound) that promotes the secretion of GLP-1 a starting from a cell, for example, an enteroendocrine cell.

The term "endogenous" will mean a material that produces a mammal naturally.

The expression "biologically fragment active "of a G-protein coupled receptor will mean a GPCR fragment that has structural and biochemical functions of a GPCR of natural origin. In certain embodiments, the biologically active fragment is coupled to a G protein. In certain embodiments, the biologically active fragment binds to a known GPCR ligand.

The term "primer" is used in this document to indicate a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and is used to hybridize with the target nucleotide sequence. A primer it serves as a starting point for nucleotide polymerization, catalyzed by a DNA polymerase, RNA polymerase or transcriptase inverse

The expression "expression vector" will mean a DNA sequence that is necessary for the transcription of a cloned DNA and translation of the transcribed mRNA in a recombinant appropriate host cell for the vector of expression. An appropriately constructed expression vector should contain an origin of replication for autonomous replication in host cells, selection markers, a limited number of Useful restriction enzyme sites, a potential for high number of copies and active promoters. The cloned DNA that is going to transcribe is operatively linked to a promoter constitutively or conditionally active within the vector of expression.

The expression "candidate compound" or "test compound" shall mean a compound (for example, and without limitation, a chemical compound) that is susceptible to undergo an exploration.

The expressions "contact" or "contact" will mean approximating at least two remains.

The terms "modular" or "modify" It should be understood that they refer to an increase or decrease in the quantity, quality or effect of an activity, function or molecule particular. By way of illustration and without limitation, the agonists, partial agonists, inverse agonists and antagonists of a G protein-coupled receptor are receptor modulators.

It should be understood that the expression "molecule small "refers to a compound that has a molecular weight less than about 10,000 grams per mole, including a peptide, peptidomimetic, amino acid, amino acid analogue, polynucleotide, polynucleotide analog, nucleotide, analog nucleotide, organic compound or inorganic compound (i.e. including a heteroorganic compound or organometallic compound), and you go out, esters and other pharmaceutically acceptable forms of same. In certain preferred embodiments, small molecules they are organic or inorganic compounds that have a molecular weight less than about 5,000 grams per mole. In certain preferred embodiments, small molecules are compounds organic or inorganic having a molecular weight less than approximately 1,000 grams per mole. In certain embodiments preferred, small molecules are organic compounds or inorganic having a molecular weight less than about 800 grams per mole. In certain preferred embodiments, the Small molecules are organic or inorganic compounds that they have a molecular weight less than about 600 grams per mol. In certain preferred embodiments, small molecules they are organic or inorganic compounds that have a molecular weight less than about 500 grams per mole.

The term "polynucleotide" shall refer to RNA, DNA or a hybrid RNA / DNA sequence of more than one nucleotide in the form of a simple chain or duplex. The polynucleotides of the invention can be prepared by any known method including synthetic, recombinant, generation <i>ex vivo</i> or one combination thereof, as well as using any method of purification known in the art.

The term "polypeptide" shall refer to a amino acid polymer regardless of the length of the polymer. Therefore, peptides, oligopeptides and proteins within the definition of polypeptide. That term neither specifies or excludes modifications post-expression of the polypeptides. For example, it expressly encompass in the term polypeptide polypeptides that include the covalent bond of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like.

The term "antibody" is intended to encompass in this document a monoclonal antibody and an antibody polyclonal

The expression "second messenger" will mean an intracellular response produced as a result of Activation of a receiver. A second messenger can include, for example, inositol 1,4,5-triphosphate (IP3), diacylglycerol (DAG), cyclic AMP (cAMP), cyclic GMP (cGMP), MAP kinase activity, MAPK / ERK kinase kinase 1 activity (MEKK1) and Ca2 +. The second messenger response can be measured for a determination of the activation of a receptor.

<pre listing-type="other">\ newpage</pre>

The expression "receiver functionality" is will refer to the normal operation of a receiver to receive a stimulation and moderate an effect on the cell, including but without limitation, regulate gene transcription, regulate the flow of Ion input or output flow, effect a reaction catalytic and / or modulate activity through G proteins, such How to provoke a second messenger response.

The terms "stimulate" or "that stimulates ", in relation to the expressions" response "or "receiver functionality" will mean that a response or a receiver functionality is increased in the presence of a compound as opposed to the absence of the compound.

The expressions "inhibit" or "that inhibits ", in relation to the expressions" response "or "receiver functionality" will mean that a response or a receiver functionality is diminished or prevented in the presence of a compound as opposed to the absence of the compound.

When a range of values ​​is provided, it is understood that each intermediate value, up to one tenth of the lower limit unless the context clearly indicates another thing, between the upper and lower limit of that interval and any other indicated or intermediate value in that interval indicated, is included within the invention. Limits upper and lower of these smaller intervals can be included independently in the smallest intervals, and Also included within the invention, subject to any limit specifically excluded in the indicated interval. When he indicated range includes one or both limits, also included in the invention intervals that exclude either or both of those limits included.

GPR119 agonists

Preferably, the GPR119 is a GPR119 of mammal. More preferably, the GPR119 is rodent GPCR119 or primate. More preferably, the GPR119 is human GPR119.

The class of GPR119 agonists useful in New therapeutic combinations of the present invention include compounds that show an acceptably high affinity for the GPR119 receiver. The agonist of GPR119 or a pharmaceutically salt acceptable can be any agonist, more preferably a GPR119 selective agonist.

Examples of GPR119 agonists are described in International Application No. PCT / US2004 / 001267 (published as WO 04/065380). It is described in the International Application No. PCT / US2004 / 001267 as a GPR119 agonist a compound of Formula (I):

<figref>20</figref>

in the what:

<dl><dt>quad</dt><dd>A and B are independently alkylene C_ {1-3} optionally substituted with 1 to 4 groups methyl;</dd></dl>

<dl><dt>quad</dt><dd>D is O, S, S (O); S (O) 2, CR 2 R 3 or N-R 2;</dd></dl>

<dl><dt>quad</dt><dd>V is selected from the group consisting of C 1-3 alkylene, ethylene and heteroalkylene C_ {1-2} where each of them is optionally substituted with 1 to 4 substituents selected from the group consisting of C 1-3 alkyl, alkoxy C 1-4, carboxy, cyano, haloalkyl C 1-3 and halogen; or</dd></dl>

<dl><dt>quad</dt><dd>V is absent;</dd></dl>

<dl><dt>quad</dt><dd>W is NR_4, O, S, S (O) or S (O) 2; or</dd></dl>

<dl><dt>quad</dt><dd>W is absent;</dd></dl>

<dl><dt>quad</dt><dd>X is N or CR5;</dd></dl>

<dl><dt>quad</dt><dd>Y is N or CR6;</dd></dl>

<dl><dt>quad</dt><dd>Z is selected from the group consisting of acyl C 1-5, C 1-5 acyloxy, alkoxy C 1-4, C 1-8 alkyl, C 1-4 alkylcarboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkylthio C 1-4, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, alkyl C_ {1-2} -amino, dialkyl C 2-4 -amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, diacil C_ {4-8} -amino, dialkyl C 2-6 -carboxamide, dialquil C 1-4 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, dialkyl C 1-4 -sulfonylamino, formyl, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -carboxamide, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, halogen, aryl, heterocyclic, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl, where each of the C 1-8 alkyl and C 1-5 acyl is optionally substituted with 1, two, 3 3 or 4 groups selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 1-4 alkoxy, alkyl C 1-4 -carboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, alkyl C_ {1-2} -amino, dialkyl C 2-4 -amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, formyl haloalkoxy C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, halogen, hydroxyl, hydroxylamino and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>Z is a group of Formula (IA):</dd></dl>

<figref>21</figref>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>R 7 is H, C 1-8 alkyl or C 3-6 cycloalkyl; and</dd></dl>

<dl><dt>quad</dt><dd>R 8 is H, nitro or nitrile;</dd></dl>

<dl><dt>quad</dt><dd>Ar_ {1} is aryl or heteroaryl, where each of they are optionally substituted with R 9 -R 13;</dd></dl>

<dl><dt>quad</dt><dd>R_ {1} is selected from the group consisting of H, C 1-5 acyloxy, alkenyl C 2-6, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, alkyl C 1-4 -amino, dialkyl C 2-8 -amino, carboxamide, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -sulfonamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C_ {1-4} -tio e hydroxyl;</dd></dl>

<dl><dt>quad</dt><dd>R2 is selected from the group consisting of H, C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, haloalkoxy C 1-4, C 1-4 haloalkyl, halogen, heteroaryl, hydroxyl and phenyl; and where each of the C 1-8 alkyl, heteroaryl and phenyl are optionally substituted with 1 to 5 substituents selected between the group consisting of C 1-5 acyl, C 1-5 acyloxy, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, cycloalkyl C 3-6 alkylene C_ {1-3}, cycloalkyl C_ {3-6} -heteroalkylene C_ {1-3}, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 1-4 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heterocyclic, hydroxy, hydroxylamino and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is -Ar_ {2} -Ar_ {3} where Ar_ {2} and Ar 3 are independently aryl or heteroaryl, each optionally substituted with 1 to 5 substituents selected from the group consisting of H, C 1-5 acyl, C 1-5 acyloxy, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, C 2-6 dialkylcarboxamide, C 1-4 haloalkoxy, haloalkyl C 1-4, halogen, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is a group of Formula (IB):</dd></dl>

<figref>22</figref>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>R 14 is C 1-8 alkyl or C 3-6 cycloalkyl; and R 15 is F, Cl, Br or CN; or R2 is a group of Formula (IC):</dd></dl>

<figref>23</figref>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>\ quad</dt><dd>G is C = O, CR 16 R 17, O, S, S (O), S (O) 2; where R_ {16} and R_ {17} are independently H or C 1-8 alkyl; and</dd></dl>

<dl><dt>quad</dt><dd>Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group that consists of C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, alkyl C 1-8, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, C 2-6 dialkylcarboxamide, C 1-4 dialkyl thiocarboxamide, C 2-6 dialkyl sulfonamide, C 1-4 alkyl -thioureyl, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4, haloalkyl C 1-4 -thio, halogen, heteroaryl, hydroxy, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>R 3 is H, C 1-8 alkyl, C 1-4 alkoxy, halogen or hydroxyl; R 4 is H or C 1-8 alkyl;</dd></dl>

<dl><dt>quad</dt><dd>R 5 and R 6 are independently H, alkyl C 1-8 or halogen;</dd></dl>

<dl><dt>quad</dt><dd>R_ {9} is selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, arylsulfonyl, carbo-alkoxy C 1-6, carboxamide, carboxy, cyano, cycloalkyl C_ {3-6}, dialkyl C 2-6 -amino, dialkyl C 2-6 -carboxamide, dialquil C 2-6 -sulfonamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heterocyclic, heterocyclic sulfonyl, heteroaryl, hydroxyl, nitro, C 4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide and sulfonic acid, and where each of the acyl C 1-5, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -sulfonamide, alkylsulfonyl, arylsulfonyl, heteroaryl, phenoxy and phenyl is optionally substituted with 1 to 5 substituents selected independently among the group consisting of acyl C 1-5, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, C 1-4 alkylcarboxamide, C 2-6 alkynyl, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heteroaryl, heterocyclic, hydroxyl, nitro and phenyl; or</dd></dl>

<dl><dt>quad</dt><dd>R_ {9} is a group of Formula (ID):</dd></dl>

<figref>24</figref>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>"p" and "r" are independently 0, 1, 2 or 3; and</dd></dl>

<dl><dt>quad</dt><dd>R 18 is H, C 1-5 acyl, C 2-6 alkenyl, alkyl C 1-8, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, heteroaryl or phenyl, and where each of the heteroaryl and phenyl is optionally substituted with 1 to 5 substituents selected independently among the group consisting of alkoxy C 1-4, amino, alkyl C 1-4 -amino, alkynyl C 2-6, dialkyl C 2-8 -amino, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4 and hydroxyl; and</dd></dl>

<dl><dt>quad</dt><dd>R_ {10} -R_ {13} are selected independently among the group consisting of acyl C 1-5, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C_ {1-4}, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, hydroxyl and nitro; or two adjacent R 10 -R 11 groups together with Ar1 form a cycloalkyl, cycloalkenyl or heterocyclic of 5, 6 or 7 members where the group of 5, 6 or 7 is optionally substituted with halogen.</dd></dl>

The present invention also includes diastereomers, as well as optical isomers, for example mixtures of enantiomers including racemic mixtures, as well as enantiomers and individual diastereomers, which arise as a result of the structural asymmetry in certain compounds of the invention. The separation of individual isomers or selective synthesis of the individual isomers is performed by application of various methods that are well known to specialists in the technique.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 001267 include the following compounds according to Formula (I) (denominated in this document Group A1): [6- (4-Benzenesulfonyl-piperidin-1-yl) -5-nitro-pyrimidin-4-yl] - (4-methanesulfonylphenyl) -amine; Ethyl acid ester {4- [6- (4-methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperazin-1-yl} -acetic acid; (2-Fluoro-phenyl) - {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; Ethyl acid ester 1- [6- (4-imidazol-1-yl-phenoxy) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5-nitro-6- (4- [1,2,4] triazol-1-yl-phenoxy) -pyrimidin-4-yl] -piperidine-4-carboxylic acid, {6- [4- (4-Fluoro-phenoxy) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; {6- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; {6- [4- (3-Cyclopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; (4-Methanesulfonylphenyl) - (5-nitro-6- {4- (3- [3-trifluoromethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} -pyrimidin- 4-yl) -amine; {6- [4- (3-Ethyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (2-fluoro-phenyl) -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin- 4-yl} -amine; {6- [4- (3-Ethyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (2-fluoro-4- methanesulfonyl-phenyl) -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (3-propyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; {6- [4- (3-Cyclopropylmethyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (pyridin-4-yloxy) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (pyrimidin-2-yloxy) -piperidin-1-yl] -pyrimidin-4-yl} -amine; Ethyl acid ester 1- [6- (4-carbamoylmethyl-phenoxy) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- {6- [4- (1,3-Dioxo-1,3-dihydro-isoindol-2-yl) -phenoxy] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Ethyl acid ester 4 '- [4- (2-Methoxycarbonylacetyl) phenoxy] -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; {6- [4- (2-Methoxy-phenylsulfanyl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4- [1,2,4] triazol-1-yl-phenyl) -amine; 4'- Ethyl acid ester (2-amino-4-ethanesulfonyl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-carboxylic acid; Ethyl acid ester 4 '- (4-imidazol-1-yl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; (4-Methoxy-2- {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yloxy} -phenyl) -phenyl-methanone; 4- {4- [6- (4-Cyclopropylmethoxymethyl-piperidin-1-yl) -5-nitro-pyrimidin-4-yloxy] -phenyl} -butan-2-one; 4- {4- [5-Nitro-6- (4-propoxymethyl-piperidin-1-yl) -pyrimidin-4-yloxy] -phenyl} -butan-2-one; 4- {4- [6- (4-Butoxymethyl-piperidin-1-yl) -5-nitro-pyrimidin-4-yloxy] -phenyl} -butan-2-one; 4- {4- [6- (4-Isobutoxymethyl-piperidin-1-yl) -5-nitro-pyrimidin-4-yloxy] -phenyl} -butan-2-one; {1- [6- (Benzo [1,3] dioxol-5-ylamino) -5-nitro-pyrimidin-4-yl] -piperidin-4-yl} - (4-fluoro-phenyl) -methanone; (2,3-Difluoro-phenyl) - {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (2,4-Difluoro-phenyl) - {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; Ethyl acid ester 1- {2-nitro-3- [4- (3-oxo-butyl) -phenoxy] -phenyl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (4-Acetyl-phenoxy) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 3'-nitro-2 '- [4- (3-oxo-butyl) -phenoxy] -3,4,5,6-tetrahydro-2H- [1,4'] bipyridinyl-4-carboxylic acid; 4- (4- {5-Nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yloxy} -phenyl) -butan-2-one; 4- (4- {5-Nitro-6- [4- (2-trifluoromethyl-phenoxy) -piperidin-1-yl] -pyrimidin-4-yloxy} -phenyl) -butan-2-one; 4- (4- {6- [4- (3-Methyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yloxy} -phenyl) -butan-2-one; 4- (2,4-Difluoro-phenoxy) -5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidine; 4- (4- {6- [4- (4-Fluoro-benzoyl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yloxy} -phenyl) -butan-2-one; 4- (4-Methanesulfonyl-phenoxy) -5-nitro-6- [4- (pyridin-2-ylsulfanyl) -cyclohexyl] -pyrimidine; 4- (4-Methanesulfonyl-phenoxy) -5-nitro-6- [4- (pyridin-4-ylsulfanyl) -cyclohexyl] -pyrimidine; 4- (4-Methanesulfonyl-phenoxy) -5-nitro-6- (4-phenylsulfanyl-cyclohexyl) -pyrimidine; Ethyl acid ester 1- {6 - [(benzo [1,3] dioxol-5-ylmethyl) -amino] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- {6- [4- (1,1-dioxo-1 [lambda] 6 -thiomorpholin-4-ylmethyl) -phenylamino] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (4-Dimethyl-sulfamoyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (3-Methoxy-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (2-Methoxy-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (4-Methanesulfonyl-phenoxy) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- {6- [4- (2-Methoxycarbonyl-acetyl) -phenoxy] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (2-Amino-4-ethanesulfonyl-phenoxy) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (2,5-Dimethoxy-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; (4- {5-Nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-ylamino} -phenyl) -phenyl-methanone; Ethyl acid ester 1- [6- (4-Cyclohexyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5-nitro-6- (4- [1,2,4] triazol-1-yl-phenylamino) -pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5-nitro-6- (4-trifluoromethanesulfonyl-phenylamino) -pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5-nitro-6- (4- [1,2,3] thiadiazol-4-yl-phenylamino) -pyrimidin-4-yl] -piperidine-4-carboxylic acid; [6- (4-Ethoxymethyl-piperidin-1-yl) -5-nitro-pyrimidin-4-yl] - (4-methanesulfonyl-phenyl) -amine; [5-Nitro-6- (4-propyl-piperidin-1-yl) -pyrimidin-4-yl] - (4- [1,2,4] triazol-1-yl-phenyl) -amine; {5-Nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} - (4- [1,2,4] triazol-1-yl-phenyl) -amine; (2-Fluoro-phenyl) - {6- [4- (3-methyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - {6- [4- (3-methyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} -amine; {6- [4- (3-Methyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4- [1,2 , 4] triazol-1-yl-phenyl) -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (3-Methoxy-phenyl) - {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; Ethyl acid ester 1- [6- (benzo [1,3] dioxol-5-ylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (2-Fluoro-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (3-Fluoro-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (3,4-dihydro-2H-benzo [b] [1,4] dioxepin-7-ylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- {6- [4- (morpholine-4-sulfonyl) -phenylamino] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Benzo [1,3] dioxol-5-yl- [5-nitro-6- (4-propyl-piperidin-1-yl) -pyrimidin-4-yl] -amine; (4-Fluoro-phenyl) - {1- [5-nitro-6- (4- [1,2,4] triazol-1-yl-phenylamino) -pyrimidin-4-yl] -piperidin-4-yl} -metanone; [5-Nitro-6- (4-phenylsulfanyl-piperidin-1-yl) pyrimidin-4-yl] - (4- [1,2,4] triazol-1-yl-phenyl) -amine; (4-Fluoro-phenyl) - {1- [6- (2-fluoro-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidin-4-yl} -methanone; (4-Methanesulfonyl-phenyl) - [5-nitro-6- (4-phenylsulfanyl-piperidin-1-yl) -pyrimidin-4-yl] -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (pyridin-2-yloxy) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (pyridin-4-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - {6- [4- (4-methoxy-phenylsulfanyl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} -amine; (2-Methoxy-phenyl) - {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - (5-nitro-6- {4- [3- (3-trifluoromethyl-phenyl) - [1,2,4] oxadiazol-5-yl] -piperidin-1-yl} - pyrimidin-4-yl) -amine; {6- [4- (3-Ethyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; (6- {4- [5- (4-Fluoro-phenyl) - [1,3,4] oxadiazol-2-yl] -piperidin-1-yl} -5-nitro-pyrimidin-4-yl) - ( 4-methanesulfonyl-phenyl) -amine; (4-Methanesulfonyl-phenyl) - [5-nitro-6- (4-pyridin-2-ylmethyl-piperidin-1-yl) -pyrimidin-4-yl] -amine; Ethyl acid ester 1- {6- [4- (2,5-Dioxo-imidazolidin-4-yl) -phenoxy] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5-nitro-6- (4-propionyl-phenoxy) -pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5-nitro-6- (4- [1,2,3] thiadiazol-4-yl-phenoxy) -pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- [4- (3-Oxo-butyl) -phenoxy] -5- (2,2,2-trifluoro-acetylamino) -pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- [6- (2-Benzoyl-5-methoxy-phenoxy) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 3'-nitro-4 '- [4- (3-oxo-butyl) -phenoxy] -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 1- [6- (4-dimethylsulfamoyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- {6- [4- (4,5-Dichloro-imidazol-1-yl) -phenylamino] -5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid; Benzo [1,3] dioxol-5-yl- {5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (4-Fluoro-phenyl) - {1- [6- (2-fluoro-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidin-4-yl} -methanone; (2,5-Difluoro-phenyl) - (5-nitro-6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; Ethyl acid ester 1- {5-nitro-6- [4- (3-oxo-butyl) -phenoxy] -pyrimidin-4-yl} -piperidine-4-carboxylic acid; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methanesulfonyl-phenoxy) -pyrimidine-5-carbonitrile; 5- [1,3] Dioxolan-2-yl-4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methanesulfonyl -phenoxy) -pyrimidine; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methanesulfonyl-phenoxy) -pyrimidine-5-carbaldehyde; 5- [1,3] Dioxolan-2-yl-4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4- [ 1,2,3] thiadiazol-4-yl-phenoxy) -pyrimidine; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4- [1,2,3] thiadiazol-4-yl-phenoxy ) -pyrimidine-5-carbaldehyde; Acid 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4- [1,2,3] thiadiazol-4-yl-phenoxy ) -pyrimidine-5-carboxylic; [4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4- [1,2,3] thiadiazol-4-yl- phenoxy) -pyrimidin-5-yl] -methanol; [4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4- [1,2,3] thiadiazol-4-yl- phenoxy) -pyrimidin-5-ylmethyl] -dimethyl-amine; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methylsulfanyl-phenylamino) -pyrimidine-5-carbonitrile; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methanesulfinyl-phenylamino) -pyrimidine-5-carbonitrile; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [4- (4-trifluoromethoxy-phenoxy) -piperidin-1-yl] -pyrimidin-4-yl} -amine; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methanesulfonyl-phenylamino) -pyrimidine-5-carbonitrile; 1- {1- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidin-4-yl} -hexan-1-one; 1- {1- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yl] -piperidin-4-yl} -hexan-1-one; {6- [4- (3-tert-Butyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl- (2-fluoro-4 -methanesulfonyl-phenyl) -amine; {6- [4- (3-tert-Butyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl- phenyl) -amine; [6- (4-Benzofuran-2-yl-piperidin-1-yl) -5-nitro-pyrimidin-4-yl] - (4-methanesulfonyl-phenyl) -amine and 5-Nitro-4- (5-phenyl- [1,3,4] oxadiazol-2-ylsulfanyl) -6- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -pyrimidine.

In International Application Nº PCT / US2004 / 005555 (published as document WO 04/076413) is describe examples of agonists of GPR119. In the request International No. PCT / US2004 / 005555 describes itself as an agonist of GPR119, a compound of Formula (II):

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>25</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

in the what:

<dl><dt>quad</dt><dd>A and B are independently alkylene C_ {1-3} optionally substituted with 1 to 4 groups methyl;</dd></dl>

<dl><dt>quad</dt><dd>U is N or CR1;</dd></dl>

<dl><dt>quad</dt><dd>D is O, S, S (O), S (O) 2, CR 2 R 3 or NR 2;</dd></dl>

<dl><dt>quad</dt><dd>V is selected from the group consisting of C 1-3 alkylene, ethylene and heteroalkylene C 1-2 optionally substituted with 1 to 4 substituents selected from the group consisting of alkyl C 1-3, C 1-4 alkoxy, carboxy, cyano, C 1-3 haloalkyl and halogen; or V is absent;</dd></dl>

<dl><dt>quad</dt><dd>W is -S (O) 2 NR 4 -, NR 4 -, -O-, -S-, -S (O) -, -S (O) 2 -; or W he is absent;</dd></dl>

<dl><dt>quad</dt><dd>X is N or CR5;</dd></dl>

<dl><dt>quad</dt><dd>Y is N or CR6;</dd></dl>

<dl><dt>quad</dt><dd>Z is selected from the group consisting of H, C 1-5 acyl, C 1-5 acyloxy, C 1-4 alkoxy, alkyl C 1-6, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, diacil C_ {4-8} -amino, dialkyl C 1-4 -carboxamide, dialkyl C 1-4 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, dialquil C 1-4 -sulfonylamino, formyl, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -carboxamide, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, halogen, aryl, heteroaryl, hydroxy, hydroxylamino, nitro and tetrazolyl; or</dd></dl>

<dl><dt>quad</dt><dd>Z is a group of Formula (IIA):</dd></dl>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>26</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>R 7 is H, C 1-6 alkyl or C 3-6 cycloalkyl; and</dd></dl>

<dl><dt>quad</dt><dd>R 8 is H, nitro or cyano;</dd></dl>

<dl><dt>quad</dt><dd>Ar1 is aryl or heteroaryl optionally substituted with R 9, R 10, R 11, R 12 and R 13;</dd></dl>

<dl><dt>quad</dt><dd>R_ {1}, R_ {5} and R_ {6} are selected independently among the group consisting of H, acyloxy C 1-5, C 2-6 alkenyl, C 1-4 alkoxy, C 1-8 alkyl, C 1-4 alkylcarboxamide, C 2-6 alkynyl, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, alkyl C 1-4 -amino, dialkyl C 2-8 -amino, carboxamide, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -sulfonamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, hydroxyl and nitro;</dd></dl>

<dl><dt>quad</dt><dd>R2 is selected from the group consisting of H, C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, haloalkoxy C 1-4, C 1-4 haloalkyl, halogen, heteroaryl, hydroxyl and phenyl; and where the rent C 1-8, heteroaryl and phenyl are optionally substituted with 1 to 5 substituents selected from the group consisting of C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkylthio C 1-4, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, cycloalkyl C_ {3-6} -heteroalkylene C_ {1-3}, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 1-4 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heterocyclic, hydroxy, hydroxylamino and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is -Ar_ {2} -Ar_ {3} where Ar_ {2} and Ar 3 are independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group that consists of H, C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, alkyl C 1-8, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, C 2-6 dialkylcarboxamide, C 1-4 haloalkoxy, haloalkyl C 1-4, halogen, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is a group of Formula (IIB):</dd></dl>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>27</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>R 14 is C 1-8 alkyl or C 3-6 cycloalkyl; and R 15 is F, Cl, Br or CN; or R2 is a group of Formula (IIC):</dd></dl>

<figref>28</figref>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>G is C = O, CR 16 R 17, O, S, S (O), S (O) 2; where R_ {16} and R_ {17} are independently H or C 1-8 alkyl; and</dd></dl>

<dl><dt>quad</dt><dd>Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group that consists of C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, alkyl C 1-8, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, C 2-6 dialkylcarboxamide, C 1-4 dialkyl thiocarboxamide, C 2-6 dialkyl sulfonamide, C 1-4 alkyl -thioureyl, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4, haloalkyl C 1-4 -thio, halogen, heteroaryl, hydroxy, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>R 3 is H, C 1-8 alkyl, C 1-4 alkoxy or hydroxy;</dd></dl>

<dl><dt>quad</dt><dd>R 4 is H or alkyl C 1-8;</dd></dl>

<dl><dt>quad</dt><dd>R_ {9} is selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, arylsulfonyl, carbo-alkoxy C 1-6, carboxamide, carboxy, cyano, cycloalkyl C_ {3-6}, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C_ {1-4}, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heterocyclic, heterocyclic sulfonyl, heteroaryl, hydroxyl, nitro, C 4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide and sulfonic acid, and where acyl C 1-5, C 1-4 alkoxy, alkyl C 1-8, alkyl C 1-4 -sulfonamide, alkylsulfonyl, arylsulfonyl, heteroaryl, phenoxy and phenyl are optionally substituted with 1 to 5 substituents selected independently among the group consisting of acyl C 1-5, C 1-5 acyloxy, C 2-6 alkynyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heteroaryl, heterocyclic, hydroxyl, nitro and phenyl; or</dd></dl>

<dl><dt>quad</dt><dd>R_ {9} is a group of Formula (IID):</dd></dl>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>29</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>"p" and "r" are independently 0, 1, 2 or 3; and</dd></dl>

<dl><dt>quad</dt><dd>R 18 is H, C 1-5 acyl, C 2-6 alkenyl, alkyl C 1-8, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, heteroaryl or phenyl, and where the heteroaryl or phenyl is optionally substituted with 1 to 5 substituents selected independently among the group consisting of alkoxy C 1-4, C 1-8 alkyl, amino, C 1-4 alkyl amino, alkynyl C 2-6, dialkyl C 2-8 -amino, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4 and hydroxyl; and</dd></dl>

<dl><dt>quad</dt><dd>R_ {10} -R_ {13} are selected independently among the group consisting of acyl C 1-5, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C_ {1-4}, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>two groups R 10 -R 11 adjacent form a cycloalkyl, cycloalkenyl or heterocyclic of 5, 6 or 7 with Ar1 where the group of 5, 6 or 7 members is optionally substituted with halogen.</dd></dl>

The present invention also includes diastereomers, as well as optical isomers, for example mixtures of enantiomers including racemic mixtures, as well as enantiomers and individual diastereomers, which arise as a result of the structural asymmetry in certain compounds of the invention. The separation of individual isomers or selective synthesis of the individual isomers is performed by application of various methods that are well known to specialists in the technique.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 005555 include the following compounds according to Formula (II) (referred to herein as Group B1): Ethyl acid ester 6 '- [4- (2-Methoxycarbonyl-acetyl) -phenoxy] -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; 1- [4- (4-Acetyl-3'-nitro-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-6'-yloxy) -phenyl] -ethanone; Ethyl acid ester 6 '- [4- (4-hydroxy-benzenesulfonyl) -phenoxy] -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (4-imidazol-1-yl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (4-benzoyl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- [4- (2-Methoxy-ethyl) -phenoxy] -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (4-cyclopentyl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (4'-cyano-biphenyl-4-yloxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 3'-nitro-6 '- (4-sulfo-phenoxy) -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 3'-nitro-6 '- (4-pyrrole-1-yl-phenoxy) -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (4-carbamoyl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 3'-nitro-6 '- (4- [1,2,4] triazol-1-yl-phenoxy) -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid ; Ethyl acid ester 6 '- (2-amino-4-ethanesulfonyl-phenoxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid, Ethyl acid ester 3'-nitro-6 '- [4- (4-oxo-cyclohexyl) -phenoxy] -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (4'-methoxy-biphenyl-4-yloxy) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 3'-nitro-6 '- (4- [1,2,3] thiadiazol-4-yl-phenoxy) -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid ; Ethyl acid ester 6 '- [4- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -phenoxy] -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-carboxylic; Ethyl acid ester 6 '- [4- (2,5-dioxo-imidazolidin-4-yl) -phenoxy] -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4- carboxylic; Ethyl acid ester 3'-nitro-6 '- [4- (3-oxo-butyl) -phenoxy] -3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Acid methyl ester 3- [4- (3'-nitro-4-propyl-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-6'-yloxy) -phenyl] -3-oxo-propionic; 4- [4- (3'-Nitro-4-propyl-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-6'-yloxy) -phenyl] -butan-2-one; 4- {4- [3'-Nitro-4- (pyridin-2-ylsulfanyl) -3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-6'-yloxy] -phenyl} - butan-2-one; and 3'-Nitro-4- (pyridin-2-ylsulfanyl) -6 '- (4- [1,2,4] triazol-1-yl-phenoxy) -3,4,5,6-tetrahydro-2H- [ 1,2 '] bipyridinyl.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 005555 include the following compounds according to Formula (II) (denominated in this document Group B2): Ethyl acid ester 1- [5- (4-Benzoyl-phenoxy) -2-nitro-phenyl] -piperidine-4-carboxylic; Ethyl acid ester 1- {5- [4- (2-Methoxycarbonyl-acetyl) -phenoxy] -2-nitro-phenyl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- [5- (2-Amino-4-ethanesulfonyl-phenoxy) -2-nitro-phenyl] -piperidine-4-carboxylic acid; Ethyl acid ester 1- {2-nitro-5- [4- (3-oxo-butyl) -phenoxy] -phenyl} -piperidine-4-carboxylic acid; 4- {4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -butan-2-one; 1- {4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -ethanone; Acid methyl ester 3- {4- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -3-oxo-propionic; 5-Etanosulfonyl-2- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenylamine; 4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -phenyl-methanone; Ethyl acid ester 1- {4-nitro-3- [4- (3-oxo-butyl) -phenoxy] -phenyl} -piperidine-4-carboxylic acid; 4- {4- [2-Nitro-5- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -butan-2-one; Ethyl acid ester 1- [3- (4-Benzoyl-phenoxy) -4-nitro-phenyl] -piperidine-4-carboxylic acid; {4- [2-Nitro-5- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -phenyl-methanone; Ethyl acid ester 1- {5- [4- (2-Carboxy-ethyl) -phenoxy] -2-nitro-phenyl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- {5- [4- (2-Carboxy-2-oxo-ethyl) -phenoxy] -2-nitro-phenyl} -piperidine-4-carboxylic acid; Ethyl acid ester 1- [2-Nitro-5- (4-vinyl-phenoxy) -phenyl] -piperidine-4-carboxylic acid; Acid 3- {4- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -propionic; Acid 3- {4- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -2-oxo-propionic; 1- [2-Nitro-5- (4-vinyl-phenoxy) -phenyl] -4-propyl-piperidine; 1- {4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -butan-1-one; 1- {4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -pentan-1-one; 1- {4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -hexan-1-one; 4- {4- [3- (4-Methoxymethyl-piperidin-1-yl) -4-nitro-phenoxy] -phenyl} -butan-2-one; 1- {4- [3- (4-Methoxymethyl-piperidin-1-yl) -4-nitro-phenoxy] -phenyl} -ethanone; {4- [3- (4-Methoxymethyl-piperidin-1-yl) -4-nitro-phenoxy] -phenyl} -phenyl-methanone; 2- (3-Methyl- [1,2,4] oxadiazol-5-yl) -1- {4- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -ethanone; 4- (4- {3- [4- (3-Methyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -4-nitro-phenoxy} -phenyl) -butan-2 -one; 4- (4- {4-Nitro-3- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -phenoxy} -phenyl) -butan-2-one; 2- {1- [2-Nitro-5- (4- [1,2,4] triazol-1-yl-phenoxy) -phenyl] -piperidin-4-ylsulfanyl} -pyridine; 2-Methyl-5- {4- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -phenyl} -2H-pyrazol-3-ol; 2- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -5-trifluoromethyl-pyridine; 5-Bromo-2- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenoxy] -pyridine; 1- (4- {4-Nitro-3- [4- (pyridin-2-ylsulfanyl) -piperidin-1-yl] -phenoxy} -phenyl) -ethanone; 2- {1- [5- (4-Methanesulfonyl-phenoxy) -2-nitro-phenyl] -piperidin-4-ylsulfanyl} -pyridine; 1- {5- [4- (5-Methyl- [1,3,4] oxadiazol-2-yl) -phenoxy] -2-nitro-phenyl} -4-propyl-piperidine; 1- {5- [3- (3-Methyl- [1,2,4] oxadiazol-5-yl) -phenoxy] -2-nitro-phenyl} -4-propylpiperidine.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 005555 include the following compound according to Formula (II) (referred to in this document as Group B3): 5-Bromo-1- [4-nitro-3- (4-propyl-piperidin-1-yl) -phenyl] -1H-pyridin-2-one.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 005555 include the following compounds according to Formula (II) (referred to herein as Group B4): Ethyl acid ester 6'-benzenesulfonylamino-3'-nitro-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (benzenesulfonyl-methyl-amino) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (benzenesulfonyl-butyl-amino) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (5-ethanesulfonyl-2-hydroxy-phenylamino) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; Ethyl acid ester 6 '- (2-Bromo-4-trifluoromethyl-benzenesulfonylamino) -3'-nitro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-carboxylic acid; {4- [3'-Nitro-4- (pyridin-2-ylsulfanyl) -3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-6'-ylamino] -phenyl} -phenyl- methanone and [3'-Nitro-4- (pyridin-2-ylsulfanyl) -3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-6'-yl] - (4- [1,2, 4] triazol-1-yl-phenyl) -amine.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 005555 include the following compounds according to Formula (II) (referred to herein as Group B5): Ethyl acid ester 1- [5- (4-Benzoyl-phenylamino) -2-nitro-phenyl] -piperidine-4-carboxylic and {4- [4-Nitro-3- (4-propyl-piperidin-1-yl) -phenylamino] -phenyl} -phenyl-methanone.

<pre listing-type="other">\ newpage</pre>

In International Application Nº PCT / US2004 / 022327 (published as document WO 05/007647) is describe examples of agonists of GPR119. In the request International No. PCT / US2004 / 022327 describes itself as an agonist of GPR119, a compound of Formula (III):

<figref>30</figref>

in the what:

<dl><dt>quad</dt><dd>each of A and B is independently alkylene C_ {1-3} optionally substituted with 1 to 4 substituents selected from the group consisting of alkyl C 1-3, C 1-4 alkoxy, carboxy, cyano, C 1-3 haloalkyl and halogen;</dd></dl>

<dl><dt>quad</dt><dd>D is O, S, S (O), S (O) 2, CR 2 R 3 or N-R 2;</dd></dl>

<dl><dt>quad</dt><dd>E is N, C or CR4;</dd></dl>

<dl><dt>quad</dt><dd>\ underline {\ text {- - -}} is a simple link when E is N or CR_ {4}, or a double bond when E is C;</dd></dl>

<dl><dt>quad</dt><dd>V_ {1} is selected from the group consisting of C 1-3 alkylene, ethylene and heteroalkylene C 1-2 optionally substituted with 1 to 4 substituents selected from the group consisting of alkyl C 1-3, C 1-4 alkoxy, carboxy, cyano, C 1-3 haloalkyl and halogen; or V_ {1} is a link;</dd></dl>

<dl><dt>quad</dt><dd>V 2 is C 3-6 cycloalkylene or C_ {1-3} alkylene where each of them is optionally substituted with 1 to 4 substituents selected between the group consisting of C 1-3 alkyl, C 1-4 alkoxy, carboxy, cyano, haloalkyl C 1-3 and halogen; or V_ {2} is a link;</dd></dl>

<dl><dt>quad</dt><dd>W is NR_5, O, S, S (O) or S (O) 2; or W is absent;</dd></dl>

<dl><dt>quad</dt><dd>Q is NR_6, O, S, S (O) or S (O) 2;</dd></dl>

<dl><dt>quad</dt><dd>X is N or CR7;</dd></dl>

<dl><dt>quad</dt><dd>Y is N or CR 8;</dd></dl>

<dl><dt>quad</dt><dd>Z is selected from the group consisting of acyl C 1-5, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, alkyl C_ {1-2} -amino, dialkyl C 2-4 -amino, carbamimidoyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, diacyl C_ {4-8} -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, dialkyl C 2-6 -sulfonylamino, formyl, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -carboxamide, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, halogen, aryl, heterocyclic, heteroaryl, hydroxyl, hydroxycarbamimidoyl, hydroxylamino, nitro and tetrazolyl, where each of the alkyl C_ {1-8}, C 3-7 cycloalkyl and heterocyclic is optionally substituted with 1, 2, 3 or 4 groups selected from the group consisting of acyl C 1-5, C 1-5 acyloxy, alkoxy C 1-4, C 1-7 alkyl, C 1-4 alkylcarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, alkyl C_ {1-2} -amino, dialkyl C 2-4 -amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, formyl, C 1-4 haloalkoxy, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkylthio, halogen, hydroxyl, hydroxylamino and nitro, and wherein said alkyl C 1-7 is optionally substituted with amino; or</dd></dl>

<dl><dt>quad</dt><dd>Z is a group of Formula (IIIA):</dd></dl>

<figref>31</figref>

in the what:

<dl><dt>quad</dt><dd>R 9 is H, C 1-8 alkyl or C 3-7 cycloalkyl; and</dd></dl>

<dl><dt>quad</dt><dd>R 10 is H, nitro or nitrile;</dd></dl>

<dl><dt>quad</dt><dd>Ar1 is aryl or heteroaryl, each optionally substituted with R 11, R 12, R 13, R 14 and R 15; where R_ {11} is selected from the group consisting in C 1-5 acyl, acyl C 1-6 -sulfonamide, acyloxy C 1-5, C 2-6 alkenyl, C 1-4 alkoxy, C 1-8 alkyl, C 1-4 alkyl amino, alkyl C 1-6 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, arylsulfonyl, carbamimidoyl, carbo-alkoxy C 1-6, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, cycloalkyl C 3-7 -oxy, dialkyl C 2-6 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, guanidinyl, halogen, C 1-4 haloalkoxy, C 1-4 haloalkyl, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heterocyclic, heterocyclic-oxy, heterocyclic sulfonyl, heterocyclic carbonyl, heteroaryl, heteroarylcarbonyl, hydroxyl, nitro, C 4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide, sulfonic acid and thiol, and where the acyl C_ {1-5}, acyl C 1-6 -sulfonamide, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-6 sulfonamide, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, arylsulfonyl, carbamimidoyl, dialkyl C 2-6 -amino, heterocyclic, heterocyclic-carbonyl, heteroaryl, phenoxy and phenyl are optionally substituted with 1 to 5 substituents independently selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-7 alkyl, C 1-4 alkyl amino, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C 3-7 cycloalkyl -oxy, dialkyl C 2-6 -amino, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heteroaryl, heterocyclic, hydroxyl, nitro, phenyl and phosphonooxy, where each one of said C 1-7 alkyl and alkyl C 1-4 -carboxamide is optionally substituted with 1 to 5 substituents selected among the group consisting of C 1-4 alkoxy e hydroxy; or</dd></dl>

<dl><dt>quad</dt><dd>R 11 is a group of Formula (IIIB):</dd></dl>

<figref>32</figref>

in the what:

<dl><dt>quad</dt><dd>each of "p" and "r" is independently 0, 1, 2 or 3; and R 16 is H, acyl C 1-5, C 2-6 alkenyl, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C 2-6 dialkylcarboxamide, halogen, heteroaryl or phenyl, and where heteroaryl or phenyl is optionally substituted with 1 to 5 substituents selected independently among the group consisting of alkoxy C 1-4, amino, alkyl C 1-4 -amino, alkynyl C 2-6, dialquil C 2-8 -amino, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4 and hydroxyl; and</dd></dl>

<dl><dt>quad</dt><dd>each of R 12, R 13, R 14 and R 15 is independently selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>two adjacent groups selected from the group consisting of R 12, R 13, R 14 and R 15 together with the carbon atoms to which they are attached form a group 5, 6 or 7-membered cycloalkyl, cycloalkenyl or heterocyclic condensed with Ar_ {1}, where the group of 5, 6 or 7 members is optionally substituted with halogen;</dd></dl>

<dl><dt>quad</dt><dd>each of R_ {1}, R_ {7} and R_ {8} is selected independently among the group consisting of H, acyloxy C 1-5, C 2-6 alkenyl, C 1-4 alkoxy, C 1-8 alkyl, C 1-4 alkylcarboxamide, C 2-6 alkynyl, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, alkyl C 1-4 -amino, dialkyl C 2-8 -amino, carboxamide, cyano, C 3-7 cycloalkyl, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -sulfonamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C_ {1-4} -tio e hydroxyl;</dd></dl>

<dl><dt>quad</dt><dd>R2 is selected from the group consisting of C 1-8 alkyl, amino, aryl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, haloalkoxy C 1-4, C 1-4 haloalkyl, halogen, heteroaryl and hydroxyl; and where the rent C 1-8, aryl or heteroaryl is optionally substituted with 1 to 5 substituents selected from the group that consists of C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, alkyl C 1-8, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, cycloalkyl C_ {3-6} -heteroalkylene C_ {1-3}, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heterocyclic, hydroxy, hydroxylamino and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R_ {2} is Ar_ {2} -Ar_ {3} where each of Ar2 and Ar3 is independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of H, acyl C 1-5, C 1-5 acyloxy, C 1-4 alkoxy, C 1-8 alkyl, C 1-4 alkylcarboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, amino, alkyl C 1-4 -amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialquil C 2-8 -amino, dialkyl C 2-6 -carboxamide, haloalkoxy C 1-4, C 1-4 haloalkyl, halogen, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is a group of Formula (IIIC):</dd></dl>

<figref>33</figref>

in the what:

<dl><dt>quad</dt><dd>R 17 is H, C 1-8 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl or OR 19; and R 18 is F, Cl, Br, CN or NR 20 R 21; where R 19 is H, C 1-8 alkyl or cycloalkyl C_ {3-7}, and each of R_ {20} and R_ {21} is independently H, C 1-8 alkyl, C 3-7 cycloalkyl, aryl or heteroaryl; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is a group of Formula (IIID):</dd></dl>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>34</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

in the what:

<dl><dt>quad</dt><dd>G is:</dd></dl>

<dl><dt>i)</dt><dd>-C (O) -, -C (O) NR_ {23} -, -C (O) O-, -OC (O) NR_ {23} -, -NR 23 C (O) O-, -OC (O) -, -C (S) -, -C (S) NR_ {23} -, -C (S) O-, -OC (S) -, -CR_ {23} R_24 -, -O-, -S-, -S (O) -o -S (O) 2 - when D is CR 2 R 3, or</dd></dl>

<dl><dt>ii)</dt><dd>-CR_ {23} R_24 C (O) -, -C (O) -, -CR_ {23} R_24 C (O) NR_25 -, -C (O) NR_ {23} -, -C (O) O-, -C (S) -, -C (S) NR_ {23} -, -C (S) O-, -CR_ {23} R_24-, -S (O) 2-, or a link when D is NR2,</dd></dl>

<dl><dt>quad</dt><dd>where each of R_ {23}, R_ {24} and R_ {25} is independently H or C 1-8 alkyl; and R_ {22} is H, C 1-8 alkyl, alkynyl C 2-6, C 3-7 cycloalkyl, phenyl, heteroaryl or heterocyclic, each optionally substituted with 1 to 5 substituents selected from the group that consists of C 1-5 acyl, acyloxy C 1-5, C 2-6 alkenyl, C 1-4 alkoxy, C 1-7 alkyl, C 1-4 alkyl amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C_ {1-4} -thio, rent C_ {1-4} -tioureílo, alkylureílo C 1-4, amino, carbo-alkoxy C 1-6, carboxamide, carboxy, cyano, cycloalkyl C_ {3-7}, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heteroaryl, heterocyclic, hydroxyl, hydroxylamino, nitro, phenyl, phenoxy and sulfonic acid, where each of said alkyl C 1-7, heteroaryl, phenyl and phenoxy are optionally substituted with 1 to 5 substituents selected from the group consisting of C 1-5 acyl, acyloxy C 1-5, C 1-4 alkoxy, alkyl C 1-8, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C_ {1-4} -ureyl, Not me, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C 2-8 dialkyl-amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heterocyclic, hydroxy, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>R 3 is H, C 1-8 alkyl, C 1-4 alkoxy or hydroxy; and</dd></dl>

<dl><dt>quad</dt><dd>each of R4, R5 and R6 is independently H, C 1-8 alkyl or C 3-7 cycloalkyl, wherein said alkyl C 1-8 is optionally substituted with alkoxy C 1-4, C 3-7 cycloalkyl or heteroaryl.</dd></dl>

The present invention also includes diastereomers, as well as optical isomers, for example mixtures of enantiomers including racemic mixtures, as well as enantiomers and individual diastereomers, which arise as a result of the structural asymmetry in certain compounds of the invention. The separation of individual isomers or selective synthesis of the individual isomers is performed by application of various methods that are well known to specialists in the technique.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (denominated in this document Group C1): Ester tert-butyl acid 3- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxymethyl] -pyrrolidine-1-carboxylic acid, Tert-butyl acid ester 4- [5-Cyano-6- (6-methylsulfanyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [5-Cyano-6- (6-methanesulfonylpyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; [6- (1-Hexylpiperidin-4-yloxy) -5-nitro-pyrimidin-4-yl] - (4-methanesulfonyl-phenyl) -amine; [6- (1-Cyclopropylmethyl-piperidin-4-yloxy) -5-nitro-pyrimidin-4-yl] - (4-methane-sulfonyl-phenyl) -amine; Isopropyl acid ester 4- [6- (4-Methanesulfonyl-phenylamino-nitro-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2-Iso-propyl-5-methyl-cyclohexyl acid ester 4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; {4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidin-1-yl} -pyridin-3-yl-methanone; (2-Chloro-pyridin-3-yl) - {4- [6- (4-methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; {4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidin-1-yl} -pyridin-2-yl-methanone; (4-Methanesulfonyl-phenyl) - [6- (1-methanesulfonyl-piperidin-4-yloxy) -5-nitro-pyrimidin-4-yl] -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [1- (propane-1-sulfonyl) -piperidin-4-yloxy] -pyrimidin-4-yl} -amine; {6- [1- (Butane-1-sulfonyl) -piperidin-4-yloxy] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; (4-Methanesulfonyl-phenyl) - {5-nitro-6- [1- (thiophene-2-sulfonyl) -piperidin-4-yloxy] -pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - {6- [1- (1-methyl-1H-imidazol-4-sulfonyl) -piperidin-4-yloxy] -5-nitro-pyrimidin-4-yl} -amine; {6- [1- (2,4-Dimethyl-thiazol-5-sulfonyl) -piperidin-4-yloxy] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; Tert-butyl acid ester 4- [5-Cyano-6- (3-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, Tert-butyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [5-Cyano-6- (4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Methanesulfonyl-pyridin-3-ylamino) -5-nitro-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [5-Acetyl-6- (6-methanesulfonyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [5-amino-6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Ethyl acid ester 4- [5-Cyano-6- (4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isobutyl acid ester 4- [5-Cyano-6- (4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 4- (4-Methanesulfonyl-phenylamino) -6- [1- (tetrahydro-furan-2-carbonyl) -piperidin-4-yloxy] -pyrimidine-5-carbonitrile; 4- [1- (3,3-Dimethyl-2-oxo-butyl) -piperidin-4-yloxy] -6- (4-methanesulfonyl-phenylamino) -pyrimidine-5-carbonitrile; 4- (4-Methanesulfonyl-phenylamino) -6- [1- (pyridine-3-carbonyl) -piperidin-4-yloxy] -pyrimidine-5-carbonitrile; 4- (1-Formyl-piperidin-4-yloxy) -6- (4-methanesulfonyl-phenylamino) -pyrimidine-5-carbonitrile and 4- (4-Methanesulfonyl-phenylamino) -6- [1- (pyridine-2-carbonyl) -piperidin-4-yloxy] -pyrimidine-5-carbonitrile.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (denominated in this document Group C2): Ester tert-butyl acid 4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (4-Methanesulfonyl-phenyl) - [5-nitro-6- (piperidin-4-yloxy) -pyrimidin-4-yl] -amine; 1- {4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidin-1-yl} -3,3-dimethyl-butan-1-one; (4-Methanesulfonyl-phenyl) - [5-nitro-6- (1-pyridin-2-ylmethyl-piperidin-4-yloxy) -pyrimidin-4-yl] -amine; (4-Methanesulfonyl-phenyl) - [5-nitro-6- (1-pyridin-3-ylmethyl-piperidin-4-yloxy) -pyrimidin-4-yl] -amine; {6- [1- (3,3-Dimethyl-butyl) -piperidin-4-yloxy] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; (4-Methanesulfonyl-phenyl) - {6- [1- (3-methyl-butyl) -piperidin-4-yloxy] -5-nitro-pyrimidin-4-yl} -amine; (4-Methanesulfonyl-phenyl) - [5-nitro-6- (3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-yloxy) -pyrimidin-4-yl] -amine; Ethyl acid ester 4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1- {4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -piperidin-1-yl} -3,3-dimethyl-butan-2-one; {6- [1- (2-Ethoxy-ethyl) -piperidin-4-yloxy] -5-nitro-pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; Tert-butyl acid ester 4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxymethyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- {2- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -ethyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 3- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxy] -pyrrolidine-1-carboxylic acid and tert-butyl acid ester 3- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-yloxymethyl] -pyrrolidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (denominated in this document Group C3): Ester tert-butyl acid 4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; N- (4-Methanesulfonyl-phenyl) -5-nitro-N'-piperidin-4-yl-pyrimidine-4,6-diamine; 1- {4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-ylamino] -piperidin-1-yl} -ethanone and 1- {4- [6- (4-Methanesulfonyl-phenylamino) -5-nitro-pyrimidin-4-ylamino] -piperidin-1-yl} -2,2-dimethyl-propan-1-one.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (denominated in this document Group C4): Isopropyl ester of acid 4- [6- (4-Cyano-2-fluoro-phenylamino) -5-ethynyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-ethynyl-6- (2-fluoro-4- [1,2,4] triazol-1-yl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 4- {5-Ethynyl-6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy) -pyrimidin-4-ylamino} -3-fluoro-benzonitrile ; {5-Ethynyl-6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrimidin-4-yl} - (2-fluoro-4- methanesulfonyl-phenyl) -amine; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-methane-sulfonyl-ethyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-sulfamoyl-ethyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Fluoro-ethyl) -2-methyl-pyridin-3-ylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {2- [4-Fluoro-6- (2-isopropoxy-ethyl) -pyridin-3-ylamino] -3-methyl-pyridin-4-yloxy) -piperidine-1-carboxylic acid, Isopropyl acid ester 4- {6- [2,5-difluoro-4- (2- [1,2,4] triazol-1-yl-ethyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1 -carboxylic; Isopropyl acid ester 4- {5-ethynyl-6- [2-fluoro-4- (4-methoxy-pyridin-2-yl) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-propionylsulfamoyl-ethyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methanesulfonyl-ethyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; and isopropyl acid ester 4- {6- [2,3-Difluoro-4- (2-methanesulfonyl-ethyl) -phenylamino) -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid.

Specific examples of GPCR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (referred to herein as Group C5): Isobutyl ester of acid 4- [5-Acetyl-6- (6-methanesulfonyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1- [4- (1-Benzyl-azetidin-3-yloxy) -6- (6-methanesulfonyl-pyridin-3-ylamino) -pyrimidin-5-yl] -ethanone; Isopropyl acid ester 4- [5-Cyano-6- (6-propylamino-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (2-fluoro-4-isopropylamino-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (2-fluoro-4-propylamino-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (2-fluoro-4-propoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (6-propyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [4- (2-dimethylamino-ethylsulfanyl) -2-fluoro-phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [4- (2-dimethylamino-ethanesulfonyl) -2-fluoro-phenylamino] -3-oxy-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [2-fluoro-4- (4-methyl-piperazin-1-yl) -phenylamino] -pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [2-fluoro-4- (3-methyl-butylamino) -phenylamino] -pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (2-fluoro-4-morpholin-4-yl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [4- (2-dimethylamino-ethylamino) -2-fluoro-phenylamino] -pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (4-dimethylamino-2-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [2-fluoro-4- (2-pyrrolidin-1-yl-ethylamino) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyano-6- [2-fluoro-4- (2-morpholin-4-yl-ethylamino) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-iodo-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyano-6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-morpholin-4-yl-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-propoxy-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-propylamino-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methoxy-ethylamino) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4 - [(tetrahydro-furan-2-ylmethyl) -amino] -phenylamino} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methanesulfonyl-ethylamino) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4 - [(2-methanesulfonyl-ethyl) -methyl-amino] -phenylamino} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Bromo-2,5-difluoro-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Cyano-2-fluoro-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Cyano-2,5-difluoro-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-morpholin-4-yl-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Chloro-2-methyl-pyridin-3-ylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-methyl-6- (2-methyl-6-morpholin-4-yl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5- (4,5-dihydro-1H-imidazol-2-yl) -6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -5-methyl-pyrimidin- 4-yl} -amine; Isopropyl acid ester 4- [6- (2-Fluoro-4-propoxy-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methanesulfonyl-ethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methoxy-ethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-isopropoxy-ethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Chloro-4-methyl-pyridin-3-ylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5- (N-hydroxycarbamimidoyl) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-carbamimidoyl-6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (tetrahydro-furan-2-ylmethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-methyl-6- (4-methyl-6-morpholin-4-yl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Methoxy-ethoxy) -2-methyl-pyridin-3-ylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Methoxy-ethoxy) -4-methyl-pyridin-3-ylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-methoxy-ethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-isopropoxy-ethylsulfamoyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (N-hydroxycarbamimidoyl) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-carbamoyl-2,5-difluoro-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6 - [(2-Fluoro-4-methanesulfonyl-phenyl) - (2-methoxy-ethyl) -amino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-carbamimidoyl-2,5-difluoro-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4- (2-Ethoxy-ethoxy) -2-fluoro-phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (tetrahydro-pyran-4-yloxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-hydroxy-ethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl) -butan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -pentan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methyl-butan-1-one; Isopropyl acid ester 4- {6- [2-Fluoro-4- (pyridin-2-ylmethoxy) -phenylamino] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [2- (2-Fluoro-4-methanesulfonyl-phenylamino) -3-methyl-pyridin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Chloro-4-fluoro-pyridin-3-ylamino) -5-cyano-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; and isopropyl acid ester 4- [5-amino-6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compound according to Formula (III) (called in this document Group C6): Ester tert-butyl acid 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-methyl-pyrimidin-4-yl] -isopropyl-amino} -methyl) -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (denominated in this document Group C7): 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -6- [1- (3-methoxy-propyl) -piperidin-4-yloxy] -5-methyl-pyrimidine; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methoxy-propan-2-ol; Isopropyl acid ester 4- {6- [2-Fluoro-4- (5-isopropoxymethyl- [1,2,4] oxadiazol-3-yl) -phenoxy] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid ; Isopropyl acid ester 4- {6- [2-Fluoro-4- (5-methoxy-pyridin-2-yl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Cyclopropoxy-ethylamino) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (pyridine-2-carbonyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methanesulfonylamino-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Methoxy-6'-methyl-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-5'-yloxy) -5-methyl-pyrimidin-4-yloxy ] -piperidine-1-carboxylic; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -2- (4-trifluoromethoxy-phenoxy) -propan- 1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -2- (4-trifluoromethoxy-phenoxy) -ethanone; N- (4-Chloro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -acetamide; N- (3-Chloro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -acetamide; N- (3,5-Dichloro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} - acetamide; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -N- (4-trifluoromethylphenyl) -acetamide; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -N-phenyl-acetamide; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -N- (4-isopropyl-phenyl) -acetamide; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -N- (4-methoxy-phenyl) -acetamide; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -N- (3-trifluoromethyl-phenyl) -acetamide; Isopropyl acid ester 4- {6- [2-Fluoro-4- (3-methoxy-propane-1-sulfonyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Isopropoxy-ethyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-methyl-6- [2-methyl-6- (2-pyridin-2-yl-ethoxy) -pyridin-3-yloxy] -pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (thiophene-2-carbonyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {6 - [(2-isopropoxy-ethyl) -methyl-amino] -2-methyl-pyridin-3-yloxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Isopropoxy-ethanesulfonyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Hydroxy-ethanesulfonyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Amino-2-methyl-pyridin-3-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-6- [1- (3-methyl-butyl) -piperidin-4-yloxy] -pyrimidine; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-morpholin-4-yl-ethanone; 1- (3,4-Dichlorophenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy) -piperidin-1-yl} -ethanone; 1- (3-Chloro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-thiophene-3-yl-ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-phenyl-ethanone; 1- (2,4-Dimethoxyphenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-6- [1- (4-methyl-pentyl) -piperidin-4-yloxy] -pyrimidine; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-isopropoxy-propan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-isopropoxy-butan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-hydroxy-propan-1-one; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (5-pyridin-2-yl-thiophene -2-yl) -ethanone; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-6- [1- (5-methyl-hexyl) -piperidin-4-yloxy] -pyrimidine; Acid 3- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-oxo-propane-1-sulfonic acid; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-thiophene-2-yl-ethanone; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-6- (1-pentyl-piperidin-4-yloxy) -pyrimidine; 4- (1-Butyl-piperidin-4-yloxy) -6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidine; Acid 4- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -cyclohexanecarboxylic acid; 1- (4-Diethylamino-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl) -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (2-methyl-4-phenyl-furan -3-yl) -ethanone; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -6- (1-hexyl-piperidin-4-yloxy) -5-methylpyrimidine; Acid 4- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -butyric acid; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -pentan-2-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -hexan-2-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -hexan-2-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-methyl-pentan-2-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -5-methyl-hexane-2-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -6-methyl-heptan-2-one; Acid 5- {4- (6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-oxo-pentanoic acid; 5- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-oxo-pentanonitrile; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -2-pyridin-2-yl-ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-4-yl-ethanone; Acid 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-ylmethyl} -acrylic; 1- [1,4] Dioxan-2-yl-2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 1- (2,3-Dihydro- [1,4] dioxin-2-yl) -2- {4- (6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy ] -piperidin-1-yl} -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-p-tolyl-ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (4-methoxy-phenyl) -ethanone; 1- (2-Chloro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy} -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 3- (2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -acetyl) -benzonitrile; 1- (2,4-Dimethylphenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 1- (4-Chloro-3-methyl-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl } -ethanone; 1- (4-Difluoromethoxy-phenyl) -2- {4- [6- (2-fluoro-4-rnetanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 1- (2,3-Dihydro-benzo [1,4] dioxin-6-yl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4- yloxy] -piperidin-1-yl} -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (5-phenyl-thiophene-2-yl ) -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-thiophene-2-yl-ethanone; Ethyl acid ester {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy) -piperidin-1-yl} -acetic acid; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methoxy-propan-2-ol; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -6- [1- (4-methoxy-cyclohexyl) -piperidin-4-yloxy] -5-methyl-pyrimidine; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -hexan-1-one; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-isobutoxy-ethoxy) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4- (2-Cyclopropoxy-ethoxy) -2-fluoro-phenoxy] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4- (2-Ethoxy-ethoxy) -2-fluoro-phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (3-methoxy-propoxy) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-pyridin-2-yl-ethoxy) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (tetrahydro-pyran-4-yloxy) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4- (2-tert-Butoxy-ethoxy) -2-fluoro-phenoxy] -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-sulfo-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-trifluoromethoxy-phenoxy) -5-ethynyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- (2,5-Difluoro-4-trifluoromethoxy-phenoxy) -5-prop-1-inyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-ethynyl-6- (2-fluoro-4-methoxy-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-ethynyl-6- (6-methoxy-4-methyl-pyridin-3-yloxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, Isopropyl acid ester 4- {5-ethynyl-6- [6- (2-isopropoxy-ethyl) -2-methyl-pyridin-3-yloxy] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Cyano-2-fluoro-phenoxy) -5-ethynyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-ethynyl-6- (2-fluoro-4- [1,2,4] triazol-4-yl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, Isopropyl acid ester 4- [5-ethynyl-6- (2-fluoro-4- [1,2,4] triazol-1-yl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1- {4- [5-ethynyl-6- (2-fluoro-4- [1,2,4] triazol-1-yl-phenoxy) -pyrimidin-4-yloxy] -piperidin-1-yl} -3 -pyridin-2-yl-propan-1-one; 4- {5-ethynyl-6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrimidin-4-yloxy} -3-fluoro-benzonitrile ; 5-ethynyl-4- (2-fluoro-4-methanesulfonyl-phenoxy) -6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrimidine ; 4- [1- (3-ethyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -5-ethynyl-6- (2-fluoro-4-methanesulfonyl-phenoxy) -pyrimidine ; 4- [1- (3-ethyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidine ; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-6- [1- (3-methyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrimidine ; Isopropyl acid ester 4- [6- (2-Fluoro-4-methylenesulfonylamino-phenoxy) -5-methyl-pyrimidin-4-yl-oxy] -piperidine-1-carboxylic acid; Isopropyl acid ester<i>cis-</i>{4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -cyclohexyl} -carbamic; Isopropyl acid ester<i>trans-</i>{4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -cyclohexyl} -carbamic; N- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -cyclohexyl} -3-methyl-butyramide; N- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -cyclohexyl} -isobutyramide; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-methanesulfonyl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4-Fluoro-6- (2-methanesulfonyl-ethyl) -pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-cyclopropyl-6- [2,5-difluoro-4- (2-hydroxy-ethyl) -phenoxy] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (5-Cyclopropyl-6- {2,5-difluoro-4- [2- (4-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -pyrimidin-4-yloxy) -piperidine-1- carboxylic; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-morpholin-4-yl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4- [2- (4-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Fluoro-ethyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (1-hydroxy-cyclopropylmethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {2- [2,5-Difluoro-4- (2-methanesulfonyl-ethyl) -phenoxy] -3-methyl-pyridin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester (R) -4- (6- {2-fluoro-4- [2- (3-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine- 1-carboxylic; Isopropyl acid ester (S) -4- (6- {2-fluoro-4- [2- (3-methoxy-piperidin-1-yl) -ethyl] -phenoxy) -5-methyl-pyrimidin-4-yloxy-pipiperidine-1 -carboxylic, Isopropyl acid ester (R) -4- (5-ethynyl-6- {2-fluoro-4- [2- (2-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -pyrimidin-4-yloxy) -piperidine- 1-carboxylic; Isopropyl acid ester (S) -4- (2- {2-fluoro-4- [2- (2-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -3-methyl-pyridin-4-yloxy) -piperidine- 1-carboxylic; Isopropyl acid ester 4- {6- [4-Fluoro-6- (2-morpholin-4-yl-ethyl) -pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-ethynyl-6- [4-fluoro-6- (2-methanesulfonyl-ethyl) -pyridin-3-yloxy] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {2- [2,5-Difluoro-4- (2-isopropoxy-ethyl) -phenoxy] -3-methyl-pyridin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-propionylsulfamoyl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-sulfamoyl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-sulfamoyl-ethyl) -phenoxy] -5-ethynyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-difluoro-4- (2- [1,2,4] triazol-1-yl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1 -carboxylic; Isopropyl acid ester 4- {6- [2,3-Difluoro-4- (2-methanesulfonyl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (2- {2-Fluoro-4- [2- (6-methoxy-pyridin-2-yl) -ethyl] -phenoxy} -3-methyl-pyridin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4- [2- (3-methoxy-pyridin-2-yl) -ethyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3-Fluoro-1-oxy-pyridin-4-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5'-Methoxy-6-methyl- [2,2 '] bipyridinyl-5-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {5-ethynyl-6- [2-fluoro-4- (4-methoxy-pyridin-2-yl) -phenoxy] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (3-methoxy-pyridin-2-yl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2,5-difluoro-4- [2- (3-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1- carboxylic; and isopropyl acid ester 4- (6- {2,5-difluoro-4- [2- (3-methoxy-piperidin-1-yl) -ethyl] -phenoxy} -5-ethynyl-pyrimidin-4-yloxy) -piperidine-1- carboxylic.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (referred to herein as Group C8): isopropyl ester of acid 4- [6- (2-Fluoro-4-morpholin-4-yl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} - [6- (2-pyrrolidin-1-yl-ethyl) -pyridin-3-yl] -methanone; (6-Amino-pyridin-3-yl) - {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; Isopropyl acid ester 4- [5-ethyl-6- (2-fluoro-4-methanesulfonyl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Isopropoxy-ethyl-amino) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Hydroxy-ethylsulfanyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-methyl-6- (2-methyl-6-pentyl-pyridin-3-yloxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (3-fluoro-phenyl) -ethanone; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-6- [1- (2-pyridin-3-yl-ethyl) -piperidin-4-yloxy] -pyrimidine; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (4-trifluoromethoxyphenyl) -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-2-yl-ethanone; Isopropyl acid ester 4- {6- [6- (2-Methoxy-ethanesulfonyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; 4- (2-Fluoro-4-methanesulfonyl-phenoxy) -6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -5-methylpyrimidine; Isopropyl acid ester 4- (6- {2-Fluoro-4 - [(2-hydroxy-ethylcarbamoyl) -methyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Iodo-pyridin-2-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4- [N- (2-isopropoxyethyl) -carbamimidoyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Carboxy-2-fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 4- (4-Bromo-2-fluoro-phenoxy) -6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -5-methyl-pyrimidine ; Isopropyl acid ester 4- [6- (5-Methanesulfonyl-pyridin-2-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Hydroxy-ethylamino) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Cyclopropyl-6- (2-fluoro-4-methanesulfonyl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Methanesulfonyl-ethylamino) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Acid 4- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-oxo-butyric acid; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (3-trifluoromethyl-phenyl) -ethanone; Isopropyl acid ester 4- {6- [6- (2-Methoxy-ethylsulfanyl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; 1- (2,5-Dimethoxy-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} - ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-2-yl-ethanone; Isopropyl acid ester 4- [6- (6-Chloro-2-methyl-pyridin-3-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (4-fluoro-phenyl) -ethanone; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (4-trifluoromethylphenyl) -ethanone; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3,3-dimethyl-butan-2-one; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-3-yl-ethanone; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -butan-2-one; Isopropyl acid ester 4- (6- {2-Fluoro-4 - [(2-iso-propoxy-ethylcarbamoyl) -methyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; 2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1- (4-methanesulfonyl-phenyl) -ethanone; 1- (4-Chloro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; 4- (2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -acetyl) -benzonitrile; 1- (3,4-Difluoro-phenyl) -2- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} - ethanone; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-isopropoxy-ethylcarbamoyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -butan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -pentan-1-one; Isopropyl acid ester 4- [6- (2,4-Difluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methyl-butan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-methyl-pentan-1-one; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -5-methyl-hexane-1-one; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methoxy-ethylcarbamoyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Bromo-2-fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (methoxy-methyl-carbamoyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; 1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methoxy-propan-1-one; Isopropyl acid ester 4- [6- (4-Cyano-2-fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5- (5-Aminomethyl-4,5-dihydro-oxazol-2-yl) -6- (2-fluoro-4-methanesulfonyl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (2-Methoxy-ethylamino) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [6- (3-Methanesulfonyl-pyrrolidin-1-yl) -2-methyl-pyridin-3-yloxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Benzylamino-2-methyl-pyridin-3-yloxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-carbamoyl-2-fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-isopropoxy-ethylamino) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4 - [(tetrahydro-furan-2-ylmethyl) -amino] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {6 - [(2-methanesulfonyl-ethyl) -methyl-amino] -2-methyl-pyridin-3-yloxy} -5-methyl-pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-hydroxycarbamoyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-pyrrolidin-1-yl-ethylcarbamoyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (4-isopropyl-piperazine-1-carbonyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-morpholin-4-yl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-methanesulfonyl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-hydroxy-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Carboxymethyl-2-fluoro-phenoxy) -methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Dimethylcarbamoylmethyl-2-fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-sulfamoyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-propionylsulfamoyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-ethynyl-6- (2-fluoro-4-methanesulfonyl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-phosphonooxy-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [5-Bromo-6- (2-fluoro-4-methanesulfonyl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2-Fluoro-4- [2- (2-methanesulfonyl-pyrrolidin-1-yl) -2-oxo-ethyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine- 1-carboxylic; Isopropyl acid ester 4- [6- (4-carbamoylmethyl-2-fluoro-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4 - {[(tetrahydro-furan-2-ylmethyl) -carbamoyl] -methyl} -phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-3-sulfamoyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; C- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -C- (4-fluoro-phenyl) -methylene- amine; 3-tert-Butoxy-1- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -propan-1-one; 2-Ethoxy-1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -ethanone; {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} - (tetrahydro-furan-2-yl) -methanone; (S) -1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methyl-2-methylamino- butan-1-one; Isopropyl acid ester 4- (6- {2-Fluoro-4- [2- (3-hydroxy-piperidin-1-yl) -2-oxo-ethyl] -phenoxy} -5-methyl-pyrimidin-4-yloxy) -piperidine- 1-carboxylic; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-morpholin-4-yl-2-oxo-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-imidazol-1-yl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2- [1,2,3] triazol-1-yl-ethyl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid ; (R) -1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methyl-2-methylamino- butan-1-one; (S) -1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-hydroxy-butan-1- ona; (R) -N- (1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carbonyl} -2-methyl-propyl ) -acetamide; (S) -N- (1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carbonyl} -2-methylpropyl) - acetamide; (R) -N- (2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-methyl-2 -oxo-ethyl) -acetamide; (S) -N- (2- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -1-methyl-2 -oxo-ethyl) -acetamide; (S) -Tetrahydro-furan-3-il acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (R) -Tetrahydro-furan-3-il acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, Isopropyl acid ester 4- [6- (2-Amino-4-ethanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester (1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carbonyl} -2-methyl-propyl) -carbamic; Isopropyl acid ester 4- {6- [2-Fluoro-4- (6-methoxy-pyridin-3-yl) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; 3-Amino-1- {4- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -4-methyl-pentan-1- ona; 2-Amino-1- {4- [6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yloxy] -piperidin-1-yl} -3-methyl-butan-1- ona; Isopropyl acid ester 4- {6- [2-Fluoro-4- (2-isopropoxy-ethoxy) -phenoxy] -5-methyl-pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; and isopropyl acid ester 4- [5-methyl-6- (4-sulfo-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compounds according to Formula (III) (denominated in this document Group C9): Ester tert-butyl acid 4 - ({cyclopropyl- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid, Isopropyl acid ester 4 - ({cyclopropyl- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yl] -isopropyl-amino} -methyl) -piperidine-1-carboxylic acid and isopropyl acid ester 4 - ({cyclopropylmethyl- [6- (2-fluoro-4-methanesulfonyl-phenoxy) -5-methyl-pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022327 include the following compound according to Formula (III) (referred to herein as Group C10): Isopropyl Ester of acid 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -5-methyl-pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid.

In International Application Nº PCT / US2004 / 022417 (published as document WO 05/007658) is describe examples of agonists of GPR119. In the request International No. PCT / US2004 / 022417 describes itself as an agonist of GPR119, a compound of Formula (IV):

<figref>35</figref>

in the what:

<dl><dt>quad</dt><dd>each of A and B is independently alkylene C_ {1-3} optionally substituted with 1 to 4 substituents selected from the group consisting of alkyl C 1-3, C 1-4 alkoxy, carboxy, cyano, C 1-3 haloalkyl and halogen;</dd></dl>

<dl><dt>quad</dt><dd>D is O, S, S (O), S (O) 2, CR 1 R 2 or N-R 2, where R 1 is select from the group consisting of H, alkyl C 1-8, C 1-4 alkoxy, halogen and hydroxyl;</dd></dl>

<dl><dt>quad</dt><dd>E is N, C or CR 3, where R 3 is H or alkyl C 1-8;</dd></dl>

<dl><dt>quad</dt><dd>\ underline {\ text {- - -}} is a simple link when E is N or CR_ {3}, or a double bond when E is C;</dd></dl>

<dl><dt>quad</dt><dd>K is a C 3-6 cycloalkylene or C_ {1-3} alkylene where each is optionally substituted with 1 to 4 substituents selected between the group consisting of C 1-3 alkyl, C 1-4 alkoxy, carboxy, cyano, haloalkyl C 1-3 and halogen; or K is a link;</dd></dl>

<dl><dt>quad</dt><dd>Q is NR_4, O, S, S (O) or S (O) 2, where R 4 is H or alkyl C 1-8 and C 1-8 alkyl is optionally substituted with dialkyl C 2-8 -amine;</dd></dl>

<dl><dt>quad</dt><dd>T is N or CR5;</dd></dl>

<dl><dt>quad</dt><dd>M is N or CR6;</dd></dl>

<dl><dt>quad</dt><dd>J is N or CR7;</dd></dl>

<dl><dt>quad</dt><dd>U is C or N;</dd></dl>

<dl><dt>quad</dt><dd>V is N, CR_8 or V is a link;</dd></dl>

<dl><dt>quad</dt><dd>W is N or C;</dd></dl>

<dl><dt>quad</dt><dd>X is O, S, N, CR 9 or NR 11;</dd></dl>

<dl><dt>quad</dt><dd>Y is O, S, N, CR 10 or NR 12;</dd></dl>

<dl><dt>quad</dt><dd>Z is C or N;</dd></dl>

<dl><dt>quad</dt><dd>each of R 5, R 6, R 7, R 8, R 9 and R 10 are independently selected from the group consisting of H, C 1-5 acyloxy, alkoxy C 2-6, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C 1-4 -ureyl, amino, alkyl C 1-4 -amino, dialkyl C 2-8 -amino, carboxamide, cyano, C 3-6 cycloalkyl, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -sulfonamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, hydroxyl, hydroxylamino and nitro; where said alkenyl C 2-6, C 1-8 alkyl, C 2-6 alkynyl and cycloalkyl C 3-6 are optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 1-4 alkoxy, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 1-4 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, hydroxyl, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>each of R_ {11} and R_ {12} is selected independently between C 2-6 alkenyl, C 1-8 alkyl, alkynyl C 2-6 or C 3-6 cycloalkyl, each optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of acyl C 1-5, C 1-5 acyloxy, alkoxy C 1-4, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C_ {1-4} -thio, rent C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 1-4 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, hydroxyl, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>Ar1 is aryl or heteroaryl, each optionally substituted with R 13, R 14, R 15, R 16 and R 17; where R_ {13} is selected from the group consisting in C 1-5 acyl, acyl C 1-6 -sulfonamide, acyloxy C 1-5, C 2-6 alkenyl, C 1-4 alkoxy, C 1-8 alkyl, C 1-4 alkyl amino, alkyl C 1-6 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, arylsulfonyl, carbamimidoyl, carbo-alkoxy C 1-6, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, cycloalkyl C 3-7 -oxy, dialkyl C 2-6 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, guanidinyl, halogen, C 1-4 haloalkoxy, C 1-4 haloalkyl, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heterocyclic, heterocyclic-oxy, heterocyclic sulfonyl, heterocyclic carbonyl, heteroaryl, heteroarylcarbonyl, hydroxyl, nitro, C 4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide, sulfonic acid and thiol, and where said acyl C_ {1-5}, acyl C 1-6 -sulfonamide, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-6 sulfonamide, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, arylsulfonyl, carbamimidoyl, dialkyl C 2-6 -amino, heterocyclic, heterocyclic-carbonyl, heteroaryl, phenoxy and phenyl are optionally substituted with 1 to 5 substituents independently selected from the group consisting of C 1-5 acyl, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-7 alkyl, C 1-4 alkyl amino, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C 3-7 cycloalkyl -oxy, dialkyl C 2-6 -amino, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, heteroaryl, heterocyclic, hydroxyl, nitro, phenyl and phosphonooxy, and where each one of said C 1-7 alkyl and alkyl C 1-4 -carboxamide is optionally substituted with 1 to 5 substituents selected among the group consisting of C 1-4 alkoxy e hydroxy; or</dd></dl>

<dl><dt>quad</dt><dd>R_ {13} is a group of Formula (VAT):</dd></dl>

<figref>36</figref>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>"p" and "r" are independently 0, 1, 2 or 3; and</dd></dl>

<dl><dt>quad</dt><dd>R 18 is H, C 1-5 acyl, C 2-6 alkenyl, alkyl C 1-8, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, heteroaryl or phenyl, and where said heteroaryl or phenyl is optionally substituted with 1 to 5 substituents selected independently among the group consisting of alkoxy C 1-4, amino, alkyl C 1-4 -amino, alkynyl C 2-6, dialquil C 2-8 -amino, halogen, C 1-4 haloalkoxy, haloalkyl C 1-4 and hydroxyl;</dd></dl>

<dl><dt>quad</dt><dd>each of R_ {14}, R_ {15}, R_ {16} and R_ {17} is independently selected from the group consisting of H, C 1-5 acyl, C 1-5 acyloxy, C 2-6 alkenyl, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkynyl C 2-6, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -ureyl, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, dialkyl C 2-6 -carboxamide, halogen, C 1-4 haloalkoxy; haloalkyl C 1-4, haloalkyl C 1-4 -sulfinyl, haloalkyl C 1-4 -sulfonyl, haloalkyl C 1-4 -thio, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>two R 14, R 15, R 16 and R 17 adjacent together with the carbon atoms to which they are attached they form a cycloalkyl, cycloalkenyl or heterocyclic group of 5, 6 or 7 members condensed with Ar_ {1}, where the group of 5, 6 or 7 is optionally substituted with halogen; and</dd></dl>

<dl><dt>quad</dt><dd>R2 is selected from the group consisting of C 1-8 alkyl, alkynyl C 2-6, amino, aryl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, haloalkoxy C 1-4, C 1-4 haloalkyl, halogen, heteroaryl and hydroxyl; and where each of said C 1-8 alkyl, aryl and heteroaryl is optionally substituted with 1 to 5 substituents selected between the group consisting of C 1-5 acyl, C 1-5 acyloxy, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, cycloalkyl C_ {3-6} -heteroalkylene C_ {1-3}, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heterocyclic, hydroxy, hydroxylamino and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is -Ar_ {2} -Ar_ {3} where each of Ar 2 and Ar 3 is independently aryl or heteroaryl, each one optionally substituted with 1 to 5 substituents selected between the group consisting of H, C 1-5 acyl, C 1-5 acyloxy, C 1-4 alkoxy, C 1-8 alkyl, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C 1-4 -thio, amino, alkyl C 1-4 -amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, haloalkoxy C 1-4, C 1-4 haloalkyl, halogen, hydroxyl and nitro; or</dd></dl>

<dl><dt>quad</dt><dd>R2 is a group of Formula (IVB):</dd></dl>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>37</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>R 19 is H, C 1-8 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl or OR 21; and R 20 is F, Cl, Br, CN or NR 22 R 23; where R 21 is H, C 1-8 alkyl or cycloalkyl C 3-7, and R 22 and R 23 are independently H, C 1-8 alkyl, C 3-7 cycloalkyl, aryl or heteroaryl;</dd></dl>

<dl><dt>quad</dt><dd>or</dd></dl>

<dl><dt>quad</dt><dd>R2 is a group of Formula (IVC):</dd></dl>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>38</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<dl><dt>quad</dt><dd>in which:</dd></dl>

<dl><dt>quad</dt><dd>G is:</dd></dl>

<dl><dt>i)</dt><dd>-C (O) -, -C (O) NR 25, NR 25 C (O) -, -NR 25 -, -NR 25 C (O) O-, -OC (O) NR 25, -CR_ {25} R_26 NR_ {27} C (O) -, -CR 25 R 26 C (O) NR 27, - C (O) O-, -OC (O) -, -C (S) -, C (S) NR 25 -, -C (S) O-, -OC (S) -, -CR_ {25} R_26 -, -O-, -S-, -S (O) -, -S (O) 2 or a link when D is CR2R3; or</dd></dl>

<dl><dt>ii)</dt><dd>-CR_ {25} R_26 (O) -, -C (O) -, -CR_ {25} R_26 C (O) NR_ {27} -, -C (O) NR 25 -, -C (O) O-, -C (S) -, -C (S) NR 25 -, -C (S) O-, -CR 25 R 26 -, -S (O) 2 -, or a link when D is NR2;</dd></dl>

<dl><dt>quad</dt><dd>where each of R_ {25}, R_ {26} and R_ {27} is independently H or C 1-8 alkyl; and R_ {24} is H, C 1-8 alkyl, cycloalkyl C 3-7, phenyl, heteroaryl or heterocyclic, each one optionally substituted with 1 to 5 substituents selected between the group consisting of C 1-5 acyl, C 1-5 acyloxy, alkenyl C 2-6, C 1-4 alkoxy, alkyl C 1-7, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 alkyl sulfonyl C 1-4 -thio, alkyl C_ {1-4} -tioureílo, rent C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C 2-8 dialkyl-amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heteroaryl, heterocyclic, hydroxyl, hydroxylamino, nitro, phenyl, phenoxy and sulfonic acid, where each of said alkoxy C 1-4, C 1-7 alkyl, alkyl C 1-4 -amino, heteroaryl, phenyl and phenoxy is optionally substituted with 1 to 5 substituents selected from the group consisting of acyl C 1-5, C 1-5 acyloxy, alkoxy C 1-4, C 1-8 alkyl, alkyl C 1-4 -amino, alkyl C 1-4 -carboxamide, alkyl C 1-4 -thiocarboxamide, alkyl C 1-4 -sulfonamide, alkyl C 1-4 -sulfinyl, alkyl C 1-4 -sulfonyl, alkyl C_ {1-4} -thio, rent C_ {1-4} -tioureílo, alkyl C 1-4 -ureyl, amino, C 1-6 carbo-alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, dialkyl C 2-8 -amino, dialkyl C 2-6 -carboxamide, dialkyl C 2-6 -thiocarboxamide, dialkyl C 2-6 -sulfonamide, alkyl C_ {1-4} -tioureyl, haloalkoxy C 1-4, C 1-4 haloalkyl, haloC 1-4 alkyl-sulfinyl, C 1-4 haloalkyl sulfonyl, C 1-4 haloalkyl, haloalkyl C 1-4 -thio, halogen, heterocyclic, hydroxy, hydroxylamino, nitro and phenyl;</dd></dl>

with the proviso that Z and U do not be both N.

The present invention also includes diastereomers, as well as optical isomers, for example mixtures of enantiomers including racemic mixtures, as well as enantiomers and individual diastereomers, which arise as a result of the structural asymmetry in certain compounds of the invention. The separation of individual isomers or selective synthesis of the individual isomers is performed by application of various methods that are well known to specialists in the technique.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D1): Ester tert-butyl acid 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -3-methyl-1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -3,6-dimethyl-1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isobutyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1- (4-Methanesulfonyl-phenyl) -4- (piperidin-4-yloxy) -1H-pyrazolo [3,4-d] pyrimidine; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -pyridin-3-yl-methanone; (3-Fluoro-phenyl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; (1-tert-Butyl-5-methyl-1 H -pyrazol-4-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; (5-tert-Butyl-2-methyl-2H-pyrazol-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; Tert-butyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; Isobutyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; Furan-2-yl- {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (1-methyl-1H-pyrrol-2-yl ) -methanone; 2- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-3-yl-ethanone; 2- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-2-yl-ethanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-yl} - (5-methyl-pyridin-3-yl) -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (2-methyl-pyridin-3-yl) - methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (6-methyl-pyridin-3-yl) - methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (5-methyl-isoxazol-3-yl) - methanone; 2- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1-thiophene-2-yl-ethanone; 4- (1-Benzyl-azetidin-3-yloxy) -1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidine; Tert-butyl acid ester 3- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; 1- {4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -3,3-dimethyl-butan-2- ona; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -pyrazin-2-yl-methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (5-methyl-pyrazin-2-yl) - methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -pyrimidin-5-yl-methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -pyridazin-4-yl-methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -thiophene-2-yl-methanone; (3,4-Dimethyl-isoxazol-5-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -methanone; 3-tert-Butoxy-1- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -propan-1- ona; Tert-butyl acid ester (3- {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -3-oxo-propyl) -methyl- carbamic; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (6-trifluoromethyl-pyridin-3-yl) - methanone; Tert-butyl acid ester {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexyl} -carbamic; N- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -cyclohexane-1,4-diamine; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (4-methyl- [1,2,3] thiadiazol-5-yl) -methanone; (3,5-Dimethyl-isoxazol-4-yl) - {4- [1- (4-methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (2,5-Dimethyl-2H-pyrazol-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (3-methyl-isoxazol-5-yl) - methanone; Acid pyridin-4-ylamide 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carbothioic; N- {4- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexyl} -nicotinamide; 3-tert-Butoxy-N- {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexyl} -propionamide; Tert-butyl acid ester {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexyl} -carbamic; (3,5-Dimethyl-isoxazol-4-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -methanone; Tert-butyl acid ester 4- [1- (3,5-bis-trifluoromethyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -azetidine-1-carboxylic acid; Butyl Acid Ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Propyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (3-Fluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (2,4-Difluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester {4- [1- (2,4-Difluorophenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexyl} -carbamic; Tert-butyl acid ester {4- [1- (3-Fluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexyl} -carbamic; N- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -cyclohexane-1,4-diamine; {3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidin-1-yl} - (6-methyl-pyridin-3-yl) - methanone; {3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidin-1-yl} - (2-methyl-pyridin-3-yl) - methanone; {3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidin-1-yl} - (5-methyl-pyridin-3-yl) - methanone; {3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidin-1-yl} -pyridin-3-yl-methanone; {3- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidin-1-yl} - (1-methyl-1H-pyrrole-3-yl ) -methanone; Tert-butyl acid ester {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -cyclohexyl} -carbamic; N- [1- (2,4-Difluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -cyclohexane-1,4-diamine; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (4-trifluoromethyl-pyridin-3-yl) - methanone; Acid cyclohexyl ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tetrahydro-piran-4-il acid ester 4- [1- (methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Cyclopentyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tetrahydro-furan-3-il acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tetrahydro-furan-3-il acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tetrahydro-thiopiran-4-il acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Acid cyclobutyl ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (6-tert-Butyl-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -methanone; Tert-butyl acid ester (4 - {[1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -methyl} -cyclohexyl) -carbamic; N- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexylmethyl} -nicotinamide; N- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -cyclohexylmethyl} -6-methyl-nicotinamide; Tert-butyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - {[1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -methyl} -piperidine-1-carboxylic acid; Tert-butyl acid ester 3 - {[1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -methyl} -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({ethyl- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- {1- [2- (2-Dimethylamino-ethoxy) -4-methanesulfonylphenyl] -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Tert-butyl acid ester 3- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; Pyridin-3-ylmethyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic tert-butyl acid ester; 2-Pyridin-3-yl-ethyl acid ester 4- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 3-Pyridin-3-yl-propyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2-Dimethylamino-ethyl ester of acid 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - {[1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -methyl-amino} -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (2,4-Difluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({ethyl- [1- (2, fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({ethyl- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6-dimethylamino-1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1- (4 - {[1- (4-Methanesulfonylphenyl) -1 H -pyrrolo [3,4-d] pyrimidin-4-yl] -methyl-amino} -piperidin-1-yl) -3,3-dimethyl- butan-2-one; Acid cyclobutyl ester 4 - {[1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -methyl-amino} -piperidine-1-carboxylic acid; and tert-butyl acid ester 4 - [({1- [4- (2-Methanesulfonyl-ethyl) -phenyl] -1 H -pyrazolo [3,4-d] pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1- carboxylic.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D2): Ester tert-butyl acid 4 - ({[1- (2,5-Difluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; 2- {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1- (4-trifluoromethoxy -phenyl) -ethanone; 2- {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1- (3-fluoro -phenyl) -ethanone; 2- {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1-pyridin-2- il-ethanone; (2,5-Dimethyl-furan-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -methanone; Tert-butyl acid ester 4 - ({(2-dimethylamino-ethyl) - [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amino} -methyl) -piperidine-1- carboxylic; Tert-butyl acid ester 4 - ({(2-dimethylamino-ethyl) - [1- (2-fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amino} -methyl) - piperidine-1-carboxylic; Tert-butyl acid ester 4- [1- (2-Dimethylamino-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- (2- {ethyl- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amino} -ethyl) -piperazine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; Ethyl acid ester 4- {2- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -ethyl} -piperazine-1-carboxylic acid; Ethyl acid ester 4- {2- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -propyl} -piperazine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidine-4-sulfinyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidine-4-sulfonyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; Butyl Acid Ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; 2-Methoxy-ethyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; 3,3-Dimethyl-butyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; 4-Methyl-pentyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl-sulfanyl] -piperidine-1-carboxylic acid; Acid cyclopropylmethyl ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; Acid cyclobutylmethyl ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; 2-Cyclopropyl-ethyl ester of acid 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; (5-Bromo-furan-2-yl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidin-1 -il} -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (5-morpholin-4-ylmethyl-furan-2 -il) -methanone; Pentyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 1-Ethyl-propyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2-Ethyl Butyl Acid Ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Cyclopentylmethyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2-Pyrrolidin-1-yl-ethyl acid ester 4- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2-Morpholin-4-yl-ethyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Ethyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 2,2-Dimethyl-propyl acid ester 4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (5-Butyl-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; Ethyl- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl] - (3,4,5,6-tetrahydro-2H- [1, 2 '] bipyridinyl-4-ylmethyl) -amine; Ethyl- [1- (2-fluoro-4-methanesulfonylphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl] - (5'-trifluoromethyl-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-ylmethyl) -amine; [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl] - (5'-trifluoromethyl-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-yl) -amine; Isopropyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 5'-Fluoro-4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -3,4,5,6-tetrahydro-2H- [1, 2 '] bipyridinyl; 4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -5'-methyl-3,4,5,6-tetrahydro-2H- [1, 2 '] bipyridinyl; 4- [1- (4-Methanesulfonylphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl oxy] -6'-trifluoromethyl-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl; [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] - [1- (3-isopropyl- [1,2,4] oxadiazol-5 -ylmethyl) -pyrrolidin-3-yl] -amine; [1- (2-Fluoro-4-methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] - [1- (3-isopropyl- [1,2,4] oxadiazol-5-ylmethyl) ) -pyrrolidin-3-yl] -amine; (4-Ethyl-pyridin-2-yl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; 1- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-ylmethyl) -pyrrolidin-3-yloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; 1- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-ylmethyl) -piperidin-4-yloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; (5'-Fluoro-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl; -4-yl) - [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -amine; (5-Bromo-pyridin-3-yl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; Tert-butyl acid ester 3- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -pyrrolidine-1-carboxylic acid; Tert-butyl acid ester 3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -pyrrolidine-1-carboxylic acid; Isopropyl acid ester 3- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylamino] -pyrrolidine-1-carboxylic acid; (6-Chloro-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (5-Chloro-pyridin-3-yl) - (4- [1- (4-methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (1-methyl-3-trifluoromethyl-1H-pyrazole -4-yl) -methanone; (2-Chloro-pyridin-4-yl) - {4- [1- (4-methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; (4-Hydroxy-3-methoxy-phenyl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (4-Chloro-3-nitro-phenyl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; 1- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -3-methyl-butan-1-one; {4- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (6-pyrazol-1-yl-pyridin-3-yl ) -methanone; (2-Hydroxy-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (5,6-Dichloro-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -methanone; (5-Bromo-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; Acid 5- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carbonyl} -nicotinic; (1H-Imidazol-4-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; Tert-butyl acid ester 3- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -pyrrolidine-1-carboxylic acid; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (6-pyrrolidin-1-yl-pyridin-3 -il) -methanone; (6-Isobutylamino-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (6-Ethylamino-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (6-Cyclobutylamino-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (6-Isopropylamino-pyridin-3-yl) - {4- [1- (4-methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; [6- (1-Ethylpropylamino) -pyridin-3-yl] - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - [6- (1-propyl-butylamino) -pyridine -3-yl] -methanone; 5-Benzyloxy-2- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carbonyl} -piran-4-one; Benzo [c] isoxazol-3-yl- {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; (4-Chloro-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (4-iodo-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; 1- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -butan-2-one; 2- (5-Bromo-pyridin-3-yl) -1- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -ethanone; (6-Fluoro-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (5-Fluoro-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (6-Chloro-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (2-Chloro-5-fluoro-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - [5- (2-methyl-pyrrolidin-1- ilmethyl) -pyridin-3-yl] -methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (6-methyl-pyridin-2-yl) - methanone; 5- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carbonyl} -nicotinonitrile; {4- [1- (4-Methanesulfonylphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (4-methoxy-pyridin-2-yl) -methanone; (2-Fluoro-pyridin-4-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (2-Fluoro-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (6-Fluoro-pyridin-3-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (4-methoxy-thiophene-3-yl) - methanone; 2- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carbonyl} -pyran-4-one; (5-Ethyl-pyridin-2-yl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; (4-Ethoxy-phenyl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; {4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrrolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (5-pyridin-2-yl-thiophene-2-yl) -methanone; (5-Amino-pyridin-2-yl) - {4- [1- (4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; (5-Amino-pyridin-2-yl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - [5- (3-methyl- butylamino) -pyridin-2-yl] -methanone; {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (4-trifluoromethoxy-phenyl) - methanone; (5-Butyl-pyridin-2-yl) - {4- [1- (2-fluoro-4-methanesulfonylphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -methanone; (5-Ethylamino-pyridin-2-yl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -methanone; {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (5-isopropoxymethyl-pyridin-2 -il) -methanone; (4-Difluoromethoxy-phenyl) - {4- [1- (2-fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - methanone; {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (5-isopropoxy-pyridin-2 -il) -methanone; Acid methyl ester 5- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carbonyl} -pyridine-2-carboxylic acid; Ethyl acid ester {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -acetic acid; {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - (3-trifluoromethoxy-phenyl) - methanone; 1- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; 1- (4-Chloro-phenyl) -2- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - ethanone; 2- {4- [1- (4-Methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -1- (3-trifluoromethyl-phenyl) - ethanone; 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -5'-isopropoxy-3,4,5,6-tetrahydro-2H - [1,2 '] bipyridinyl; 1- (4-Methanesulfonyl-phenyl) -4- [1- (4-trifluoromethoxy-phenyl) -piperidin-4-yloxy] -1H-pyrazolo [3,4-d] pyrimidine; 1- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (4-trifluoromethoxy-phenyl) -piperidin-4-yloxy] -1H-pyrazolo [3,4-d] pyrimidine; 1- (4-Chloro-3-methyl-phenyl) -2- {4- [1- (4-methanesulfonylphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1 -il} -ethanone; 1- (3,4-Dichloro-phenyl) -2- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -ethanone; 5'-Bromo-4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -3,4,5,6-tetrahydro-2H- [1, 2 '] bipyridinyl; 1- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (3-trifluoromethoxy-phenyl) -piperidin-4-yloxy] -1H-pyrazolo [3,4-d] pyrimidine; 4- [1- (4-Methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -5'-trifluoromethyl-3,4,5,6-tetrahydro-2H- [1, 2 '] bipyridinyl; 1- (2,4-Dimethoxy-phenyl) -2- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl } -ethanone; 1- (4-Difluoromethoxy-phenyl) -2- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - ethanone; 1- (4-Diethylamino-phenyl) -2- {4- [1- (4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} - ethanone; (2- {4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidin-1-yl} -5-methyl-pyrimidin -4-yl) -dimethyl-amine; 1- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (5-methyl-4-pyrrolidin-1-yl-pyrimidin-2-yl) -piperidin-4-yloxy] -1H-pyrazolo [ 3,4-d] pyrimidine; Isopropyl acid ester 4- [1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-ylsulfanyl] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Methyl-4-propylamino-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Isopropylamino-2-methyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Methyl-4-morpholin-4-yl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {1- [4- (2-Methoxy-ethylamino) -2-methyl-phenyl] -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (1- {4 - [(2-methanesulfonyl-ethyl) -methyl-amino] -2-methyl-phenyl} -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy) -piperidine-1- carboxylic; Isopropyl acid ester 4- [1- (4-Bromo-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Propylamino-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Isopropylamino-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (1- {4- [4- (2-Methanesulfonyl-ethyl) -piperazin-1-yl] -2-methyl-phenyl} -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy) - piperidine-1-carboxylic; Isopropyl acid ester 4- (1- {2-methyl-4 - [(tetrahydro-furan-2-ylmethyl) -amino] -phenyl} -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy) -piperidine-1- carboxylic; Isopropyl acid ester 4- [1- (4-Cyclopropylamino-2-methyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {1- [4- (2-Dimethylamino-ethylamino) -2-methyl-phenyl] -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Morpholin-4-yl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -isopropyl-amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Fluoro-4-morpholin-4-yl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Fluoro-4-isopropylamino-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (1- {4 - [(2-methanesulfonyl-ethyl) -methyl-amino] -phenyl} -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {1- [4- (2-Methoxy-ethylamino) -phenyl] -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (1- {4 - [(tetrahydro-furan-2-ylmethyl) -amino] -phenyl} -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (1- {4- [4- (2-Methanesulfonyl-ethyl) -piperazin-1-yl] -phenyl} -1H-pyrazolo [3,4-d] pyrimidin-4-yloxy) -piperidine-1- carboxylic; Isopropyl acid ester 4- [1- (4-Aminophenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({[1- (2-Fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yl] -isopropyl-amino} -methyl) -piperidine-1-carboxylic acid; 4- [1- (5-Ethyl-pyrimidin-2-yl) -piperidin-4-ylsulfanyl] -1- (2-fluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidine; Isopropyl acid ester 4- [1- (2-Fluoro-4-sulfamoyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Fluoro-4-propionylsulfamoyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Cyano-2-fluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic; 1- (2,5-Difluoro-4-methoxy-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadinol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3,4 -d] pyrimidine; Isopropyl acid ester 4- [1- (2,5-Difluoro-4-methanesulfonyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Fluoro-6-methoxy-pyridin-3-yl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (6-Methoxy-2-methyl-pyridin-3-yl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2,5-Difluoro-4-sulfamoyl-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Fluoro-4-hydroxy-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [3,4-d] pyrimidin-1- il} -N-propionyl benzenesulfonamide; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [3,4-d] pyrimidin-1- il} -benzonitrile; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [3,4-d] pyrimidin-1- il} -benzenesulfonamide; 1- (2,5-Difluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H-pyrazolo [3,4-d] pyrimidine; 1- (4-Fluoro-6-methoxy-pyridin-3-yl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H -pyrazolo [3,4-d] pyrimidine; 4- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1- (6-methoxy-2-methyl-pyridin-3-yl) -1H -pyrazolo [3,4-d] pyrimidine; 2,5-Difluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [3,4-d] pyrimidin- 1-yl} -benzenesulfonamide; 1- (2-Fluoro-4-methanesulfanyl-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3,4-d ] pyrimidine; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [3,4-d] pyrimidin-1-yl} -N -propionyl benzenesulfonamide; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [3,4-d] pyrimidin-1-yl} -benzonitrile ; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [3,4-d] pyrimidin-1-yl} -benzenesulfonamide ; 1- (2,5-Difluoro-4-methanesulfonyl-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3,4 -d] pyrimidine; 1- (4-Fluoro-6-methoxy-pyridin-3-yl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1- (6-methoxy-2-methyl-pyridin-3-yl) -1H-pyrazolo [3 , 4-d] pyrimidine; 2,5-Difluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [3,4-d] pyrimidin-1-yl} -benzenesulfonamide; Isopropyl acid ester 4- [1- (2-Fluoro-4-methoxy-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (4-Difluoromethoxy-2-fluoro-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2-Fluoro-4-trifluoromethoxy-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [1- (2,5-Difluoro-4-methoxy-phenyl) -1 H -pyrazolo [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [3,4-d] pyrimidin-1- il} -phenol; 1- (2-Fluoro-4-methoxy-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; 1- (4-Difluoromethoxy-2-fluoro-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; 1- (2-Fluoro-4-trifluoromethoxy-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H-pyrazolo [3 , 4-d] pyrimidine; 1- (2,5-Difluoro-4-methoxy-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1H-pyrazolo [3,4-d] pyrimidine; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [3,4-d] pyrimidin-1-yl} -phenol ; 1- (2-Fluoro-4-methoxy-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3,4-d ] pyrimidine; 1- (4-Difluoromethoxy-2-fluoro-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3,4-d ] pyrimidine; and 1- (2-Fluoro-4-trifluoromethoxy-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1H-pyrazolo [3,4-d ] pyrimidine

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (referred to herein as Group D3): Isobutyl ester of acid 4- [9- (6-methanesulfonyl-pyridin-3-yl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; {4- [9- (6-Methanesulfonyl-pyridin-3-yl) -9H-purin-6-yloxy] -piperidin-1-yl} -pyridin-3-yl-methanone; Tert-butyl acid ester 4- [9- (4-methanesulfonyl-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [9- (6-methanesulfonyl-pyridin-3-yl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid and tert-butyl acid ester 4- [9- (2-Fluoro-4-methanesulfonyl-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D4): Isopropyl ester of acid 4- [9- (2-Fluoro-4-propionylsulfamoyl-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [9- (4-cyano-2-fluoro-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [9- (2-Fluoro-4-sulfamoyl-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; 9- (2-Fluoro-4-methanesulfonyl-phenyl) -6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -9H-purine; 3-Fluoro-4- {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -purin-9-yl} -N-propionyl-benzenesulfonamide ; 3-Fluoro-4- {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -purin-9-yl} -benzonitrile; 3-Fluoro-4- {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -purin-9-yl} -benzenesulfonamide; Isopropyl acid ester 4- [9- (2,5-Difluoro-4-methanesulfonyl-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [9- (4-Fluoro-6-methoxy-pyridin-3-yl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [9- (6-Methoxy-2-methyl-pyridin-3-yl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [9- (2,5-Difluoro-4-sulfamoyl-phenyl) -9H-purin-6-yloxy] -piperidine-1-carboxylic acid; 9- (2,5-Difluoro-4-methanesulfonyl-phenyl) -6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -9H-purine ; 9- (4-Fluoro-6-methoxy-pyridin-3-yl) -6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -9H -purine; 6- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -9- (6-methoxy-2-methyl-pyridin-3-yl) -9H -purine; 2,5-Difluoro-4- {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -purin-9-yl} -benzenesulfonamide; 9- (2-Fluoro-4-methanesulfonyl-phenyl) -6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -9H-purine; 3-Fluoro-4- {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -purin-9-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -purin-9-yl} -benzonitrile; 3-Fluoro-4- {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -purin-9-yl} -benzenesulfonamide; 9- (2,5-Difluoro-4-methanesulfonyl-phenyl) -6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -9H-purine; 9- (4-Fluoro-6-methoxy-pyridin-3-yl) -6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -9H-purine; 6- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -9- (6-methoxy-2-methyl-pyridin-3-yl) -9H-purine; and 2,5-Difluoro-4- {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -purin-9-yl} -benzenesulfonamide.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compound according to Formula (IV) (called in this document Group D5): Ester tert-butyl acid 4- [3- (4-Methanesulfonyl-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D6): 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3H- [1, 2,3] triazolo [4,5-d] pyrimidine; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] - [1,2,3] triazolo [4,5 -d] pyrimidin-3-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] - [1,2,3] triazolo [4,5 -d] pyrimidin-3-yl} -benzonitrile; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] - [1,2,3] triazolo [4,5 -d] pyrimidin-3-yl} -benzenesulfonamide; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3H- [1,2,3] triazolo [4,5-d] pyrimidine; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] - [1,2,3] triazolo [4,5-d] pyrimidin -3-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5, yl) -cyclohexyloxy] - [1,2,3] triazolo [4,5-d] pyrimidin -3-yl} -benzonitrile; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] - [1,2,3] triazolo [4,5-d] pyrimidin -3-yl} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonylphenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3H- [1,2,3] triazolo [4,5-d] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3H- [1, 2,3] triazolo [4,5-d] pyrimidine; 7- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -3H- [1, 2,3] triazolo [4,5-d] pyrimidine; 2,5-Difluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] - [1,2,3] triazolo [4,5-d ] pyrimidin-3-yl} -benzenesulfonamide; Isopropyl acid ester 4- [3- (2-Fluoro-4-methanesulfonyl-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-propionylsulfamoyl-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Cyano-2-fluoro-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-sulfamoyl-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Fluoro-6-methoxy-pyridin-3-yl) -3H- [1,2,3] triazolo [4,5-d) pyrimidin-7-yloxy] -piperidine-1-carboxylic ; Isopropyl acid ester 4- [3- (6-Methoxy-2-methyl-pyridin-3-yl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid ; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-sulfamoyl-phenyl) -3H- [1,2,3] triazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) - [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3H- [1, 2,3] triazolo [4,5-d] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3H - [1,2,3] triazolo [4,5-d] pyrimidine; 7- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -3H - [1,2,3] triazolo [4,5-d] pyrimidine; and 2,5-Difluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] - [1,2,3] triazolo [4 , 5-d] pyrimidin-3-yl} -benzenesulfonamide.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compound according to Formula (IV) (referred to in this document as Group D7): Ester tert-butyl acid 4- [3- (4-Methanesulfonyl-phenyl) -isoxazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D8): Ester tert-butyl acid 4 - ({ethyl- [3- (4-methanesulfonyl-phenyl) -isoxazolo [4,5-d] pyrimidin-7-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [3- (4-Methanesulfonyl-phenyl) -isoxazolo [4,5-d] pyrimidin-7-ylsulfanyl] -piperidine-1-carboxylic acid; and isopropyl acid ester 4- [3- (4-Methanesulfonylphenyl) -isoxazolo [4,5-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compound according to Formula (IV) (referred to in this document as Group D9): Isopropyl Ester of acid 4- [8- (2-Fluoro-4-methanesulfonyl-phenyl) - [1,7] naphthyridin-4-yloxy] -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D10): Isopropyl ester of acid 4- [8- (2-Fluoro-4-methanesulfonyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Methylsulfanyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-methanesulfonyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Isopropoxy-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Bromo-2-fluoro-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2-Fluoro-4-propionylsulfamoyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Cyano-2-fluoro-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2-Fluoro-4-sulfamoyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2,5-Difluoro-4-methanesulfonyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Fluoro-6-methoxy-pyridin-3-yl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (6-Methoxy-2-methyl-pyridin-3-yl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2,5-Difluoro-4-sulfamoyl-phenyl) -quinolin-4-yloxy] -piperidine-1-carboxylic acid; 2,5-Difluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinolin-8-yl} -benzenesulfonamide; 4- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -8- (6-methoxy-2-methyl-pyridin-3-yl) -quinoline ; 8- (4-Fluoro-6-methoxy-pyridin-3-yl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinoline ; 8- (2,5-Difluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinoline; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinolin-8-yl} -benzenesulfonamide; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinolin-8-yl} -benzonitrile; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinolin-8-yl} -N-propionyl-benzenesulfonamide ; 8- (2-Fluoro-4-methanesulfonylphenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -quinoline; 2,5-Difluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinolin-8-yl} -benzenesulfonamide; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -8- (6-methoxy-2-methyl-pyridin-3-yl) -quinoline; 8- (4-Fluoro-6-methoxy-pyridin-3-yl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinoline; 8- (2,5-Difluoro-4-methanesulfonyl-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinoline; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinolin-8-yl} -benzenesulfonamide; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinolin-8-yl} -benzonitrile; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinolin-8-yl} -N-propionyl-benzenesulfonamide; and 8- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -quinoline.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D11): Isopropyl ester of acid 4- [8- (2-Fluoro-4-methanesulfonyl-phenyl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2-Fluoro-4-propionylsulfamoyl-phenyl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Cyano-2-fluoro-phenyl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2-Fluoro-4-sulfamoyl-phenyl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2,5-Difluoro-4-methanesulfonyl-phenyl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (4-Fluoro-6-methoxy-pyridin-3-yl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (6-Methoxy-2-methyl-pyridin-3-yl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [8- (2,5-Difluoro-4-sulfamoyl-phenyl) -pyrido [3,4-d] pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; 8- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3,4 -d] pyrimidine; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3,4-d] pyrimidin-8- il} -N-propionyl benzenesulfonamide; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3,4-d] pyrimidin-8- il} -benzonitrile; 3-Fluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3,4-d] pyrimidin-8- il} -benzenesulfonamide; 8- (2,5-Difluoro-4-methanesulfonyl-phenyl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3 , 4-d] pyrimidine; 8- (4-Fluoro-6-methoxy-pyridin-3-yl) -4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3,4-d] pyrimidine; 4- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -8- (6-methoxy-2-methyl-pyridin-3-yl) -pyrido [3,4-d] pyrimidine; 2,5-Difluoro-4- {4- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrido [3,4-d] pyrimidin- 8-yl} -benzenesulfonamide; 8- (2-Fluoro-4-methanesulfonyl-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4-d] pyrimidine ; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4-d] pyrimidin-8-yl} -N -propionyl benzenesulfonamide; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4-d] pyrimidin-8-yl} -benzonitrile ; 3-Fluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4-d] pyrimidin-8-yl} -benzenesulfonamide ; 8- (2,5-Difluoro-4-methanesulfonyl-phenyl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4-d ] pyrimidine; 8- (4-Fluoro-6-methoxy-pyridin-3-yl) -4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4 -d] pyrimidine; 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -8- (6-methoxy-2-methyl-pyridin-3-yl) -pyrido [3,4 -d] pyrimidine; and 2,5-Difluoro-4- {4- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrido [3,4-d] pyrimidin-8-yl} -benzenesulfonamide.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D12): 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5-a] pyrimidine ; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5-a] pyrimidin-3-yl} -N -propionyl benzenesulfonamide; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5-a] pyrimidin-3-yl} -benzonitrile ; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5-a] pyrimidin-3-yl} -benzenesulfonamide ; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5-a ] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5 -a] pyrimidine; 7- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -pyrazolo [1,5 -a] pyrimidine; 2,5-Difluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -pyrazolo [1,5-a] pyrimidin-3-yl} -benzenesulfonamide; Isopropyl acid ester 4- [3- (2-Fluoro-4-methanesulfonyl-phenyl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-propionylsulfamoyl-phenyl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Cyano-2-fluoro-phenyl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-sulfamoyl-phenyl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Fluoro-6-methoxy-pyridin-3-yl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (6-Methoxy-2-methyl-pyridin-3-yl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-sulfamoyl-phenyl) -pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1,5 -a] pyrimidine; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1,5-a] pyrimidin-3- il} -N-propionyl benzenesulfonamide; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1,5-a] pyrimidin-3- il} -benzonitrile; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1,5-a] pyrimidin-3- il} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1 , 5-a] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1,5-a] pyrimidine; 7- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -pyrazolo [1,5-a] pyrimidine; 2,5-Difluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrazolo [1,5-a] pyrimidin- 3-yl} -benzenesulfonamide; Isopropyl acid ester 4- [3- (2-Fluoro-4-methanesulfonyl-phenyl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-propionylsulfamoyl-phenyl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Cyano-2-fluoro-phenyl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-sulfamoyl-phenyl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Fluoro-6-methoxy-pyridin-3-yl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (6-Methoxy-2-methyl-pyridin-3-yl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-sulfamoyl-phenyl) -2-methyl-pyrazolo [1,5-a] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; 2,5-Difluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-pyrazolo [1,5- a] pyrimidin-3-yl} -benzenesulfonamide; 7- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -2 -methyl-pyrazolo [1,5-a] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2 -methyl-pyrazolo [1,5-a] pyrimidine; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl -pyrazolo [1,5-a] pyrimidine; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin-3-yl} -benzenesulfonamide; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin-3-yl} -benzonitrile; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadinol-5-yl) -piperidin-4-yloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin-3-yl} -N-propionyl-benzenesulfonamide; 3- (2-Fluoro-4-methanesulfonylphenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-pyrazolo [1 , 5-a] pyrimidine; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1,5 -a] pyrimidine; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin-3- il} -N-propionyl benzenesulfonamide; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin-3- il} -benzonitrile; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin-3- il} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1 , 5-a] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1,5-a] pyrimidine; 7- [4- (3-Isopropyl- [1,2,4] oxadinol-5-yl) -cyclohexyloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -2-methyl-pyrazolo [1,5-a] pyrimidine; and 2,5-Difluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-pyrazolo [1,5-a] pyrimidin- 3-yl} -benzenesulfonamide.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D13): Isopropyl ester of acid 4- [3- (2-Fluoro-4-methanesulfonyl-phenyl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-propionylsulfamoyl-phenyl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Cyano-2-fluoro-phenyl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-sulfamoyl-phenyl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Fluoro-6-methoxy-pyridin-3-yl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (6-Methoxy-2-methyl-pyridin-3-yl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-sulfamoyl-phenyl) -1-methyl-1 H -pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1-methyl-1H -pyrazolo [4,3-d] pyrimidine; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1-methyl-4H-pyrazolo [4,3- d] pyrimidin-3-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1-methyl-1H-pyrazolo [4,3- d] pyrimidin-3-yl} -benzonitrile; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1-methyl-1H-pyrazolo [4,3- d] pyrimidin-3-yl} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1-methyl -1H-pyrazolo [4,3-d] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1 -methyl-1H-pyrazolo [4,3-d] pyrimidine; 7- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -1 -methyl-1H-pyrazolo [4,3-d] pyrimidine; 2,5-Difluoro-4- (7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -1-methyl-1H-pyrazolo [4, 3-d] pyrimidin-3-yl) -benzenesulfonamide; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H-pyrazolo [4 , 3-d] pyrimidine; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H-pyrazolo [4,3-d] pyrimidin- 3-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H-pyrazolo [4,3-d] pyrimidin- 3-yl} -benzonitrile; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H-pyrazolo [4,3-d] pyrimidin- 3-yl} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H-pyrazolo [4,3-d] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H -pyrazolo [4,3-d] pyrimidine; 7- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -1-methyl-1H -pyrazolo [4,3-d] pyrimidine; and 2,5-Difluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -1-methyl-1H-pyrazolo [4,3-d] pyrimidin-3-yl} -benzenesulfonamide.

Specific examples of GPR119 agonists described in International Application No. PCT / US2004 / 022417 include the following compounds according to Formula (IV) (denominated in this document Group D14): Isopropyl ester of acid 4- [3- (2-Fluoro-4-methanesulfonyl-phenyl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2-Fluoro-4-propionylsulfamoyl-phenyl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Cyano-2-fluoro-phenyl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic; Isopropyl acid ester 4- [3- (2-Fluoro-4-sulfamoyl-phenyl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (4-Fluoro-6-methoxy-pyridin-3-yl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (6-Methoxy-2-methyl-pyridin-3-yl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [3- (2,5-Difluoro-4-sulfamoyl-phenyl) -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-7-yloxy] -piperidine-1-carboxylic acid; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-2H -pyrazolo [4,3-d] pyrimidine; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-2H-pyrazolo [4,3- d] pyrimidin-3-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-2H-pyrazolo [4,3- d] pyrimidin-3-yl} -benzonitrile; 3-Fluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-2H-pyrazolo [4,3- d] pyrimidin-3-yl} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl -2H-pyrazolo [4,3-d] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2 -methyl-2H-pyrazolo [4,3-d] pyrimidine; 7- [1- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -2 -methyl-2H-pyrazolo [4,3-d] pyrimidine; 2,5-Difluoro-4- {7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -2-methyl-2H-pyrazolo [4, 3-d] pyrimidin-3-yl} -benzenesulfonamide; 3- (2-Fluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H-pyrazolo [4 , 3-d] pyrimidine; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H-pyrazolo [4,3-d] pyrimidin- 3-yl} -N-propionyl-benzenesulfonamide; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H-pyrazolo [4,3-d] pyrimidin- 3-yl} -benzonitrile; 3-Fluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H-pyrazolo [4,3-d] pyrimidin- 3-yl} -benzenesulfonamide; 3- (2,5-Difluoro-4-methanesulfonyl-phenyl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H-pyrazolo [4,3-d] pyrimidine; 3- (4-Fluoro-6-methoxy-pyridin-3-yl) -7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H -pyrazolo [4,3-d] pyrimidine; 7- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -3- (6-methoxy-2-methyl-pyridin-3-yl) -2-methyl-2H -pyrazolo [4,3-d] pyrimidine; and 2,5-Difluoro-4- {7- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -cyclohexyloxy] -2-methyl-2H-pyrazolo [4,3-d] pyrimidin-3-yl} -benzenesulfone- measure

In U.S. Patent Application No. 60 / 577,354 examples of agonists of GPR119 are described. In the U.S. Patent Application No. 60 / 577,354 is described, As an agonist of GPR119, a compound of Formula (V):

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<figref>39</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

or an N-oxide thereof; where:

<dl><dt>quad</dt><dd>A 1 and A 2 are independently alkylene C_ {1-3} optionally substituted with one or more substituents independently selected from the group that consists of C 1-6 alkyl, alkoxy C 1-6 and carboxy;</dd></dl>

<dl><dt>quad</dt><dd>D is CR 1 R 2 or NR 2, where R 1 is select from the group consisting of H, alkyl C 1-6, C 1-6 alkoxy, halogen and hydroxyl;</dd></dl>

<dl><dt>quad</dt><dd>E is N, C or CR 3, where R 3 is H or alkyl C 1-6;</dd></dl>

<dl><dt>quad</dt><dd>\ underline {\ text {- - -}} is a simple link when E is N or CR_ {3}, or a double bond when E is C;</dd></dl>

<dl><dt>quad</dt><dd>K is absent or is a cycloalkylene group C 3-6 or C 1-3 alkylene optionally substituted with one or more selected substituents independently among the group consisting of alkyl C 1-6, C 1-6 alkoxy, carboxy, cyano and halogen;</dd></dl>

<dl><dt>quad</dt><dd>Q_ {1} is NR_ {4}, O, S, S (O) or S (O) 2, where R 4 is H, acyl C 1-6, C 1-6 alkyl, C 2-6 alkenyl, alkynyl C 2-6, C 3-7 cycloalkyl, or C 3-7 cycloalkyl-alkylene C_ {1-3}, where said alkyl C 1-6 is optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 acyl, acyloxy C 1-6, C 2-6 alkenyl, C 1-6 alkoxy, alkyl C 1-6, alkyl C 1-6 -amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, rent C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, haloalkoxy C 1-6, C 1-6 haloalkyl, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, hydroxyl, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>Q_ {2} is absent or is NR_ {5}, or O, where R 5 is H, C 1-6 acyl, alkyl C 1-6, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl C 3-7 or cycloalkyl C 3-7 -alkylene C_ {1-3}, where said alkyl C 1-6 is optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 acyl, acyloxy C 1-6, C 2-6 alkenyl, C 1-6 alkoxy, alkyl C 1-6, alkyl C 1-6 -amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, rent C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, haloalkoxy C 1-6, C 1-6 haloalkyl, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, hydroxy, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>W is N or CH;</dd></dl>

<dl><dt>quad</dt><dd>X is N or CR6;</dd></dl>

<dl><dt>quad</dt><dd>Y is N or CR7;</dd></dl>

<dl><dt>quad</dt><dd>Z is N or CR 8;</dd></dl>

<dl><dt>quad</dt><dd>V is absent or is heteroalkylene C_ {1-3} or C_ {1-3} alkylene where each is optionally substituted with one or more substituents independently selected from the group that consists of C 1-3 alkyl, alkoxy C 1-6, carboxy, cyano, haloalkyl C 1-3 and halogen;</dd></dl>

<dl><dt>quad</dt><dd>each of R 6, R 7 and R 8 is selected independently among the group consisting of H, acyl C 1-6, C 1-6 acyloxy, C 2-6 alkenyl, alkoxy C 1-6, C 1-6 alkyl, alkyl C 1-6 -amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, C 1-6 haloalkoxy, haloalkyl C 1-6, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, hydroxyl, hydroxylamino and nitro, where each of said alkenyl C 2-6, C 1-6 alkyl, C 2-6 alkynyl and cycloalkyl C_ {3-6} is optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 acyl, acyloxy C 1-6, C 2-6 alkenyl, C 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkyl-amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C_ {1-6} -ureyl, amino dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, haloalkoxy C 1-6, C 1-6 haloalkyl, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, hydroxyl, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>Ar is optionally substituted aryl or heteroaryl with R 9 -R 13;</dd></dl>

<dl><dt>quad</dt><dd>R_ {9} is selected from the group consisting of C 1-6 acyl, C 1-6 acyloxy, C 2-6 alkenyl, alkoxy C 1-6, C 1-6 alkyl, alkyl C 1-6 -amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, aryl, arylcarbonyl, arylsulfonyl, dialkyl C 1-6 -amino, carbamimidoyl, C 1-6 alkoxycarbonyl, carboxamide, carboxy, cyano, cycloalkyl C_ {3-6}, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, guanidine, C 1-6 haloalkoxy, haloalkyl C 1-6, halogen, haloalkylsulfinyl C 1-6, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, heterocyclic, heterocyclic sulfonyl, heteroaryl, hydroxy, hydroxylamino, nitro, C 3-6 oxocycloalkyl, phenoxy, sulfonamide, sulfonic acid and thiol; and where every R_ {9} available is optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 acyl, acyl C 1-6 -sulfonamide, acyloxy C 1-6, C 2-6 alkenyl, C 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkyl-amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, rent C 1-6 -ureyl, amino, aryl, arylcarbonyl, arylsulfonyl, dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, C 1-6 haloalkoxy, haloalkyl C 1-6, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, heteroaryl, heteroarylcarbonyl, heteroarylsulfonyl, heterocyclic, hydroxyl, hydroxylamino and nitro;</dd></dl>

<dl><dt>quad</dt><dd>R_ {10} -R_ {13} are selected independently among the group consisting of acyl C 1-6, C 1-6 acyloxy, C 2-6 alkenyl, alkoxy C 1-6, C 1-6 alkyl, alkyl C 1-6 -amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, haloalkoxy C 1-6, C 1-6 haloalkyl, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, hydroxyl, hydroxylamino, nitro and thiol; or two adjacent groups along with the atoms to which they are attached form a cycloalkyl group, 5, 6 or 7-membered cycloalkenyl or heterocyclic where the group 5, 6 or 7 members is optionally substituted with halogen or oxo; and</dd></dl>

<dl><dt>quad</dt><dd>R2 is selected from the group consisting of H, C 1-6 acyl, acyloxy C 1-6, C 2-6 alkenyl, C 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkyl-amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, aryl, arylcarbonyl, aryloxy, dialkyl C 1-6 -amino, carbamimidoyl, C 1-6 alkoxycarbonyl, C 3-7 cycloalkoxycarbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, C 1-6 dialkylcarboxamide, C 1-6 dialkyl sulfonamide, C 1-6 dialkyl thiocarboxamido, guanidine, C 1-6 haloalkoxy, haloalkyl C 1-6, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, heteroaryl, C 1-3 heteroaryl-alkylene, heteroarylcarbonyl, heteroaryloxy, heterocyclic carboxamide, hydroxyl, hydroxylamino and nitro; where each variable R_ {2} is optionally substituted with one or more selected substituents independently among the group consisting of acyl C 1-6, C 1-6 acyloxy, C 2-6 alkenyl, alkoxy C 1-6, C 1-6 alkyl, C 1-6 alkyl-amino, alkyl C 1-6 -carboxamide, alkynyl C 2-6, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -thiocarboxamide, alkyl C_ {1-6} -tioureílo, alkyl C 1-6 -ureyl, amino, aryl, C 1-6 dialkyl-amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialkyl C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, dialkyl C 1-6 -thiocarboxamido, haloalkoxy C 1-6, C 1-6 haloalkyl, halogen, C 1-6 haloalkyl sulfinyl, C 1-6 haloalkyl sulfonyl, C 1-6 haloalkylthio, heterocyclic, heteroaryl, hydroxyl, hydroxylamino and nitro and where C 1-6 alkyl is optionally further substituted with one or more selected substituents independently among the group consisting of acyl C 1-6, C 1-6 alkoxy, alkyl C 1-6 -amino, alkyl C 1-6 -carboxamide, alkyl C 1-6 sulfonamide, alkyl C 1-6 -sulfinyl, alkyl C 1-6 -sulfonyl, alkyl C 1-6 -thio, alkyl C 1-6 -ureyl, amino, dialkyl C 1-6 -amino, alkoxy C 1-6 -carbonyl, carboxamide, carboxy, cyano, C 3-6 cycloalkyl, dialquil C 1-6 -carboxamide, dialkyl C 1-6 -sulfonamide, haloalkoxy C 1-6, C 1-6 haloalkyl, halogen, haloalkyl C 1-6 -sulfinyl, haloalkyl C 1-6 -sulfonyl, haloalkyl C 1-6 -thio, heterocyclic, hydroxyl, hydroxylamino and nitro.</dd></dl>

The present invention also includes diastereomers, as well as optical isomers, for example mixtures of enantiomers including racemic mixtures, as well as enantiomers and individual diastereomers, which arise as a result of the structural asymmetry in certain compounds of the invention. The separation of individual isomers or selective synthesis of the individual isomers is performed by application of various methods that are well known to specialists in the technique.

Specific examples of GPR119 agonists described in US Patent Application No. 60 / 577,354 include the following compounds according to the Formula (V) (denominated in this document Group E1): 4- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -6- (4-methanesulfonyl-phenoxy) -pyrimidine; {6- [4- (3-Isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin-4-yl} - (4-methanesulfonyl-phenyl) -amine; Tert-butyl acid ester 4 - {[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,5-Difluoro-benzylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [({6 - [(benzo [1,3] dioxol-5-ylmethyl) -amino] -pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1-carboxylic acid; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (3-fluoro-phenoxy) -piperidin-1-yl] -pyrimidin-4-yl} -amine; Tert-butyl acid ester 4 - ({methyl- [6- (2-pyridin-4-yl-ethylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (2-pyridin-3-yl-ethylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [(methyl- {6 - [(pyridin-3-ylmethyl) -amino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [({6 - [(2-Fluoro-4-methanesulfonyl-phenyl) -methyl-amino] -pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Cyano-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid, Tert-butyl acid ester 4 - [({6- [4- (2-Methanesulfonyl-ethyl) -phenylamino] -pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Ethylsulfanyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid, Tert-butyl acid ester 4 - ({[6- (4-Isopropylsulfanyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-ethylsulfamoyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (4-methylsulfamoyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-dimethylsulfamoyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (4-methylsulfamoylmethyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (4-sulfamoyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (4- [1,2,4] triazol-1-yl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (4- [1,2,4] triazol-1-ylmethyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [(methyl- {6- [4- (2- [1,2,4] triazol-1-yl-ethyl) -phenylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1 -carboxylic; Tert-butyl acid ester 4 - ({[6- (benzo [1,3] dioxol-5-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (6-methanesulfonyl-pyridin-3-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (3,5-dimethoxy-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [(methyl- {6- [4- (2-oxo-oxazolidin-4-yl-methyl) -phenylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [({6- [4- (1,1-dioxo-1 [lambda] 6 -thiomorpholin-4-ylmethyl) -phenylamino] -pyrimidin-4-yl} -methyl-amino) -methyl] - piperidine-1-carboxylic; Tert-butyl acid ester 4 - ({methyl- [6- (4-pyrazol-1-yl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,2-Difluoro-benzo [1,3] dioxol-5-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (4-trifluoromethanesulfonyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [(methyl- {6- [4- (morpholine-4-sulfonyl) -phenylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [(methyl- {6- [2- (pyridine-2-carbonyl) -phenylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Fluoro-5-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; N-Ethyl-3-fluoro-4- [6- (methyl-piperidin-4-ylmethyl-amino) -pyrimidin-4-ylamino] -benzenesulfonamide; 3-Fluoro-N-isopropyl-4- [6- (methyl-piperidin-4-ylmethyl-amino) -pyrimidin-4-ylamino] -benzenesulfonamide; Tert-butyl acid ester 4 - ({[6- (3,4-Difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,6-Difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,5-Difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,3-Difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (2,3,5-trifluoro-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-f luoro-4-methyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (3-Chloro-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,4-Difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [methyl- {6- [2- (1-oxy-pyridin-3-yl) -ethylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - [(methyl- {6- [2- (1-oxy-pyridin-3-yl) -ethylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[6- (2,5-Difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[6- (4-Cyano-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [({6- [2- (2-Fluoro-phenoxy) -ethylamino] -pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Fluoro-phenoxy) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,5-Difluoro-phenoxy) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [({6- [2- (2-Chloro-phenoxy) -ethylamino] -pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Chloro-phenoxy) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - [({6- [2- (4-Fluoro-phenoxy) -propylamino] -pyrimidin-4-yl} -methyl-amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Ethylsulfamoyl-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Fluoro-4-isopropylsulfamoyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Cyano-2,5-difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Bromo-2,5-difluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (5-carboxy-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (6-Methoxy-pyridin-3-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,6-dimethoxy-pyridin-3-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Acid 6- {6 - [(1-tert-butoxycarbonyl-piperidin-4-ylmethyl) -methyl-amino] -pyrimidin-4-ylamino} -nicotinic; Tert-butyl acid ester 4 - ({[6- (6-Acetylamino-pyridin-3-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (5-Fluoro-pyridin-2-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- {4-cyano-2-ethyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Butyryl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (5-Bromo-3-methyl-pyridin-2-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (3-Bromo-5-methyl-pyridin-2-ylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({methyl- [6- (5-trifluoromethyl-pyridin-2-ylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Bromo-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (3-carboxy-4-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[6- (4-ethoxycarbonyl-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[6- (4-carboxy-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({[6- (4-Cyano-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Butyl Acid Ester 4 - ({[6- (4-Cyano-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Acid cyclopropylmethyl ester 4 - ({[6- (4-Cyano-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Ethyl acid ester {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -piperazin-1-yl} -acetic acid; (2-Fluoro-4-granddanesulfonyl-phenyl) - {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-ylmethyl) -piperazin-1-yl] -pyrimidin-4-yl} -amine; Isobutyl acid ester 4 - ({[6- (2,5-Difluoro-4-hydroxy-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[6- (4-ethylcarbamoyl-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - [({6- [2-Fluoro-4- (N-hydroxycarbamimidoyl) -phenylamino] -pyrimidin-4-yl) -methyl-amino) -methyl] -piperidine-1-carboxylic acid; 3-Methyl Butyl Acid Ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,5-Difluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; (5-Butyl-pyridin-2-yl) - [4 - ({[6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidin-1 -il] -methanone; N- (2-Fluoro-4-methanesulfonyl-phenyl) -N '- (5'-fluoro-3,4,5,6-tetrahydro-2H- [1,2'] bipyridinyl-4-ylmethyl) -N ' -methyl-pyrimidine; -4,6-diamine; Isobutyl acid ester 4 - ({[6- (4-carbamimidoyl-2-fluoro-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Acid cyclobutyl ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-ylamino] -piperidine-1-carboxylic acid; N- (2-Fluoro-4-methanesulfonyl-phenyl) -N '- [1- (3-isopropyl- [1,2,4] oxadiazol-5-ylmethyl) -piperidin-4-ylmethyl] -N'-methyl -pyrimidine; -4,6-diamine; 1-Ethyl-propyl acid ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({ethyl- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({ethyl- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - ({[6- (4-Cyano-2,5-difluoro-phenylamino) -pyrimidin-4-yl] -ethyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-amino-2,5-difluoro-phenoxy) -pyrimidin-4-yl] -ethyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2,5-Difluoro-4-methoxy-phenylamino) -pyrimidin-4-yl] -ethyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- {2,5-difluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -ethyl-amino} -methyl) -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({ethyl- [6- (2,4,5-trifluoro-phenylamino) -pyrimidin-4-yl) -amino} -methyl) -piperidine-1-carboxylic acid; (2-Fluoro-4-methanesulfonylphenyl) - {6- [4- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin-4-yl} -amine ; Isopropyl acid ester 4 - [(ethyl- {6- [4- (N-ethylcarbamimidoyl) -2,5-difluoro-phenylamino] -pyrimidin-4-yl} -amino) -methyl] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (4-Bromo-2,5-difluoro-phenylamino) -pyrimidin-4-yl] -ethyl-amino} -methyl) -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - [({6- [5- (2-Aminoethylamino) -4-cyano-2-fluoro-phenylamino] -pyrimidin-4-yl} -ethyl-amino) -methyl] -piperidine-1-carboxylic acid; Acid methyl ester {1- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -piperidin-4-yl} -acetic acid; Ethyl acid ester 3- {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl) -piperazin-1-yl) -propionic; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (4-isobutyl-phenyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (4-isopropyl-phenyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; {6- [4- (3-Cyclopropylmethyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin-4-yl} -2-fluoro-4-methanesulfonyl-phenyl-amine ; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (3-isobutyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (4-isopropoxy-phenyl) -piperazin-1-yl] -pyrimidin-4-yl} -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (4-isopropoxy-phenyl) -piperidin-1-yl] -pyrimidin-4-yl} -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (5-isopropoxy-pyridin-2-yl) -piperazin-1-yl] -pyrimidin-4-yl} -amine; {6- [4- (3-Dimethylaminomethyl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin-4-yl} - (2-fluoro-4-methanesulfonyl-phenyl) -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - (6- {4- [2- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -ethyl] -piperazin-1-yl} - pyrimidin-4-yl) -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (5-isopropoxy-pyridin-2-yloxy) -piperidin-1-yl] -pyrimidin-4-yl) -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [4- (3-pyridin-3-yl- [1,2,4] oxadiazol-5-yl) -piperidin-1-yl] -pyrimidin- 4-yl} -amine; 2,5-Difluoro-4- {6- [4- (4-isopropoxy-phenyl) -piperazin-1-yl] -pyrimidin-4-ylamino} -benzonitrile; Tert-butyl acid ester 4 - {[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-ylamino] -methyl} -piperidine-1-carboxylic acid; Isopropyl acid ester 4 - {[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-ylamino] -methyl} -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - ({[6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yl] -isopropyl-amino} -methyl) -piperidine-1-carboxylic acid; Isobutyl acid ester 4 - ({[4- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyridin-2-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid; and isobutyl acid ester 4 - ({[2- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyridin-4-yl] -methyl-amino} -methyl) -piperidine-1-carboxylic acid.

Specific examples of GPR119 agonists described in US Patent Application No. 60 / 577,354 include the following compounds according to the Formula (V) (denominated in this document Group E2): Ester tert-butyl acid 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-ylmethyl) -piperidin-4-yloxy] -pyrimidin-4-yl} -amine; Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (6-Chloro-pyridin-2-yl) - {4- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; (6-Bromo-pyridin-2-yl) - {4- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} - (6-methyl-pyridin-2-yl) -methanone; {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} - (6-fluoro-pyridin-2-yl) -methanone; {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} -pyridin-2-yl-methanone; (5-Bromo-pyridin-3-yl) - {4- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; {4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} - (5-methyl-pyridin-3-yl) -methanone; (5,6-Dichloro-pyridin-3-yl) - {4- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; Tert-butyl acid ester 4- [6- (4-Cyano-2,5-difluoro-phenylamino) -pyrimidin-4-yl-oxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2,5-Difluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2,4,5-Trifluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (4-Bromo-2,5-difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (3-Fluoro-4-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (3-Hydroxy-4-methoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Cyano-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (3-Chloro-4-cyano-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Chloro-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (3-Fluoro-4-methoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (3,4-Dimethoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2,3-dihydro-benzo [1,4] dioxin-6-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Cyano-2,5-difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (4-Cyano-5-ethylamino-2-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Ethoxy-2,5-difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (4-Ethylsulfanyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (4-Isopropylsulfanyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (5-Butyl-pyridin-2-yl) - {4- [6- (2-fluoro-4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidin-1-yl} -methanone; Tert-butyl acid ester 4- [6- (5-Chloro-3-methyl-pyridin-2-ylamino) -pyrimidin-4-yl-oxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Acetylamino-4-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (5-Fluoro-4-methyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Methoxy-5-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Methoxy-2-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Fluoro-5-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Chloro-6-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (4-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, Tert-butyl acid ester 4- [6- (6-Chloro-2-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Fluoro-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Chloro-4-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Methoxy-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (5-Fluoro-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Fluoro-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (6-Chloro-5-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Methyl-pyridin-4-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Methoxy-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2,5-Difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (4-Chloro-2-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Methoxy-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Cyano-3-methoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3-Fluoro-4-hydroxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Methoxy-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-isopropoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; (2-Fluoro-4-methanesulfonyl-phenyl) - [6- (5'-isopropoxy-3,4,5,6-tetrahydro-2H- [1,2 '] bipyridinyl-4-yloxy) -pyrimidin-4- il] -amine; (2-Fluoro-4-methanesulfonyl-phenyl) - {6- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) -piperidin-4-yloxy] -pyrimidin-4-yl} -amine; Isopropyl acid ester 4- [6- (4-Cyano-2-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (pyridin-4-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-propoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-ethylamino-2-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Dimethylamino-2-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-propylamino-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-isopropylamino-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Methyl-6-propylamino-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Isopropylamino-2-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-methyl-6-propoxy-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Iodo-2-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-iodo-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [methyl- (2-methyl-4,5,6,7-tetrahydro-2H-indazol-3-yl) -amino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-methyl-2H-pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Phenyl-2H-pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-tert-Butyl-1 H -pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-p-tolyl-1H-pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Methoxy-5-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Acetylamino-3-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3-Chloro-4-fluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3,5-Dimethoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Ethyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-methyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6-2-methyl-quinolin-6-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Methylsulfanyl-benzothiazol-6-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-morpholin-4-yl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Benzenesulfonyl-thiophene-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Piperidin-1-yl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3-Trifluoromethoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Oxo-5,6,7,8-tetrahydro-naphthalen-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-methyl-1 H -pyrazolo [3,4-b] pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Cyano-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Bromo-2,5-difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Trifluoromethyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-methyl-1 H -pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Cyclopropyl-1H-pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,6-Dimethyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Cyano-2-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Methoxy-2-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,4-Dimethoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [acetyl- (2-fluoro-4-methanesulfonyl-phenyl) -amino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-carbamoyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4- (3,4-Difluoro-phenyl) -thiazol-2-ylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Oxo-1-phenyl-4,5-dihydro-1 H -pyrazol-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3-Oxazol-5-yl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Trifluoromethyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, Isopropyl acid ester 4- [6- (4-Chloro-2-trifluoromethoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6 - [(5-pyridin-2-yl-thiophen-2-ylmethyl) -amino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [5- (4-Chloro-phenyl) -2H-pyrazol-3-ylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (1-Oxo-indan-5-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [5- (1-methyl-pyrrolidin-2-yl) -pyridin-2-ylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (6-Methoxy-2-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (5-Bromo-3-methyl-pyridin-2-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Chloro-6-methyl-pyridin-3-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-ethynyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Bromo-2-trifluoromethoxy-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3-Iodo-4-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-5-methyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [5- (4-methoxy-phenyl) - [1,3,4] thiadiazol-2-ylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (3,5-Dimethyl-isoxazol-4-ylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [2- (2,5-Difluoro-4-propoxy-phenylamino) -pyridin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-propylamino-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,5-Difluoro-4-morpholin-4-yl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-methyl-4-propylamino-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (4-methyl-piperazin-1-yl) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-pyrrolidin-1-yl-ethoxy) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [4- (2-Dimethylamino-ethoxy) -2,5-difluoro-phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-morpholin-4-yl-ethoxy) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,4-Difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,4,5-Trifluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-methanesulfonyl-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [acetyl- (4-methanesulfonyl-phenyl) -amino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; (2,5-Difluoro-4-propoxy-phenyl) - {6- [1- (5-isopropyl- [1,2,4] oxadiazol-3-yl) -piperidin-4-yloxy] -pyrimidin-4- il} -amine; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (morpholin-4-ylamino) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-methoxy-ethylamino) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- (6- {2,5-Difluoro-4 - [(tetrahydro-furan-2-ylmethyl) -amino] -phenylamino} -pyrimidin-4-yloxy) -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Butylamino-2,5-difluoro-phenylamino) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (3-methyl-butylamino) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid, Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -2-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (2-morpholin-4-yl-ethylamino) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid, Isopropyl acid ester 4- {6- [2- (2,5-Difluoro-phenoxy) -ethylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2,3-Difluoro-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (4-Bromo-2-fluoro-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-morpholin-4-yl-phenoxy) -pyrimidin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- {6- [2,5-Difluoro-4- (tetrahydro-furan-2-ylmethoxy) -phenylamino] -pyrimidin-4-yloxy} -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyridin-2-yloxy] -piperidine-1-carboxylic acid; Tert-butyl acid ester 4- [5- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyridin-3-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [6- (2-Fluoro-4-methanesulfonyl-phenylamino) pyridin-2-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [4- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyridin-2-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [4- (2,5-Difluoro-4-propoxy-phenylamino) -pyridin-2-yloxy] -piperidine-1-carboxylic acid; and isopropyl acid ester 4- [2- (2-Fluoro-4-methanesulfonyl-phenylamino) -pyridin-4-yloxy] -piperidine-1-carboxylic acid; Isopropyl acid ester 4- [2- (2,5-Difluoro-4-propoxy-phenylamino) -pyridin-4-yloxy] -piperidine-1-carboxylic acid.

In International Application Nº PCT / GB2004 / 050046 (published as document WO 2005/061489) is describe examples of agonists of GPR119. In the request International No. PCT / GB2004 / 050046 describes itself as an agonist of GPR119, a compound of Formula (VI):

(VI) R 1 -AVBR 2

in the what:

<dl><dt>quad</dt><dd>V is a 5-membered heteroaryl ring that it contains up to four heteroatoms selected from O, N and S, optionally substituted with alkyl C 1-4;</dd></dl>

<dl><dt>quad</dt><dd>A is -CH = CH- or (CH 2) n;</dd></dl>

<dl><dt>quad</dt><dd>B is -CH = CH- or (CH2) n, where one of the CH2 groups can replace with O, NR 5, S (O) m, C (O) or C (O) NR 12;</dd></dl>

<dl><dt>quad</dt><dd>n is independently 0, 1, 2 or 3;</dd></dl>

<dl><dt>quad</dt><dd>m is independently 0, 1 or 2;</dd></dl>

<dl><dt>quad</dt><dd>R1 is 3- or 4-pyridyl, 4- or 5-pyrimidinyl or 2-pyrazinyl, any of them may be optionally substituted with one or more substituents selected from halo, alkyl C 1-4, C 1-4 fluoroalkyl, C 2-4 alkenyl, alkynyl C 2-4, C 3-7 cycloalkyl, aryl, OR 6, CN, NO 2, S (O) m R 6, CON (R 6) 2, N (R 6) 2, NR 10 COR 6, NR 10 SO 2 R 6, SO 2 N (R 6) 2, a heterocyclyl group of 4 to 7 members or a 5 or 6 member heteroaryl group;</dd></dl>

<dl><dt>quad</dt><dd>R2 is substituted 4 to 7 membered cycloalkyl with R 3, C (O) OR 3 C (O) R 3 or S (O) 2 R2, or 4- to 7-membered heterocyclyl which contains one or two nitrogen atoms that is unsubstituted or substituted with C (O) OR 4, C (O) R 3, S (O) 2 R 3, C (O) NHR 4, P (O) (OR 11) 2 or a heteroaryl group containing 5 or 6 nitrogen members;</dd></dl>

<dl><dt>quad</dt><dd>R 3 is C 3-8 alkyl, C 3-8 alkenyl or alkynyl C_ {3-8}, any of them can be optionally substituted with up to 5 fluorine or chlorine atoms, and it can contain a group CH_ {2} that can be replaced by O, or C 3-7 cycloalkyl, aryl, heterocyclyl, heteroaryl, alkyl C 1-4 -cycloalkyl C 3-7, alkyl C 1-4 -aryl, alkyl C 1-4 -heterocyclyl or alkyl C 1-4 -heteroaryl, being able be any of them optionally substituted with one or more substituents selected from halo, alkyl C 1-4, C 1-4 fluoroalkyl, OR 6, CN, CO 2 C 1-4 alkyl, N (R 6) 2 and NO 2;</dd></dl>

<dl><dt>quad</dt><dd>R 4 is C 2-8 alkyl, C 2-8 alkenyl or alkynyl C_ {2-8}, any of them can be optionally substituted with up to 5 fluorine or chlorine atoms, and it can contain a group CH_ {2} that can be replaced by O or C 3-7 cycloalkyl, aryl, heterocyclyl, heteroaryl, alkyl C 1-4 -cycloalkyl C 3-7, alkyl C 1-4 -aryl, alkyl C 1-4 -heterocyclyl or alkyl C 1-4 -heteroaryl, being able be any of them substituted with one or more substituents selected from halo, C 1-4 alkyl, C 1-4 fluoroalkyl, OR 6, CN, CO 2 C 1-4 alkyl, N (R 6) 2 and NO 2;</dd></dl>

<dl><dt>quad</dt><dd>R 5 is hydrogen, C (O) R 7, S (O) 2 R 8, cycloalkyl C 3-7 or C 1-4 alkyl optionally substituted with OR 6, cycloalkyl C 3-7, aryl, heterocyclyl or heteroaryl, where cyclic groups may be substituted with one or more substituents selected from halo, alkyl C 1-2, C 1-2 fluoroalkyl, OR 6, CN, N (R 6) 2 and NO 2;</dd></dl>

<dl><dt>quad</dt><dd>R 6 are independently hydrogen, alkyl C 1-4, C 3-7 cycloalkyl, aryl, heterocyclyl or heteroaryl, where cyclic groups they may be substituted with one or more selected substituents between halo, C 1-4 alkyl, fluoroalkyl C 1-4, OR 9, CN, SO 2 CH 3, N (R 10) 2 and NO 2; or a group (N (R 10) n can form a ring 4- to 7-membered heterocyclic optionally containing a additional heteroatom selected from O and NR 10.</dd></dl>

<dl><dt>quad</dt><dd>R 7 is hydrogen, alkyl C 1-4, OR 6, N (R) 2, aryl or heteroaryl;</dd></dl>

<dl><dt>quad</dt><dd>R 8 is C 1-4 alkyl, C 1-4 fluoroalkyl, aryl or heteroaryl;</dd></dl>

<dl><dt>quad</dt><dd>R 9 is hydrogen, alkyl C 1-2 or fluoroalkyl C 1-2;</dd></dl>

<dl><dt>quad</dt><dd>R 10 is hydrogen or alkyl C 1-4;</dd></dl>

<dl><dt>quad</dt><dd>R 11 is phenyl; and</dd></dl>

<dl><dt>quad</dt><dd>R 12 is hydrogen, alkyl C 1-4 or cycloalkyl C_ {3-7}.</dd></dl>

The present invention also includes diastereomers as well as optical isomers, for example mixtures of enantiomers including racemic mixtures, as well as enantiomers and individual diastereomers, which arise as a result of the structural asymmetry in certain compounds of the invention. The separation of individual isomers or selective synthesis of the individual isomers is performed by application of various methods that are well known to specialists in the technique.

Specific examples of GPR119 agonists described in International Application No. PCT / GB2004 / 050046 include the following compounds according to Formula (VI) (denominated in this document Group F1): Ester<i>tert</i>-butyl acid 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid; 3- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid Ester <i>tert</i>-butyl of the acid; 4- [5- (4-pentylcyclohexylmethyl) - [1,2,4] oxadiazol-3-yl] pyridine;<i>trans-</i>2-Chloro-4- [5- (4-pentylcyclohexane) - [1,2,4] oxadiazol-3-yl] pyridine;<i>trans-</i>4- [5- (4-Pentylcyclohexane) - [1,2,4] oxadiazol-3-ylmethyl] pyridine; Ester <i>tert</i>-butyl acid 4- (3-pyridin-4-ylmethyl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid;<i>trans-</i>3- [5- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-3-ylmethyl] pyridine; 4- [5- (4-Butylcyclohexane) - [1,2,4] oxadiazol-3-yl] pyridine; 4- [5- (4-n-Propylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine;<i>trans-</i>4- [5- (4-Pentylcyclohexane) - [1,2,4] oxadiazol-3-yl] pyridine; Ester <i>tert</i>-butyl acid 4- [2- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-yl) -ethyl] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) piperidine-1-carboxylic acid; 3- [5- (4-Propylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine; 3- [5- (4-Butylcyclohexane) - [1,2,4] oxadiazol-3-yl] pyridine; Acid methylamide<i>trans-</i>4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine-2-carboxylic acid; Acid amide<i>trans</i>-4- [5- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine-2-carboxylic acid;<i>trans-</i>4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Chloro-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>3- [3- (4-Pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Methyl-3- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Chloro-6-methyl-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>4- [3- (4-Pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine-2-carbonitrile;<i>trans-</i>2-Chloro-3- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Chloro-6-methyl-3- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Methyl-5- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>3-Methyl-5- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2,6-Dichloro-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Chloro-6-methoxy-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>5- [3- (4-Pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] -2- [1,2,4] triazol-1-ylpyridine; 2- [3- (4-Pentyl-cyclohexyl) - [1,2,4] oxadiazol-5-yl] pyrazine; 4- [3- (4-Pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyrimidine;<i>trans-</i>5- [3- (4-Pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine-2-carbonitrile;<i>trans-</i>5-Chloro-2-methylsulfanyl-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyrimidine;<i>trans-</i>2-Fluoro-5- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Fluoro-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine; trans-2-Imidazol-1-yl-5- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>2-Methyl-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>3-Methyl-4- [3- (4-pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] pyridine;<i>trans-</i>4- {2- [3- (4-Pentylcyclohexyl) - [1,2,4] oxadiazol-5-yl] vinyl} pyridine; Tert-butyl acid ester 4- (5-pyridin-4-yl- [1,2,4] oxadiazol-3-ylmethoxy) piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [5- (2-Cyanopyridin-4-yl) - [1,2,4] oxadiazol-3-ylmethoxy] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid (<i>AND</i>) -4- [5- (2-Pyridin-3-yl-vinyl) - [1,2,4] oxadiazol-3-ylmethoxy] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid (<i>AND</i>) -4- [5- (2-pyridin-3-yl-vinyl) - [1,2,4] oxadiazol-3-yl] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid (<i>AND</i>) -4- [5- (2-Pyridin-3-yl-vinyl) - [1,2,4] oxadiazol-3-ylmethyl] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid (E) -4- [5- (2-Pyridin-4-yl-vinyl) - [1,2,4] oxadiazol-3-yl] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [5- (2-Pyridin-4-yl-ethyl) - [1,2,4] oxadiazol-3-yl] -piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- {5- [2- (2-Cyanopyridin-4-yl) ethyl] - [1,2,4] oxadiazol-3-yl} piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- {5- [2- (2-Cyanopyridin-4-yl) ethyl] - [1,2,4] oxadiazol-3-ylmethoxy} piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- {5- [2- (2-Cyanopyridin-4-yl) ethyl] - [1,2,4] oxadiazol-3-ylmethyl} piperidine-1-carboxylic acid; 4- (5-Piperidin-4-yl- [1,2,4] oxadiazol-3-yl) pyridine; Isobutyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid; 2-Methoxyethyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid; Ethyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid; 3,3-Dimethyl-1- [4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidin-1-yl] butan-1-one; 2-Cyclopentyl-1- [4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidin-1-yl] ethanone; 4- {5- [1- (Butane-1-sulfonyl) piperidin-4-yl] - [1,2,4] oxadiazol-3-yl} pyridine; Acid Propylamide 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid; acid tert-Butylamide 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidine-1-carboxylic acid; Cyclopentyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl-methoxy) piperidine-1-carboxylic acid; Benzyl Acid Ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Isobutyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Ethyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Cycloheptyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Acid methyl ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 2-Methoxyethyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Isopropyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 4-Methoxy-phenyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 2,2,2-Trichlorethyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 4-Chloro-phenyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Phenyl Acid Ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 2-Ethyl hexyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Propyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Hexyl Acid Ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; (7<i>R</i>,2<i>S</i>,5<i>R</i>) -2-Isopropyl-5-methylcyclohexyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; (1S, 2R, 5S) -2-Isopropyl-5-methylcyclohexyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 2,2-Dimethylpropyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Naphthalen-1-yl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 2-Methoxy-phenyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 3-Trifluoromethylphenyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Prop-2-Inyl Acid Ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; But-2-Inyl Acid Ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Pentyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; P-tolic acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 2-Chloro-phenyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Naphthalen-2-yl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Butyl Acid Ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 4-Methoxycarbonyl-phenyl ester of acid 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 4-Fluoro-phenyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; 3-Methyl-1- [4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] -butan-1-one; Phenyl- [4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] methanone; 1- [4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] butan-1-one; 2,2-Dimethyl-1- [4-3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] propan-1-one; Cyclopentyl- [4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] methanone; [4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] -p-tolylmethanone; 3,3-Dimethyl-1- [4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] butan-1-one; 4- {5- [1- (Butane-1-sulfonyl) piperidin-4-yloxymethyl] - [1,2,4] oxadiazol-3-yl} pyridine; 4- {5- [1- (Propane-1-sulfonyl) piperidin-4-yloxymethyl] - [1,2,4] oxadiazol-3-yl} pyridine; <i>tert</i>-Butylamide of acid 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; acid o-Tolylamide 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidine-1-carboxylic acid; Propyl acid ester <i>trans-</i>4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) cyclohexanecarboxylic acid; Butyl Acid Ester trans-4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) cyclohexanecarboxylic acid; Isobutyl acid ester trans-4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) cyclohexanecarboxylic acid;<i>trans-</i>4- [5- (4-Propoxymethylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine;<i>trans-</i>4- [5- (4-Butoxymethylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine; cis-4- [5- (3-Butoxymethylcyclopentyl) - [1,2,4] oxadiazol-3-yl] pyridine;<i>cis-</i>4- [5- (3-Propoxymethylcyclopentyl) - [1,2,4] oxadiazol-3-yl] pyridine;<i>cis-</i>4- [5- (3-Butoxymethylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine; 4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) -3,4,5,6-tetrahydro-2H- [1,3 '] bipyridinyl; 2- [4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] pyrazine; 2- [4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] pyrimidine; (4-Pentylcyclohexyl) - (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amine; (4-Pentylcyclohexyl-methyl) - (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amine; Ester <i>tert</i>-butyl acid 4 - [(3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic; Ester <i>tert</i>-butyl acid 4 - {[3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] methyl} -piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4 - {[5- (2-Cyanopyridin-4-yl) - [1,2,4] oxadiazol-3-ylmethyl] amino} -piperidine-1-carboxylic acid; Methyl- (4-pentylcyclohexyl) - (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amine; Methyl- (4-pentylcyclohexylmethyl) - (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amine; Ester <i>tert</i>-butyl acid 4- [methyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [ethyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [propyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic acid, Ester <i>tert</i>-butyl acid 4- [cyclopropylmethyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [butyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic acid, Ester <i>tert</i>-butyl acid 4 - {[methyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] methyl} -piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4 - {[ethyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] methyl} -piperidine-1-carboxylic acid; Tert-butyl acid ester 4 - {[5- (2-Cyanopyridin-4-yl) - [1,2,4] oxadiazol-3-ylmethyl] ethylamino} -piperidine-1-carboxylic acid; Cyclopentyl acid ester 4- [methyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] piperidine-1-carboxylic acid, 2,2,2-Trichlorethyl acid ester 4 - {[methyl- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) amino] methyl} -piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxymethyl) piperidine-1-carboxylic acid, Ester <i>tert</i>-butyl acid 4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethyl) piperazine-1-carboxylic acid, Tert-butyl acid ester 4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethylsulfanyl) piperidine-1-carboxylic acid, Ester <i>tert</i>-butyl acid 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethanesulfonyl) piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- (5-pyridin-4-yl- [1,3,4] oxadiazol-2-ylmethoxy) piperidine-1-carboxylic acid; (4-Pentylcyclohexyl) acid amide 3-pyridin-4-yl- [1,2,4] oxadiazol-5-carboxylic acid; Diphenyl Acid Ester [4- (3-Pyridin-4-yl- [1,2,4] oxadiazol-5-ylmethoxy) piperidin-1-yl] phosphonic; Ester <i>tert</i>-butyl acid 4- (4-pyridin-4-yl-thiazol-2-ylmethoxy) piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- (2-pyridin-4-yl-thiazol-4-ylmethyl) piperidine-1-carboxylic acid;<i>trans-</i>4- [5- (4-Pentyl-cyclohexyl) - [1,3,4] thiadiazol-2-yl] pyridine; Ester <i>tert</i>-butyl acid 4- (5-pyridin-4-yl- [1,3,4] thiadiazol-2-ylmethoxy) piperidine-1-carboxylic acid, Ester <i>tert</i>-butyl acid 4- (5-pyridin-4-yl-4H- [1,2,4] triazol-3-ylmethoxy) piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [2- (5-Pyridin-4-yl-isoxazol-3-yl) ethyl] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- (5-pyridin-4-yl-isoxazol-3-ylmethoxy) piperidine-1-carboxylic acid; Tert-butyl acid ester 4- (5-pyridin-4-yl-isoxazol-3-ylmethyl) piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [2- (1-methyl-5-pyridin-4-yl-1H-pyrazol-3-yl) ethyl] piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid 4- [2- (2-methyl-5-pyridin-4-yl-2H-pyrazol-3-yl) ethyl] -piperidine-1-carboxylic acid; Ester <i>tert</i>-butyl acid (<i>AND</i>) -4- {S- [2- (2-Cyanopyridin-4-yl) vinyl] - [1,2,4] oxadiazol-3-yl} piperidine-1-carboxylic; Ester <i>tert</i>-butyl acid 4- {S- [2- (2H-tetrazol-5-yl) pyridine-4-yl] - [1,2,4] oxadiazol-3-ylmethoxy} -piperidine-1-carboxylic acid, Isopropyl acid ester 4- [5- (2-Cyanopyridin-4-yl) - [1,2,4] oxadiazol-3-yl-methoxypiperidine-1-carboxylic acid; and phenyl acid ester 4- [5- (2-Cyanopyridin-4-yl) - [1,2,4] oxadiazol-3-ylmethoxy] piperidine-1-carboxylic.

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (I).

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (II).

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (III).

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (IV).

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (V).

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (VI).

In one aspect of the present invention, the GPR119 agonist is a compound of Formula (VI), with the condition that the compound is not 4- (5-piperidin-4-yl- [1,2,4] oxadiazol-3-yl) pyridine, butyl acid ester 4- (3-pyridin-4-yl- [1,2,4] oxadiazol-5-yl) piperidin-1-carboxylic acid, 4- [5- (4-Butylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine, 3- [5- (4-Butylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine or 3- [5- (4-propylcyclohexyl) - [1,2,4] oxadiazol-3-yl] pyridine.

In one aspect of the present invention, the GPR119 agonist is selected from Group A1, Group B1, Group B2, Group B3, Group B4, Group B5, Group C1, Group C2, Group C3, Group C4, Group C5, Group C6, Group C7, Group C8, Group C9, Group C10, Group D1, Group D2, Group D3, Group D4, Group D5, Group D6, Group D7, Group D8, Group D9, Group D10, Group D11, Group D12, Group D13, Group D14, Group E1, Group E2 or Group F1.

In one aspect, the GPR119 agonist is select from the left column of Table B.

Specific examples of GPR119 agonists include thiobenzoate 2- (pyridine-4-yl) ethyl and oil L-? -Lysophosphatidyl-choline, as described in EP 1338651.

Examples of agonists from GPR119 in International Application WO 03/026661. The agonists of GPR119 described in WO 03/026661 include, but not limitation, the compounds of Table C.

TABLE C

<figref>40</figref>

<figref>41</figref>

<figref>42</figref>

<pre listing-type="other">\ newpage</pre>

Examples of agonists from GPR119 in JP International Application 2004269468. Agonists of GPR119 described in JP 2004269468 include, but not limitation, the compounds of Table D.

TABLE D

<figref>43</figref>

<figref>44</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Examples of agonists from GPR119 in JP International Application 2004269469. Agonists of GPR119 described in JP 2004269469 include, but not limitation, the compounds of Table E.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

TABLE E

<figref>45</figref>

<figref>46</figref>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

In one aspect of the present invention, the GPR119 agonist is a compound that comprises Group A1, Group B1, Group B2, Group B3, Group B4, Group B5, Group C1, Group C2, Group C3, Group C4, Group C5, Group C6, Group C7, Group C8, Group C9, Group C10, Group D1, Group D2, Group D3, Group D4, Group D5, Group D6, Group D7, Group D8, Group D9, Group D10, Group D11, Group D12, Group D13, Group D14, Group E1, Group E2 or Group F1.

In one aspect of the present invention, it can exclude one or more of any GPR119 agonist from any embodiment of the present invention.

In one aspect of the present invention, the GPR119 agonist has an EC50 of less than about 10 µM, less than about 1 µM, less than about 100 nM, less than about 75 nM, less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less of approximately 3 nM, less than about 2 nM or less than approximately 1 nM. Preferably, the GPR119 agonist has an EC50 of less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less of about 2 nM or less than about 1 nM.

In one aspect of the present invention, the GPR119 agonist is a selective agonist of GPR119, in which the GPR119 selective agonist has a selectivity for GPR119 by on top of the releasing factor receptor corticotropin-1 (CRF-1) of at least about 100 times

In one aspect of the present invention, the GPR119 agonist is active orally.

In one aspect of the present invention, the GPR119 agonist is a human GPR119 agonist.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

DPP-IV inhibitors

The class of inhibitors of DPP-IV useful in new combinations Therapeutics of the present invention include compounds that have an acceptably high affinity for DPP-IV DPP-IV inhibitor or pharmaceutically acceptable salt can be any inhibitor of DPP-IV, more preferably a selective inhibitor of dipeptidyl peptidase and, more preferably, an inhibitor DPP-IV selective.

Examples of inhibitors of DPP-IV in Villhauer <i>et al</i>., J Med Chem (2003) 46: 2774-2789, for LAF237; Ahren<i>et al</i>J Clin Endocrinol Metab (2004) 89: 2078-2084; Villhauer <i>et al</i>., J Med Chem (2002) 45: 2362-2365 for NVP-DPP728; Ahren<i>et al</i>, Diabetes Care (2002) 25: 869-875 for NVP-DPP728; Peters<i>et al</i>., Bioorg Med Chem Lett (2004) 14: 1491-1493; Caldwell<i>et al</i>, Bioorg Med Chem Lett (2004) 14: 1265-1268; Edmondson <i>et al</i>., Bioorg Med Chem Lett (2004) 14: 5151-5155; and Abe<i>et al</i>., J Nat Prod (2004) 67: 999-1004.

Specific examples of inhibitors of DPP-IV include, but is not limited to, derivatives dipeptides or dipeptide mimetics such as alanine-pyrrolidide, isoleucine-thiazolidide and pseudosustrate N-Valyl prolyl, O-benzoyl hydroxylamine, as described for example in the Patent of United States No. 6,303,661.

<pre listing-type="other">\ newpage</pre>

Examples of inhibitors of DPP-IV in United States Patents No. 6,869,947, 6,867,205, 6,861,440, 6,849,622, 6,812,350, 6,803,357, 6,800,650, 6,727,261, 6,716,843, 6,710,040, 6,706,742, 6,645,995, 6,617,340, 6,699,871, 6,573,287, 6,432,969, 6,395,767, 6,380,398, 6,303,661, 6,242,422, 6,166,063, 6,100,234, 6,040,145. They can examples of DPP-IV inhibitors can be found in U.S. Patent Applications No. 2005059724, 2005059716, 2005043292, 2005038020, 2005032804, 2005004205, 2004259903, 2004259902, 2004259883, 2004254226, 2004242898, 2004229926, 2004180925, 2004176406, 2004138214, 2004116328, 2004110817, 2004106656, 2004097510, 2004087587, 2004082570, 2004077645, 2004072892, 2004063935, 2004034014, 2003232788, 2003225102, 2003216450, 2003216382, 2003199528, 2003195188, 2003162820, 2003149071, 2003134802, 2003130281, 2003130199, 2003125304, 2003119750, 2003119738, 2003105077, 2003100563, 2003087950, 2003078247, 2002198205, 2002183367, 2002103384, 2002049164, 2002006899.

Examples of inhibitors of DPP-IV in WO International Applications 2005/087235, WO 2005/082348, WO 2005/082849, WO 2005/079795, WO 2005/075426, WO 2005/072530, WO 2005/063750, WO 2005/058849, WO 2005/049022, WO 2005/047297, WO 2005/044195, WO 2005/042488, WO 2005/040095, WO 2005/037828, WO 2005/037779, WO 2005/034940, WO 2005/033099, WO 2005/032590, WO 2005/030751, WO 2005/030127, WO 2005/026148, WO 2005/025554, WO 2005/023762, WO 2005/020920, WO 05/19168, WO 05/12312, WO 05/12308, WO 05/12249, WO 05/11581, WO 05/09956, WO 05/03135, WO 05/00848, WO 05/00846, WO 04/112701, WO 04/111051, WO 04/111041, WO 04/110436, WO 04/110375, WO 04/108730, WO 04/104216, WO 04/104215, WO 04/103993, WO 04/103276, WO 04/99134, WO 04/96806, WO 04/92128, WO 04/87650, WO 04/87053, WO 04/85661, WO 04/85378, WO 04/76434, WO 04/76433, WO 04/71454, WO 04/69162, WO 04/67509, WO 04/64778, WO 04/58266, WO 04/52362, WO 04/52850, WO 04/50022, WO 04/50658, WO 04/48379, WO 04/46106, WO 04/43940, WO 04/41820, WO 04/41795, WO 04/37169, WO 04/37181, WO 04/33455, WO 04/32836, WO 04/20407, WO 04/18469, WO 04/18468, WO 04/18467, WO 04/14860, WO 04/09544, WO 04/07468, WO 04/07446, WO 04/04661, WO 04/00327, WO 03/106456, WO 03/104229, WO 03/101958, WO 03/101448, WO 03/99279, WO 03/95425, WO 03/84940, WO 03/82817, WO 03/80633, WO 03/74500, WO 03/72556, WO 03/72528, WO 03/68757, WO 03/68748, WO 03/57666, WO 03/57144, WO 03/55881, WO 03/45228, WO 03/40174, WO 03/38123, WO 03/37327, WO 03/35067, WO 03/35057, WO 03/24965, WO 03/24942, WO 03/22871, WO 03/15775, WO 03/04498, WO 03/04496, WO 03/02530, WO 03/02596, WO 03/02595, WO 03/02593, WO 03/02553, WO 03/02531, WO 03/00181, WO 03/00180, WO 03/00250, WO 02/83109, WO 02/83128, WO 02/76450, WO 02/68420, WO 02/62764, WO 02/55088, WO 02/51836, WO 02/38541, WO 02/34900, WO 02/30891, WO 02/30890, WO 02/14271, WO 02/02560, WO 01/97808, WO 01/96295, WO 01/81337, WO 01/81304, WO 01/68603, WO 01/55105, WO 01/52825, WO 01/34594, WO 00/71135, WO 00/69868, WO 00/56297, WO 00/56296, WO 00/34241, WO 00/23421, WO 00/10549, WO 99/67278, WO 99/62914, WO 99/61431, WO 99/56753, WO 99/25719, WO 99/16864, WO 98/50066, WO 98/50046, WO 98/19998, WO 98/18763, WO 97/40832, WO 95/29691, WO 95/15309, WO 93/10127, WO 93/08259, WO 91/16339, EP 1517907, EP 1513808, EP 1492777, EP 1490335, EP 1489088, EP 1480961, EP 1476435, EP 1476429, EP 1469873, EP 1465891, EP 1463727, EP 1461337, EP 1450794, EP 1446116, EP 1442049, EP 1441719, EP 1426366, EP 1412357, EP 1406873, EP 1406872, EP 1406622, EP 1404675, EP 1399420, EP 1399471, EP 1399470, EP 1399469, EP 1399433, EP 1399154, EP 1385508, EP 1377288, EP 1355886, EP 1354882, EP 1338592, EP 1333025, EP 1304327, EP 1301187, EP 1296974, EP 1280797, EP 1282600, EP 1261586, EP 1258476, EP 1254113, EP 1248604, EP 1245568, EP 1215207, EP 1228061, EP 1137635, EP 1123272, EP 1104293, EP 1082314, EP 1050540, EP 1043328, EP 0995440, EP 0980249, EP 0975359, EP 0731789, EP 0641347, EP 0610317, EP 0528858, CA 2466870, CA 2433090, CA 2339537, CA 2289125, CA 2289124, CA 2123128, DD 296075, DE 19834591, DE 19828113, DE 19823831, DE 19616486, DE 10333935, DE 10327439, DE 10256264, DE 10251927, DE 10238477, DE 10238470, DE 10238243, DE 10143840, FR 2824825, FR 2822826, JP 2005507261, JP 2005505531, JP 2005502624, JP 2005500321, JP 2005500308, JP 2005023038, JP 2004536115, JP 2004535445, JP 2004535433, JP 2004534836, JP 2004534815, JP 2004532220, JP 2004530729, JP 2004525929, JP 2004525179, JP 2004522786, JP 2004521149, JP 2004503531, JP 2004315496, JP 2004244412, JP 2004043429, JP 2004035574, JP 2004026820, JP 2004026678, JP 2004002368, JP 2004002367, JP 2003535898, JP 2003535034, JP 2003531204, JP 2003531191, JP 2003531118, JP 2003524591, JP 2003520849, JP 2003327532, JP 2003300977, JP 2003238566, JP 2002531547, JP 2002527504, JP 2002517401, JP 2002516318, JP 2002363157, JP 2002356472, JP 2002356471, JP 2002265439, JP 2001510442, JP 2000511559, JP 2000327689, JP 2000191616, JP 1998182613, JP 1998081666, JP 1997509921, JP 1995501078, JP 1993508624.

In one aspect of the present invention, the DPP-IV inhibitor is valine-pyrrolidide [Deacon <i>et al</i>Diabetes (1998) 47: 764769.

In one aspect of the present invention, the DPP-IV inhibitor is 3- (L-Isoloucil) thiazolidine (isoleucine-thiazolidide). The Isoleucine-thiazolidide can be found in JP 2001510442, WO 97/40832, US 6,303,661 and DE 19616486.

Isoteucine-thiazolidide is describes as a selective DPP-IV inhibitor and orally active [Pederson <i>et al</i>, Diabetes (1998) 47: 1253-1258.

NVP-DPP728 is described as a selective and active DPP-IV inhibitor via oral [Villhauer <i>et al</i>, J Med Chem (2002) 45: 2362-2365].

In one aspect of the present invention, the DPP-IV inhibitor is 3 (R) -Amino-1- [3- (trifluoromethyl) -5,6,7,8-tetrahydro [1,2,4] triazolo [4,3-a] pyrazin-7-yl] -4- ( 2,4,5-trifluoropbenyl) butan-1-one (MK-0431). The MK-0431 can found in EP 1412357, WO 03/04498, US 6,699,871 and US 2003100563. The MK-0431 is described as a selective and active oral DPP-IV inhibitor [Weber <i>et al</i>, Diabetes (2004) 53 (Sup1.2): A151, 633-P (Summary).

In one aspect of the present invention, the DPP-IV inhibitor is (1 - [[3-hydroxy-1-adamantyl) amino] acetyl] -2-cyano- (S) -pyrrolidine (LAF237). LAF237 can be found in US documents 6,166,063, WO 00/34241, EP 1137635 and JP 2002531547.

LAF237 is described as an inhibitor of Selective and active oral DPP-IV [Villhauer<i>et al</i>, J Med Chem (2003) 46: 2774-2789].

In one aspect of the present invention, the DPP-IV inhibitor is (1S, 3S, SS) -2- [2 (S) -Amino-2- (3-hydroxiadamantan-1-yl) acetyl] -2-azabicyclo [3.1.0] hexane-3-carbonitrile (BMS-477118).

In one aspect of the present invention, the DPP-IV inhibitor is acidic [1- [2 (S) -Amino-3-methylbutyryl] pyrrolidin-2 (R) -yl] boronic (PT-100).

In one aspect of the present invention, the DPP-IV inhibitor is GSK-823093.

In one aspect of the present invention, the DPP-IV inhibitor is PSN-9301.

In one aspect of the present invention, the DPP-IV inhibitor is T-6666.

In one aspect of the present invention, the DPP-IV inhibitor is SYR-322.

In one aspect of the present invention, the DPP-IV inhibitor is SYR-619.

In one aspect of the present invention, the DPP-IV inhibitor is CR-14023.

In one aspect of the present invention, the DPP-IV inhibitor is CR-14025.

In one aspect of the present invention, the DPP-IV inhibitor is CR-14240.

In one aspect of the present invention, the DPP-IV inhibitor is CR-13651.

In one aspect of the present invention, the DPP-IV inhibitor is NNC-72-2138.

In one aspect of the present invention, the DPP-IV inhibitor is NN-7201.

In one aspect of the present invention, the DPP-IV inhibitor is PHX-1149.

In one aspect of the present invention, the DPP-IV inhibitor is PHX-1004.

In one aspect of the present invention, the DPP-IV inhibitor is SNT-189379.

In one aspect of the present invention, the DPP-IV inhibitor is GRC-8087.

In one aspect of the present invention, the DPP-IV inhibitor is PT-630.

In one aspect of the present invention, the DPP-IV inhibitor is SK-0403.

In one aspect of the present invention, the DPP-IV inhibitor is GSK-825964.

In one aspect of the present invention, the DPP-IV inhibitor is TS-021.

In one aspect of the present invention, the DPP-IV inhibitor is GRC-8200.

In one aspect of the present invention, the DPP-IV inhibitor is GRC-8116.

In one aspect of the present invention, the DPP-IV inhibitor is FE107542.

In one aspect of the present invention, the DPP-IV inhibitor is selected from the column right of Table B.

In one aspect of the present invention, the DPP-IV inhibitor is not identical to 1- [2- [5-Cyanopyridin-2-yl) amino] ethylamino] acetyl-2-cyano- (S) -pyrrolidine (NVP-DPP728).

In one aspect of the present invention, it can exclude one or more of any DPP-IV inhibitor of any embodiment of the present invention.

In one aspect of the present invention, the DPP-IV inhibitor has an IC50 of less than about 10 µM, less than about 1 µM, less of about 100 nM, less than about 75 nM, less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM or less than about 1 nM. Preferably, the DPP-IV inhibitor has a IC50 of less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less of about 2 nM or less than about 1 nM.

In one aspect of the present invention, the DPP-IV inhibitor is a selective inhibitor of DPP-IV, in which the selective inhibitor of DPP-IV has a selectivity for Human plasma DPP-IV above one or more of PPCE, DPP-II, DPP-8 and DPP-9 at least about 10 times, more preferably at least about 100 times and, more preferably, at least about 1000 times.

In one aspect of the present invention, the DPP-IV inhibitor is active orally.

<i>In one aspect of the present invention, the DPP-IV inhibitor is an inhibitor of Human DPP-IV</i>.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Combination of GPR119 Agonist and Inhibitor DPP-IV

By way of illustration and not as a limitation, provides an exemplary combination of GPR119 agonist and DPP-IV inhibitor according to the present invention by selecting a GPR119 agonist from the column left of Table B and a DPP-IV inhibitor of the right column of Table B. It is expressly contemplated that each individual combination of GPR119 agonist and inhibitor of DPP-IV provided by selection of an agonist of GPR119 from the left column of Table B and an inhibitor of DPP-IV of the right column of Table B is a separate embodiment within the scope of this invention.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

(Table goes to page following)

TABLE B

<figref>47</figref>

<figref>48</figref>

<figref>49</figref>

<figref>50</figref>

<figref>51</figref>

<figref>52</figref>

<figref>53</figref>

<figref>54</figref>

<figref>55</figref>

In addition, the compounds of the composition of the invention, including those illustrated in TABLE B, include all the pharmaceutically acceptable salts, solvates and hydrates of same. See, for example, Berge<i>et al</i> (1977), Journal of Pharmaceutical Sciences 66: 1-19; and Polymorphism in Pharmaceutical Solids (1999) Brittain, ed, Marcel Dekker, Inc.

Regarding combination therapy described above, the compositions according to the The invention can be administered in any suitable way. The tracks Suitable administration include oral, nasal, administration rectal, transmucosal, transdermal or intestinal, supply parenteral, including intramuscular, subcutaneous and intramedullary, as well as intrathecal, intraventricular injections direct, intravenous, intraperitoneal, intranasal, intrapulmonary (inhaled) or intraocular using methods known in the art. Other suitable routes of administration are aerosol and formulation extended release. Formulations are expressly contemplated sustained release, particularly prolonged release, of the medicaments of the invention. In certain embodiments preferred compositions according to the present invention They are administered orally. The compositions according to the The present invention can be prepared in solid or liquid form, such as tablets, capsules, powders, syrups, elixirs and the like, sterile aerosols, solutions, suspensions or emulsions and Similar. In certain embodiments, one or both of the agonist of GPR119 and DPP-IV inhibitor are administered by orally.

Formulations for oral administration they can be in the form of aqueous solutions and suspensions, in addition of solid formulations of tablets and capsules. The solutions and aqueous suspensions can be prepared from powders or sterile granules The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, oil cotton, peanut oil, sesame oil, benzyl alcohol, sodium chloride and / or various buffers. They know each other well and widely other adjuvants in the art.

It will be appreciated that the GPR119 agonist and the DPP-IV inhibitor may be present as a Combined preparation for simultaneous, separate or sequential use for the treatment or prevention of diabetes or a condition related to it. Such combined preparations they may be, for example, in the form of a double container.

Therefore, it will be further appreciated that the invention contemplates a product that comprises or consists essentially in a GPR119 agonist and an inhibitor of DPP-IV, as a combined preparation for use simultaneous, separate or sequential in the prevention or treatment of diabetes or a condition related to it.

A combination of the present can be prepared invention that comprises or consists essentially of an agonist of GPR119 and a DPP-IV inhibitor, by mixing the GPR119 agonist and DPP-IV inhibitor in together or independently with a vehicle, excipient, binder, diluent, etc. pharmaceutically acceptable, as described in this document, and administration of the mixture or mixtures orally or non-orally as a composition or compositions Pharmaceuticals

Therefore, it will be further appreciated that the GPR119 agonist and DPP-IV inhibitor or the Pharmaceutical composition can be administered in forms of Dosage separately or in a single dosage form.

It is further appreciated that when the agonist of GPR119 and the DPP-IV inhibitor are in forms separate dosage, the GPR119 agonist and the inhibitor of DPP-IV can be administered by different routes.

The pharmaceutical compositions of the agonist of GPR119 and DPP-IV inhibitor, individually or in combination, they can be prepared by methods well known in the technique, for example, by means of mixing, dissolution processes, granulation, dragee preparation, levigation, emulsion, conventional encapsulation, immobilization and lyophilization or spray drying.

They can be formulated in a conventional way Pharmaceutical compositions for use in accordance with the present invention, using one or more physiologically acceptable vehicles, comprising excipients and adjuvants that facilitate the processing of active compounds in preparations that can be used pharmaceutically They are available to specialists suitable pharmaceutically acceptable vehicles [see, for example, Remington: The Science and Practice of Pharmacy, (Gennaro<i>et al</i>., eds.), 20th Edition, 2000, Lippincott Williams and Wilkins; and Handbook of Pharmaceutical Excipients (Rowe<i>et to the</i>., eds.), 4th Edition, 2003, Pharmaceutical Press]. The appropriate formulation depends on the route of administration selected The term material "vehicle" or material "excipient" means in this document any substance, not properly a therapeutic agent, used as an excipient and / or diluent and / or adjuvant or vehicle for delivery of an agent therapeutic to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to allow or facilitate the formation of a unit dose of the composition in a separate article, such as a capsule or tablet suitable for oral administration. Excipients can include, by way of illustration and not as a limitation, diluents, disintegrants, bonding agents, adhesives, wetting agents, polymers, lubricants, emollients, substances added for mask or counteract an unpleasant taste or smell, flavorings, dyes, fragrances and substances added for Improve the appearance of the composition. The acceptable excipients include stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, magnesium carbonate, talc, gelatin, gum arabic, alginate sodium, peptin, dextrin, mannitol, sorbitol, lactose, sucrose, starches, gelatin, cellulosic materials, such as esters of cellulose of alkanoic acids and cellulose alkyl esters, wax Low melting point, cocoa butter or powder, polymers, such such as polyvinyl pyrrolidone, polyvinyl alcohol and polyethylene glycols and other pharmaceutically acceptable materials. The components of the pharmaceutical composition can be encapsulated or conform to tablets for administration convenient.

The pharmaceutically acceptable expression is refers to the properties and / or substances that are acceptable to the patient from a pharmacological / toxicological point of view and for the pharmaceutical chemist who makes it from a point of view physical / chemical regarding the composition, formulation, stability, patient acceptance and bioavailability.

When the GPR119 agonist and the inhibitor of DPP-IV are in separate dosage forms, it understand that a pharmaceutically acceptable vehicle used for the GPR119 agonist formulation does not have to be identical to a pharmaceutically acceptable carrier used for the formulation of a DPP-IV inhibitor.

Dragee cores are provided with suitable coatings. For this purpose, solutions of concentrated sugars that may optionally contain gum Arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. They can dyes or pigments are added to the tablet coatings or dragees for identification or to characterize different dose combinations of active compound.

The pharmaceutical compositions that can used orally include two-piece capsules made of jelly, as well as sealed soft capsules made of jelly and a plasticizer, such as glycerol or sorbitol. The two capsules pieces may contain the active ingredients in admixture with a filler such as lactose, a binder such as starch and / or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the compounds assets can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, polyethylene glycols liquids, cremofor, capmul or mono-, di- or triglycerides medium or long chain. Stabilizers may also be added to these formulations.

Additionally, the agonist of GPR119 e DPP-IV inhibitor can be supplied using a sustained release system. They have established themselves and are well various materials known to those skilled in the art of sustained release. Tablets or tablets are particularly preferred. sustained release capsules. For example, a Temporary delay material such as glyceryl monostearate or glyceryl distearate. The dosage form can also coated by the techniques described in the Patents of United States No. 4,256,108, 4,166,452 and 4,265,874 to form osmotic therapeutic tablets for controlled release.

It is expressly contemplated that a therapy of combination of the present invention can be administered or be provided alone or in combination with one or more others Pharmaceutically or physiologically acceptable compounds. In a aspect of the present invention, the other compound pharmaceutically or physiologically acceptable is not an agonist of GPR119 and is not a DPP-IV inhibitor. In one aspect of the present invention, the other compound pharmaceutically or physiologically acceptable is a selected pharmaceutical agent from the group consisting of sulfonylurea (for example, glibenclamide, glipizide, gliclazide, glimepiride), meglitinide (for example, repaglinide, nateglinide), biguanide (for example, metformin), alpha-glucosidase inhibitor (for example, acarbose, epalrestat, miglitol, voglibose), thiazolidinedione (by example, rosiglitazone, pioglitazone), insulin analog (for example, insulin lispro, insulin aspart, insulin glargine), chromium / biotin picolinate and a biological agent (for example, adiponectin or a fragment that comprises the globular domain C-terminal thereof, or a multimer of adiponectin or said fragment thereof; or an agonist of a AdipoR1 or AdipoR2 adiponectin receptor, preferably in the that said agonist is active orally). In an aspect of the In the present invention, the pharmaceutical agent is metformin. In a aspect of the present invention, the pharmaceutical agent is a agonist for an AdipoR1 or AdipoR2 adiponectin receptor, preferably in which the agonist is active orally.

In a combination therapy according to the present invention, the agonist of GPR119 according to the present invention and the DPP-IV inhibitor of according to the present invention can be administered simultaneously or at separate intervals. When administered simultaneously, the GPR119 agonist and the inhibitor of DPP-IV can be incorporated in a single composition pharmaceutical or in separate compositions, for example, the agonist of GPR119 in a composition and the inhibitor of DPP-IV in another composition. Each of these compositions can be formulated with excipients, diluents or common vehicles and compressed into tablets, or formulated in elixirs or solutions; and as release dosage forms Sustained and similar. The GPR119 agonist and the inhibitor of DPP-IV can be administered by different routes. By example, the GPR119 agonist can be administered orally using a tablet and DPP-IV inhibitor It can be administered by inhalation.

When administered separately, it administer therapeutically effective amounts of the agonist of GPR119 and DPP-IV inhibitor according to the present invention in a different program. It can be administered one before the other provided the time between the two administrations are within a therapeutically range effective. A therapeutically effective interval is a period of time which begins when one of the GPR119 agonist is administered or (b) the DPP-IV inhibitor to a mammal and terminates in the limit of the beneficial effect in the treatment of combination of (a) and (b).

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle.

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also relates to a dosage form of the pharmaceutical composition, in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide an effect of lowering the glucose level in blood in a subject In certain embodiments, the glucose level in blood is an elevated blood glucose level.

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also refers to a dosage form a form dosing of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide a diminishing effect of blood glucose level in a subject, and in which the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone are therapeutically ineffective in lowering blood glucose in the subject In certain embodiments, the glucose level in Blood is an elevated blood glucose level.

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also relates to a dosage form of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide an effect of lowering the glucose level in blood in a subject, and in which the effect is a synergistic effect. In certain embodiments, the blood glucose level is a level. of high blood glucose.

In one aspect, the present invention relates to to a pharmaceutical composition that comprises or consists essentially in a combination of an amount of an agonist of GPR119 according to the present invention and an amount of a DPP-IV inhibitor according to the present invention, together with at least one pharmaceutical vehicle acceptable. The present invention also relates to a form of dosage of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide a diminishing effect of the level of blood glucose in a subject, in which the effect is a synergistic effect, and in which the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone they are therapeutically ineffective in decreasing blood glucose level in the subject. In certain embodiments, the blood glucose level is a blood glucose level high.

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also relates to a dosage form of the pharmaceutical composition, in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide an effect of increasing the level of GLP-1 in blood in a subject.

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also relates to a dosage form of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide an effect of increasing the level of GLP-1 in blood in a subject, and in which the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone are therapeutically ineffective in increasing the level of GLP-1 in blood in the subject.

In one aspect, the present invention presents a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also relates to a dosage form of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide an effect of increasing the level of GLP-1 in blood in a subject, and in which the effect It is a synergistic effect.

In one aspect, the present invention relates to a pharmaceutical composition that essentially comprises or consists in a combination of an amount of a GPR119 agonist from according to the present invention and an amount of an inhibitor of DPP-IV according to the present invention, together with at least one pharmaceutically acceptable vehicle. The present invention also relates to a dosage form of the pharmaceutical composition in which the agonist of GPR119 and the DPP-IV inhibitor are in sufficient quantities to provide an effect of increasing the level of GLP-1 in blood in a subject, in which the effect is a synergistic effect, and in which the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone they are therapeutically ineffective in increasing the level of GLP-1 in blood in the subject.

Pharmaceutical compositions suitable for use in the present invention include compositions in which the active ingredients are contained in an amount to Get your desired purpose. In some embodiments, it understands that a pharmaceutical composition of the present invention It is useful for treating or preventing diabetes and conditions related to it. Diabetes and related conditions with it they agree with the present invention. In some embodiments, it is understood that a pharmaceutical composition of the The present invention is useful for treating or preventing a condition that It is improved by increasing the level of GLP-1 in the blood. Conditions that are improved by increasing the level of GLP-1 in blood are in accordance with this invention.

In certain embodiments of the therapy of combination of the present invention, the amount of agonist of GPR119 in accordance with the present invention and the amount of DPP-IV inhibitor according to the present invention are provided in amounts to provide an effect synergistic in lowering blood glucose level in a subject. In certain embodiments, the blood glucose level is a high blood glucose level. The determination of amounts of GPR119 agonist and inhibitor of DPP-IV that provide a synergistic effect on the decreased blood glucose level in a subject is fine within the capacity of specialists in the art, especially in light of the detailed description that provided in this document. In one embodiment of the therapy of combination of the present invention, the amount of agonist of GPR119 in accordance with the present invention and the amount of DPP-IV inhibitor according to the present invention are provided in amounts to provide an effect synergistic in lowering blood glucose level in a subject, where the amount of the agonist of GPR119 alone and the Amount of DPP-IV inhibitor alone are therapeutically ineffective in lowering the glucose level in blood in the subject. In certain embodiments, the level of Blood glucose is an elevated blood glucose level. The determination of the amounts of GPR119 agonist and inhibitor of DPP-IV that provide a synergistic effect on the decrease in blood glucose level in a subject, where the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone are therapeutically ineffective in lowering the glucose level in blood in the subject, it is well within the capacity of the technical specialists, especially in light of the Detailed description provided in this document.

In certain embodiments of the therapy of combination of the present invention, the amount of agonist of GPR119 in accordance with the present invention and the amount of DPP-IV inhibitor according to the present invention are provided in amounts to provide an effect synergistic in increasing the level of GLP-1 in blood in a subject The determination of the amounts of agonist of GPR119 and DPP-IV inhibitor that provide a synergistic effect on increasing the level of GLP-1 in blood in a subject is well within the ability of the specialists in the art, especially in light of the Detailed description provided in this document. In a realization of the combination therapy of the present invention, the amount of GPR119 agonist in accordance with this invention and the amount of DPP-IV inhibitor of according to the present invention are provided in amounts for provide a synergistic effect in increasing the level of GLP-1 in blood in a subject, where the amount of GPR119 agonist alone and the amount of inhibitor DPP-IV alone are therapeutically ineffective in increasing the level of GLP-1 in blood in the subject. The determination of the agonist amounts of GPR119 and of DPP-IV inhibitor that provide an effect synergistic in increasing the level of GLP-1 in blood in a subject, where the amount of the GPR119 agonist alone and the amount of DPP-IV inhibitor alone they are therapeutically ineffective in increasing the level of GLP-1 in blood in the subject, is well within the ability of specialists in the art, especially to the light of the detailed description provided in this document.

The data obtained from animal studies, including, but not limited to, studies using mice, rats, rabbits, pigs and nonhuman primates, can be used in formulation of a dosage range for use in beings humans. In general, a specialist in the art understands how extrapolate data <i>in vivo</i> obtained in a model system animal to another, such as a human being. In some circumstances, these extrapolations can simply be based on the weight of the animal model compared to another, such as a human being. In other circumstances, these extrapolations are not simply based in weights but rather incorporate a variety of factors. Representative factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as activity, efficacy, pharmacokinetic and toxicology profiles of particular compound employed, if a system of drug supply or if an acute pathology is being treated or chronic or prophylaxis is performed, or if compounds are administered additional assets in addition to the compounds herein invention and as part of a combination of drugs. The regime of dosage to treat a pathology with the compounds and / or compositions of this invention are selected according to a diversity of factors, as mentioned above. For the Therefore, the actual dosage regimen used may vary widely and, therefore, can deviate from a regime of preferred dosage and a person skilled in the art will recognize what dosage and dosage regimen outside these intervals typical can be tested and, when appropriate, can be used in The methods of this invention.

An exemplary and preferred animal model system is the oral glucose tolerance test (oGTT) in mice (<i>see</i>, Example 1). In this model, by way of illustration and not as a limitation, an amount of a GPR119 agonist in solitary or a solo DPP-IV inhibitor that is therapeutically ineffective is an amount of the agonist of GPR119 alone or DPP-IV inhibitor alone which produces an inhibition of the Area Under the Curve (AUC) of the glycemic oscillations less than or equal to approximately 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10% or less than about 5%, more preferably less than approximately 25%, less than approximately 20%, less than approximately 15%, less than approximately 10% or less than approximately 5%. In this model, by way of illustration and not as a limitation, an amount of a GPR119 agonist alone or a solo DPP-IV inhibitor that is Therapeutically ineffective is an amount of agonist agonist of GPR119 alone or of the DPP-IV inhibitor in solitary that produces an inhibition of the Under Curve Area (AUC) of glycemic oscillations of approximately the 0-30%, of about 0-25%, of about 0-20%, of about 0-15%, of about 0-10%, or about 0-5%, more preferably of approximately 0-25%, of approximately 0-20%, of about 0-15%, of about 0-10% or about 0-5% In this model, by way of illustration and not as a limitation, a therapeutically effective amount of a combination of a GPR119 agonist and an inhibitor of DPP-IV according to the present invention is a amount of the combination that produces a Low Area inhibition Curve (AUC) of glycemic oscillations greater than approximately 30%, greater than approximately 35%, higher to about 40%, greater than about 45%, greater than approximately 50%, greater than approximately 55%, greater than approximately 60%, greater than approximately 65%, greater than approximately 70%, greater than approximately 75%, greater than approximately 80%, higher to about 85%, greater than about 90% or greater than about 95%, more preferably, greater than approximately 35%, greater than approximately 40%, higher to about 45%, greater than about 50%, greater than approximately 55%, greater than approximately 60%, greater than approximately 65%, greater than approximately 70%, or greater than approximately 75%, greater than approximately 80%, greater than approximately 85%, higher to about 90% or more than about 95%.

The amount and dosage interval can be adjusted to provide a synergistic effect on the decrease in blood glucose level in the subject according with the present invention, or to provide a synergistic effect in increasing the level of GLP-1 in blood in the subject according to the present invention. In certain embodiments, the blood glucose level is a glucose level in high blood. It will be appreciated that the exact dosage of a GPR119 agonist or DPP-IV inhibitor of according to the present invention will vary depending on the combination of GPR119 agonist and inhibitor of DPP-IV, its potency, the mode of administration, the age and weight of the patient and the severity of the condition being treated. The exact formulation, route of administration and dosage can selected by the individual doctor in view of the state of the patient. By way of illustration and not as a limitation, a quantity of GPR119 agonist or DPP-IV inhibitor that provides a synergistic effect in decreasing the level of blood glucose in the subject according to the present invention, or that provides a synergistic effect in increasing the blood GLP-1 level in the subject according with the present invention it is less than about 0.001 mg / kg of body weight, less than about 0.005 mg / kg weight bodily, less than about 0.01 mg / kg body weight, less than about 0.05 mg / kg body weight, less than approximately 0.1 mg / kg body weight, less than about 0.5 mg / kg body weight, less than about 1 mg / kg body weight, less than about 5 mg / kg weight body, less than about 10 mg / kg body weight, less of approximately 50 mg / kg body weight or less than approximately 100 mg / kg body weight. In certain embodiments, the blood glucose level is a glucose level in high blood. In some embodiments, a quantity of GPR119 agonist or DPP-IV inhibitor that provides a synergistic effect in decreasing the level of blood glucose in the subject according to the present invention, or that provides a synergistic effect in increasing the level of GLP-1 in blood in the subject according to the present invention, is less than about 0.001-100 mg / kg body weight, less than approximately 0.001-50 mg / kg body weight, less than about 0.001-10 mg / kg weight body, less than about 0.001-5 mg / kg of body weight, less than about 0.001-1 mg / kg body weight, less than about 0.001 to 0.5 mg / kg of body weight, less than about 0.001-0.1 mg / kg body weight, less than about 0.001-0.05 mg / kg body weight, less than approximately 0.001-0.01 mg / kg body weight or less than about 0.001-0.005 mg / kg weight bodily. In certain embodiments, the blood glucose level is a high blood glucose level. In some embodiments, an amount of GPR119 agonist or inhibitor of DPP-IV that provides a synergistic effect on decrease in blood glucose level in the subject according with the present invention or that provides a synergistic effect on the increase in blood GLP-1 level in the subject according to the present invention is approximately 0.001-100 mg / kg body weight, of approximately 0.001-50 mg / kg body weight, from approximately 0.001-10 mg / kg body weight, of approximately 0.001-5 mg / kg body weight, of approximately 0.001 to 1 mg / kg body weight, approximately 0.001-0.5 mg / kg body weight, of approximately 0.001-0.1 mg / kg body weight, of approximately 0.001-0.05 mg / kg body weight, about 0.001-0.01 mg / kg body weight or about 0.001-0.005 mg / kg of weight bodily. In certain embodiments, the blood glucose level is a high blood glucose level.

An exemplary and preferred animal model system additional is the increase in blood GLP-1 level after exposure to glucose in mice (see Example 3).

The amount and dosage interval can be adjusted individually to provide levels Plasma agonist of GPR119 in accordance with this invention and of DPP-IV inhibitor according to the present invention, which provide a synergistic effect on the decrease in blood glucose level in the subject according with the present invention, or that provide a synergistic effect on the increase in blood GLP-1 level in the subject according to the present invention. In certain embodiments, the blood glucose level is a glucose level in high blood. You can also determine intervals of dosage using the value for a selected range of agonist concentration of GPR119 or the value for an interval selected from DPP-IV inhibitor concentration that provides a synergistic effect in decreasing the level of blood glucose in the subject according to the present invention, or that provides a synergistic effect in increasing the level of GLP-1 in blood in the subject according to the present invention In certain embodiments, the glucose level in Blood is an elevated blood glucose level. The agonist of GPR119 and DPP-IV inhibitor should be administered using a regimen that maintains levels plasma within the selected concentration range of GPR119 agonist and inhibitor concentration DPP-IV, respectively, during 10-90% of the time, preferably between 30-99% of the time and, more preferably, between 50-90% of the time. In cases of local administration or selective uptake, the agonist concentration range of GPR119 or the inhibitor concentration range of DPP-IV that provides a synergistic effect on decrease in blood glucose level in the subject according with the present invention, or that provides a synergistic effect on the increase in blood GLP-1 level in the subject according to the present invention, may not be related to plasma concentration. In certain embodiments, the blood glucose level is a glucose level in high blood.

The amount of composition administered it will, of course, depend on the subject in question, on the weight of the subject, of the severity of the affliction, of the form of administration and the judgment of the prescribing physician.

This method describes a method of treatment or prevention of diabetes or a condition related to it that includes administering to a subject that a therapeutically effective amount of a composition needs it which comprises or consists essentially of an amount of a GPR119 agonist in accordance with the present invention and a amount of a DPP-IV inhibitor according to the present invention

A method is also described in this document. of treatment or prevention of diabetes or a condition related to it that includes administering to a subject that a therapeutically effective amount of a composition needs it which comprises or consists essentially of an amount of a GPR119 agonist in accordance with the present invention and a amount of a DPP-IV inhibitor according to the present invention In a related aspect, the present invention presents said method in which the GPR119 agonist and the DPP-IV inhibitor are administered in amounts sufficient to provide an effect of decreasing the level of blood glucose in the subject. In certain embodiments, the level Blood glucose is an elevated blood glucose level.

This method describes a method of treatment or prevention of diabetes or a condition related to it, which includes administering to a subject that a therapeutically effective amount of a composition needs it which comprises or consists essentially of an amount of a GPR119 agonist in accordance with the present invention and a amount of a DPP-IV inhibitor according to the present invention This method is also described in which the GPR119 agonist and DPP-IV inhibitor will administered in sufficient quantities to provide an effect of decreased blood glucose level in the subject and in the that the amount of the agonist of GPR119 alone and the amount of the DPP-IV inhibitor alone are therapeutically ineffective in lowering the glucose level in blood in the subject. In certain embodiments, the level of Blood glucose is an elevated blood glucose level.

This method describes a method of treatment or prevention of diabetes or a related condition with the same that includes administering to a subject that needs it a therapeutically effective amount of a composition that comprises or consists essentially of an amount of an agonist of GPR119 according to the present invention and an amount of a DPP-IV inhibitor according to the present invention. Also described is said method in which the agonist of GPR119 and the DPP-IV inhibitor are administered in sufficient quantities to provide a diminishing effect of the level of blood glucose in the subject, and in which the effect It is a synergistic effect. In certain embodiments, the level of Blood glucose is an elevated blood glucose level.

This method describes a method of treatment or prevention of diabetes or a related condition with it, which includes administering to a subject that needs it a therapeutically effective amount of a composition that comprises or consists essentially of an amount of an agonist of GPR119 according to the present invention and an amount of a DPP-IV inhibitor according to the present invention. Also described is said method in which the agonist of GPR119 and the DPP-IV inhibitor are administered in sufficient quantities to provide a diminishing effect of the level of blood glucose in the subject, in which the effect is a synergistic effect and in which the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone they are therapeutically ineffective in decreasing blood glucose level in the subject. In certain embodiments, the blood glucose level is a blood glucose level high.

A combination therapy of the present invention is useful in the treatment or prevention of diabetes or of a condition related to it in a mammal including and, more preferably, in a human being. In some embodiments, diabetes is Type 1 diabetes. In some preferred embodiments, Diabetes is Type 2 diabetes. A condition related to diabetes includes, but is not limited to, hyperglycemia, tolerance impaired glucose, insulin resistance, insufficiency of pancreatic beta cells, cell insufficiency enteroendocrines, glucosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic coronary artery disease, cerebrovascular disease diabetic, diabetic peripheral vascular disease, syndrome metabolic, hyperlipidemia, atherosclerosis, stroke, hypertension and obesity It is understood that the conditions related to diabetes can be included in embodiments individually or in any combination

This method describes a method of treatment or prevention of a condition that is improved by augmentation of the level of GLP-1 in blood, which comprises administer to a subject that needs an amount therapeutically effective of a composition comprising or consisting essentially in an amount of a GPR119 agonist agree with the present invention and an amount of an inhibitor of DPP-IV in accordance with the present invention.

This method describes a method of treatment or prevention of a condition that is improved by augmentation of the level of GLP-1 in blood, which comprises administer to a subject that needs an amount therapeutically effective of a composition comprising or consisting essentially in an amount of a GPR119 agonist agree with the present invention and an amount of an inhibitor of DPP-IV in accordance with the present invention. This method is also described in which the GPR119 agonist and the DPP-IV inhibitor are administered in amounts sufficient to provide an effect of increasing the level of GLP-1 in blood in the subject.

This method describes a method of treatment or prevention of a condition that is improved by augmentation of the level of GLP-1 in blood, which comprises administer to a subject that needs an amount therapeutically effective of a composition comprising or consisting essentially in an amount of a GPR119 agonist agree with the present invention and an amount of an inhibitor of DPP-IV in accordance with the present invention. This method is also described in which the GPR119 agonist and the DPP-IV inhibitor are administered in amounts sufficient to provide an effect of increasing the level of GLP-1 in blood in the subject, and in which the amount of the agonist of GPR119 alone and the amount of DPP-IV inhibitor alone are therapeutically ineffective in increasing the level of GLP-1 in blood in the subject.

This method describes a method of treatment or prevention of a condition that is improved by augmentation of the level of GLP-1 in blood, which comprises administer to a subject that needs an amount therapeutically effective of a composition comprising or consisting essentially in an amount of a GPR119 agonist agree with the present invention and an amount of an inhibitor of DPP-IV in accordance with the present invention. This method is also described in which the GPR119 agonist and the DPP-IV inhibitor are administered in amounts sufficient to provide an effect of increasing the level of GLP-1 in blood in the subject, and in which the effect It is a synergistic effect.

This method describes a method of treatment or prevention of a condition that is improved by augmentation of the level of GLP-1 in blood, which comprises administer to a subject that needs an amount therapeutically effective of a composition comprising or consisting essentially in an amount of a GPR119 agonist agree with the present invention and an amount of an inhibitor of DPP-IV in accordance with the present invention. This method is also described in which the GPR119 agonist and the DPP-IV inhibitor are administered in amounts sufficient to provide an effect of increasing the level of GLP-1 in blood in the subject, in which the effect it is a synergistic effect, and in which the amount of the agonist of GPR119 alone and the amount of inhibitor DPP-IV alone are therapeutically ineffective in increasing the level of GLP-1 in blood in the subject.

A combination therapy is useful in the treatment or prevention of a condition that is improved by increased level of GLP-1 in blood in a mammal, including and, more preferably, in a human being. A condition which is improved by increasing the level of GLP-1 in blood includes, but is not limited to, diabetes, a condition related to diabetes, myocardial infarction, disorder learning, memory impairment and a disorder neurodegenerative, where a condition related to diabetes includes, but is not limited to, hyperglycemia, impaired tolerance to glucose, insulin resistance, cell insufficiency beta-pancreatic, cell insufficiency enteroendocrines, glucosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic coronary artery disease, cerebrovascular disease diabetic, diabetic peripheral vascular disease, syndrome metabolic, hyperlipidemia, atherosclerosis, stroke, hypertension and obesity, where a neurodegenerative disorder, includes, but without limitation, excitotoxic brain injury caused by attacks severe epileptic, Alzheimer's disease, disease of Parkinson's, Huntington's disease, disease associated with prions, motor neuron disease, traumatic brain injury, spinal cord injury and peripheral neuropathy. In some embodiments, diabetes is Type 1 diabetes. In some preferred embodiments, diabetes is Type 2 diabetes. understands that conditions that are improved by increasing the level of GLP-1 in blood can be included in embodiments individually or in any combination.

Without further elaboration, it is thought that a Technician can, using the above description, Carry out the present invention to its fullest extent. The Detailed description above is provided for clarity of understanding only and should not be understood from it No unnecessary limitation, as they can become apparent for those skilled in the art modifications within the scope of the invention.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Examples

Without further elaboration, it is thought that a Technician can, using the above description, Carry out the present invention to its fullest extent. The following detailed examples should be interpreted as merely illustrative and not as limitations of the previous description of No way at all. The specialists in the technique immediately recognize appropriate variations of procedures

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 1

Synergistic effect of a GPR119 agonist and an inhibitor of DPP-IV in decreasing a glucose level in elevated blood in an oral glucose tolerance test (OGTT) in mice

An oral tolerance test to the glucose (oGTT) in mice as described herein. TO fasting mice overnight (n = 6 mice per treatment) they were administered by means of an oral probe (PET), an agonist from GPR119 (AR231453) to 1 mkg (milligram of compound per kilogram body weight), a DPP-IV inhibitor (AR247810) at 0.1 mkg, or a combination of the GPR119 agonist (1 mkg) and DPP-IV inhibitor (0.1 mkg). Thirty minutes later, a bolus of glucose was then administered (3 grams / kg) orally. Glucose levels were determined in plasma at the indicated time points over a period of two hours using blood (\ sim5 \ mul) collected from the cleft of the tail and a glucometer. The curve of glycemic oscillations based on data from 6 mice and provided in average values ​​+/- ETM (Figure 1A). He Calculated the Area Under the Curve (AUC) of glycemic oscillations for each mouse and described the inhibition of AUC (%) in the Figure 1B

In this Example, the agonist of GPR119 administered at 1 mkg alone or the inhibitor of DPP-IV administered at 0.1 mkg alone produced an AUC inhibition of glycemic oscillations less than 15-20% in this mouse model, which considered therapeutically ineffective for glycemic control to Long term in diabetic patients. On the other hand, the combination of both compounds at their therapeutically inefficient dose (0.1 mkg for the DPP-IV inhibitor and 1 mkg for the agonist of GPR119 in his Example) produced a superior AUC inhibition at 60% Typically, a therapeutically effective dose would generate a AUC inhibition above 30% in this model study of mouse, as observed for incretin mimetic Exendin-4 at sim60%.

Both DPP-IV inhibitor as the agonist of GPR119 alone can produce a effective therapeutic response (at approximately 40% of the AUC inhibition) in this type of mouse model study, but only at significantly higher doses (Figure 1C and Figure 1D, respectively).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example two

Combination of a GPR119 agonist and an inhibitor of DPP-IV to treat or prevent diabetes and conditions related to it

A GPR119 agonist is selected according with the present invention. An inhibitor of DPP-IV in accordance with the present invention.

The GPR119 agonist's assessment with regarding the percentage of inhibition of the Area Under the Curve (AUC) in an oral glucose tolerance test (oGTT) in mice, determined by a dose range of approximately 0.01 mkg (milligrams of compound per kilogram of body weight) to approximately 100 mkg See Example 1. One is selected. dose of the GPR119 agonist that causes an AUC inhibition of glycemic oscillations of approximately the 15-20% Typically, a dose of GPR119 agonist which produces an AUC inhibition of 30% or less is Therapeutically ineffective in this mouse model.

The inhibitor titration of DPP-IV with respect to the percentage of inhibition of Under the Curve Area (AUC) in an oral tolerance test glucose (oGTT) in mice is determined by a dose range of approximately 0.01 mkg (milligrams of compound per kilogram of body weight) at approximately 100 mkg. See Example 1. It select a dose of DPP-IV inhibitor that produces an AUC inhibition of glycemic oscillations of approximately 15-20%. Typically, a dose of DPP-IV inhibitor that produces an inhibition of AUC of 30% or less is therapeutically ineffective in this model mouse

AUC inhibition of oscillations glycemic produced by the combination of the selected dose of the GPR119 agonist and the selected dose of the inhibitor of DPP-IV is determined in a mouse oGTT assay. The therapeutic efficacy of the agonist combination is determined of GPR119 and DPP-IV inhibitor. Typically, an amount of the combination that produces an inhibition of AUC above 30% is therapeutically effective in this model of mouse. The synergism between the agonist of GPR119 and the DPP-IV inhibitor.

The data obtained from this model of mouse can be used to formulate a dosage range for Use in humans. In general, a specialist in the art, understand how to extrapolate the data <i>in vivo</i> obtained in a animal model system to another, such as a human being. A combination of GPR119 agonist and inhibitor of DPP-IV according to the present invention is useful in the treatment or prevention of diabetes and conditions related to it.

It is understood that the above is intended to be Illustrative and not limiting.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 3

Synergistic effect of a GPR119 agonist and an inhibitor of DPP-IV in increasing the level of GLP-1 in blood after exposure to glucose in mice

C57blk / 6 male mice (8 weeks old) they fasted for 18 hours and were assigned randomly to twelve groups with n = 6 for each group. To the mice were administered orally vehicle (PET), agonist of GPR119 (10 mg / kg), DPP-IV inhibitor (1 mg / kg), or a combination of GPR119 agonist and inhibitor of DPP-IV, as indicated. The agonist of GPR119 (AR231453) and DPP-IV inhibitor (AR247810) used in this document were identical to those used in the Example 1. Thirty minutes after treatment, a bolus was administered of glucose at 3 g / kg orally and the plasmas were collected at 0 minutes (without glucose bolus) and 2 minutes and 5 minutes after glucose bolus The levels of GLP-1 in plasma using an ELISA kit GLP-1 purchased from Linco Research Laboratory [kit Glucagon-like Peptide ELISA 1 (Active), Catalog No. EGLP-35K].

It was discovered that the administration of a GPR119 agonist together with a DPP-IV inhibitor produced a synergistic effect in increasing the level of GLP-1 in blood. See Figure 2.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 4

Melanophores assay to determine the agonist activity of GPR119

Melanophores were maintained in culture as described by Potenza <i>et al</i> [Pigment Cell Research (1992) 5: 372-378] and were transfected with a vector of expression encoding a GPR119 receiver (GPR119; for example, Human GPR119, GenBank® Accession Number AAP72125 and alleles thereof) using electroporation. After electroporation, the cells Transfected seeds are plated in 96-well plates for testing. Then, the cells are allowed to grow for 48 hours, both so that they recover from the electroporation procedure as to reach maximum receptor expression levels.

On the day of the test, the culture medium of the cells are replaced with serum-free buffer containing melatonin 10 nM Melatonin acts through a GPCR coupled to Gi endogenous in the melanophores decreasing cAMP levels intracellular In response to decreased levels of cAMP, the Memophores translocate their pigment towards the center of the cell. He net effect of this is a significant increase in the reading of absorbance of the cell monolayer in the well, measured at 600-650 nM.

After a 1 hour incubation in melatonin, the cells present the pigment completely aggregate. At this point a baseline absorbance reading is collected. Then serial dilutions of compounds are added to the plate Assay and compounds having agonist activity of GPR119 produce increases in intracellular cAMP levels. In response at these increased cAMP levels, the melanophores translocate their pigment back to the cell periphery. After an hour, stimulated cells have their pigment completely dispersed. The monolayer of cells in the dispersed state absorbs a lot more light in the range of 600-650 nm. Increasing measured in absorbance compared to baseline reading allows quantify the degree of receptor stimulation and represent a dose response curve.

Related materials and methods are found with the melanophores test in US Pat. Nos. 5,462,856 and 6,051,386, the description of which is incorporated herein document as a reference in its entirety.

Other tests to identify a compound as a GPR119 agonist will be readily apparent to the specialist (see, for example, Example 7, below).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 5

Full length cloning of endogenous human GPR119

A polynucleotide encoding the Endogenous human GPR119 by PCR using specific primers from GPR119:

5'-GTCCTGCCACTTCGAGAC<u>ATG</u>G-3 ' (SEQ ID NO: 3; sense, <u>ATG</u> as start codon)

5'-GAAACTTCTCTGCCCTTACCGTC-3 ' (SEQ ID NO: 4; antisense, 3 'of termination codon)

and human genomic DNA as a template. The DNA polymerase TaqPlus Precision? (Stratagene) was used to amplification by the next cycle, repeating itself from the stage 2 to stage 4 35 times: 94 ° C, 3 minutes; 94 ° C, 1 minute; 58 ° C, 1 minute; 72 ° C, 2 minutes; 72 ° C, 10 minutes. An isolated 1.0 Kb PCR fragment of the predicted size and was cloned into the pCRII-TOPO? vector (Invitrogen) and sequenced completely using the T7 sequential DNA kit (Amersham). See, SEQ ID NO: 1 for the nucleic acid sequence and SEC ID No.: 2 for the amino acid sequence deducted

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 6

Receiver expression

Although a variety of cells in the art for the expression of receptors coupled to G protein, it is more preferred that mammalian cells or melanophores The following are illustrative; to the specialists in the art they are attributed the ability to determine the techniques that are preferably beneficial to the needs of the specialist. See, for example, Example 4, above, since it refers to melanophores.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

to. Transient Transfection

On day one, they are planted in 6 x plates 10 6/10 cm plate of 293 cells. On day two, two are prepared reaction tubes (the proportions that follow for each tube are per plate): tube A is prepared by mixing 4 µg of DNA (for example, pCMV vector; pCMV vector with receptor cDNA, etc.) at 0.5 ml of serum-free DMEM (Gibco BRL); tube B is prepared by mixing 24 µl of lipofectamine (Gibco BRL) in 0.5 ml of DMEM without serum. Tubes A and B are mixed by inversion (several times), followed by incubation at room temperature for 30-45 min. The mixture is referred to as the "mixture of transfection. "293 cells seeded on plates are washed with 1X PBS, followed by the addition of 5 ml of serum-free DMEM. 1 is added ml of the transfection mixture to the cells, followed by incubation for 4 h at 37 ° C / 5% CO2. The mixture of transfection is removed by aspiration, followed by the addition of 10 ml of DMEM / 10% Fetal Bovine Serum. The cells are incubated at 37 ° C / 5% CO 2. After a 48 h incubation, the cells They are collected and used for analysis.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

b. Stable Cell Lines

About 12 x 10 6 are seeded 293 cells in a 15 cm tissue culture plate. They are cultivated in Glucose Rich DME Medium containing fetal bovine serum at ten percent and one percent sodium pyruvate, L-glutamine and antibiotics. Twenty four hours after planting of 293 cells (or at a confluence of 8080%), cells are transfected using 12 µg of DNA (per example, pCMV-neo r vector with cDNA of receiver). The 12 µg of DNA is combined with 60 µl of Lipofectamine and 2 ml of Glucose-Rich DME Medium without serum. He medium is aspirated from the plates and the cells are washed once with serum-free medium DNA, lipofectamine and medium mixture are add to the plate together with 10 ml of serum-free medium. After the incubation at 37 ° C for four to five hours, the medium is aspirate and add 25 ml of serum-containing medium. Twenty four hours after transfection, the medium is aspirated again and add freshly prepared medium with serum. Forty-eight hours after transfection, the medium is aspirated and medium is added with serum containing geneticin (drug G418) at a concentration end of approximately 12 x 10 6 293 cells that are seeded in a 15 cm tissue culture plate. They are grown in medium Glucose-rich DME containing fetal bovine serum at ten times one hundred and one percent sodium pyruvate, L-glutamine and antibiotics. Twenty four hours after sowing on 293 cell plates (or at a confluence \80%), cells are transfected using 12 µg of DNA (for example, pCMV vector with receptor cDNA). The 12 \ mug of DNA is combined with 60 µl of lipofectamine and 2 ml of DME Medium Glucose rich without serum. The medium is aspirated from the plates and cells are collected once with medium without serum. The DNA, the Lipofectamine and the medium mixture are added to the plate along with 10 ml of medium without serum. After incubation at 37 ° C for four to five hours, the medium is aspirated and 25 ml of medium containing serum. Twenty four hours after the transfection, the medium is aspirated again and fresh medium is added prepared with serum. Forty-eight hours after the transfection, the medium is aspirated and medium is added with serum that contains geneticin (drug G418) at a final concentration of 500 \ mug / ml. Transfected cells now experience a selection for positively transfected cells containing the G418 resistance gene. The medium is replaced every four to five days as the selection occurs. During the selection, cells are grown to generate combinations stable or split for a stable clonal selection.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 7

Essays to explore candidate compounds as agonists of GPR119

A variety of approaches are available to explore candidate compounds as GPCR119 agonists. The Following are illustrative; to those skilled in the art will attributes the ability to determine the techniques that are preferably beneficial to the needs of the specialist. Trials to explore are well known to the specialist compounds as agonists of a G-protein coupled receptor (see, for example, International Application WO 02/42641).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

1. Membrane Bonding Tests: Test of [35 S] GTPγS

When a G-protein coupled receptor is in its active state, as a result of ligand binding or activation constitutive, the receptor is coupled to a G protein and stimulates the GDP release and subsequent GTP binding to protein G. The alpha subunit of the G-receptor protein complex acts as a GTPase and slowly hydrolyzes the GTP to GDP, point in which the receiver normally deactivates. Receivers activated continue to exchange GTP for GDP. GTP analog non-hydrolyzable, [35 S] GTPγS, can be used to demonstrate an increased binding of [35 S] GTPγS to membranes expressing activated receptors. The advantage of using the binding of [35 S] GTPγS to measure activation is that: (a) it is generically applicable to all receivers G protein coupled; (b) is proximal to the surface of the membrane, making it less likely to pick up molecules that affect the intracellular cascade.

The assay uses the capacity of receptors G-protein coupled to stimulate the binding of [35 S] GTPγS to membranes expressing the relevant receivers. The test is generic and has application in drug discovery in all receptors coupled to protein G.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Membrane Preparation

In some embodiments, membranes that comprise a G protein coupled receptor of the invention and for the use in the identification of candidate compounds as, by example, receptor agonists, are preferably prepared from the following form:

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

to. materials

The "Membrane Scraping Buffer" is composed of 20 mM HEPES and 10 mM EDTA, pH 7.4; the "Buffer of Membrane Wash "is composed of 20 mM HEPES and 0.1 EDTA mM, pH 7.4; the "Union Buffer" is composed of HEPES 20 mM, 100 mM NaCl and 10 mM MgCl2, pH 7.4.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

b. Process

All materials will be kept on ice throughout the procedure In the first place, the means of a confluent monolayer of cells, followed by rinsing with 10 ml of cold PBS, followed by aspiration. After that, it add 5 ml of Membrane Scraping Buffer to scrape off the cells; this will continue to transfer the cell extract to 50 ml centrifuge tubes (centrifuged at 20,000 rpm for 17 minutes at 4 ° C). After that, the supernatant will be aspirated and the sediment will be resuspended in 30 ml of Membrane Wash Buffer followed by centrifugation at 20,000 rpm for 17 minutes at 4 ° C. Then the supernatant will be aspirated and the sediment will be resuspended in Union Buffer. This will then be homogenized using a Brinkman Polytron ™ homogenizer (bursts of 15-20 seconds until all the material is in suspension). This is called in this document "Protein of Membrane".

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Bradford Protein Assay

After homogenization, the protein concentration of membranes using the Test of Bradford proteins (protein can be diluted to approximately 1.5 mg / ml, divide into aliquots and freeze (-80 ° C) for later use; when it freezes, the protocol of Use will be as follows: the day of the test, Membrane Protein frozen thaw at room temperature, followed by stirring vortex and then homogenized with a Polytron to approximately 12 x 1,000 rpm for approximately 5-10 seconds; it is noted that for preparations multiple, the homogenizer should be thoroughly cleaned between homogenization of different preparations).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

to. materials

Union Buffer (as above); Reagent Bradford Coloring; Bradford Protein Pattern will be used following the manufacturer's instructions (Biorad, cat. no. 500-0006).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

b. Process

Tubes will be prepared in duplicate, one including the membrane and another as "white" control. Every one contained 800 µl of Union Buffer. After that, it add 10 µl of Bradford Protein Standard (1 mg / ml) to each tube and then 10 µL of membrane protein will be added to a single tube (not white). After that, 200 µl will be added of Bradford Coloring Reagent to each tube, followed by stirring Vortex of each. After five (5) minutes, the tubes are they will vortex again and their material will will transfer to buckets. Then the cuvettes will be read using a CECIL 3041 spectrophotometer at a wavelength of 595.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Identification Test

to. materials

The GDP Buffer consists of 37.5 ml of Buffer of Union and 2 mg of GDP (Sigma, cat. G-7127), followed by a series of dilutions in Union Buffer to obtain 0.2 µM GDP (the final GDP concentration in each well was of 0.1 µM GDP); each well comprising a compound candidate has a final volume of 200 \ mul consisting of 100 µl of GDP Buffer (final concentration, 0.1 µM GDP), 50 mul of Membrane Protein in Binding Buffer and 50 mul of [35 S] GTPγS (0.6 nM) in Binding Buffer (2.5 mul [35 S] GTP γ per 10 ml of Buffer Union).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

b. Process

The candidate compounds will be explored preferably using a 96-well plate format (these may be frozen at -80 ° C). The protein of Membrane (or membranes with the expression vector minus GPCR Diana as a control), it will be homogenized briefly until it is in suspension. Then the protein concentration will be determined using the Bradford Protein Assay set forth above. The Membrane protein (and the control) will then be diluted to 0.25 mg / ml in Binding Buffer (final test concentration, 12.5 \ mug / well). After that, 100 µl of Buffer was added of GDP to each well of a Wallac Scintistrip? (Wallac). Then a needle pipetting head will be used (<i>pin tool</i>) 5 µl to transfer 5 µl of a candidate compound to said well (ie 5 µl in a total test volume of 200 µl is a ratio of 1:40, so that the concentration Final scan of the candidate compound is 10 µM). From again, to avoid contamination, after each stage of transfer the needle pipetting head should be clarified in three tanks comprising water (1X), ethanol (1X) and water (2X) -It should shake off excess liquid from the head of pipette after each rinse and dry with paper and tissue type Kimwipes After that, 50 µl of Protein from Membrane to each well (a control well was also used which comprises membranes without GPCR Diana) and will be pre-incubated during 5-10 minutes at room temperature. After that, 50 µL of [35 S] GTPγS (0.6 nM) will be added in Binding Buffer to each well, followed by incubation in a stirrer for 60 minutes at room temperature (again, in this example, the plates were covered with aluminum foil). Then, the test will be interrupted by centrifugation of the plates at 4000 RPM for 15 minutes at 22 ° C. The plates will be sucked then with an 8 channel manifold and they will be sealed with caps plates. The plates will then be read on a Wallac 1450 using the setting "Prot. No. 37" (according to the instructions of the maker).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

two. Adenilil Cyclase Assay

A kit of Adenilil Cyclase Flash Plate? (New England Nuclear; Cat. No. SMP004A) designed for testing cell-based can be modified for use with membranes gross plasma. The wells of the Flash Plate may contain a scintillation coating that also contains an antibody specific that the cAMP recognizes. CAMP generated in wells can be quantified by direct competition for union of a radioactive cAMP indicator to cAMP antibody. The Following serves as a brief protocol for measuring changes in cAMP levels in whole cells expressing the receivers

In certain embodiments, a kit of Modified Adenilil Cyclase Flash Plate? (New England Nuclear; Cat. No. SMP004A) for the identification of compounds candidate as, for example, agonists of GPR119 according to the following protocol

Cells transfected with a receptor are collected G-protein coupled of the invention approximately three days after transfection. Membranes are prepared by homogenization of cells suspended in buffer containing HEPES 20 mM, pH 7.4 and 10 mM MgCl2. Homogenization is performed in ice using a Brinkman Polytron? for approximately 10 seconds. The resulting homogenate is centrifuged at 49,000 xg for 15 minutes at 4 ° C. The resulting sediment is resuspended then in buffer containing 20 mM HEPES, pH 7.4 and 0.1 mM EDTA, homogenize for 10 seconds, followed by centrifugation at 49,000 xg for 15 minutes at 4 ° C. The resulting sediment is then store at -80 ° C until used. The day of Direct identification scan, membrane sediment thaw slowly at room temperature, resuspend in buffer containing 20 mM HEPES, pH 7.4 and 10 mM MgCl2 to give a final protein concentration of 0.60 mg / ml (the membranes resuspended are placed on ice until use).

CAMP and buffer patterns are prepared Detection (comprising 2 µCl of {[125 I] cAMP indicator (100 µl) in 11 ml of Detection Buffer] and maintained in accordance with the manufacturer's instructions. He prepared fresh Test Buffer for exploration and contained HEPES 20 mM, pH 7.4 and 10 mM MgCl2, 20 mM phosphocreatine (Sigma), Creatine phosphokinase 0.1 units / ml (Sigma), 50 µM GTP (Sigma) and 0.2 mM ATP (Sigma); the Test Buffer was then stored in Ice until it was used.

Candidate compounds are added, preferably, for example to wells of a 96-well plate (3 µl / well; final test concentration 12 µM), together with 40 µl Membrane Protein (30 µg / well) and 50 mul of Test Buffer. This mixture was then incubated for 30 minutes at room temperature, with gentle agitation.

After incubation 100 µl was added of Detection Buffer to each well, followed by incubation for 2-24 hours. Then a count was made of the plates in a Wallac MicroBeta? plate reader using "Prot. No. 31" (according to the manufacturer's instructions).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

3. CRE-Luc Indicator Test

293 and 293T cells were plated in 96-well plates at a density of 2 x 10 cells per well and were transfected using Lipofectamine Reagent (BRL) daily Following according to the manufacturer's instructions. He prepared a DNA / lipid mixture for each transfection of 6 wells as follows: 260 ng of plasmid DNA in 100 µm of DMEM mix gently with 2 µl of lipid in 100 µm of DMEM (the 260 ng of plasmid DNA consist of 200 ng of an 8xCRE-Luc indicator plasmid, 50 ng of pCMV that comprises a G protein coupled receptor of the invention or pCMV alone, and 10 ng of a GPRS expression plasmid [GPRS ​​in pcDNA3 (Invitrogen)]. The indicator plasmid 8xCRE-Luc was prepared as follows: obtained the vector SRIF-? -gal by cloning the rat somatostatin promoter (-71 / + 51) in the BgIV-HindIII site in the Vector p ?gal-Basic (Clontech). Eight (8) were obtained copies of cAMP response element by PCR from a AdpCF126CCRE8 adenovirus template [see, Suzuki <i>et al</i>., Hum Gene Ther (1996) 7: 1883-1893] and was cloned into the vector SRIF-? -gal on site Kpn-BgIV, resulting in the indicator vector 8xCRE-? -Gal. Plasmid 8xCRE-Luc indicator was generated by replacing the beta-galactosidated gene in the indicator vector 8xCRE-? -Gal with the gene of Luciferase obtained from the pGL3-basic vector (Promega) on the HindTII-BamHI site. After 30 min of incubation at room temperature, the DNA / lipid mixture is dilute with 400 µl of DMEM and add 100 µl of the mixture diluted to each well. 100 µl of DMEM with 10% FCS are added to each well after a 4 h incubation in an incubator of cell cultures. The next day, transfected cells they are changed with 200 µl / well of DMEM with 10% FCS. Eight (8) hours later, the wells are changed to 100 µl / well of DMEM without phenol red, after washing with PBS. Activity is measured Luciferase the next day using the gene test kit LucLite ™ indicator (Packard), following the instructions of the manufacturer, and it reads in a scintillation and luminescence counter 1450 MicroBeta? (Wallac).

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 8

Radiolabelled Compound

In certain embodiments, a radiolabel is radiolabelled. compound known to be a ligand of a receptor coupled to G protein of the invention. A radiolabeled compound can be used as described in this paper in a screening test for Identify / evaluate compounds. Generally speaking, you can evaluate a newly synthesized or identified compound (i.e. test compound) for its ability to reduce the binding of the known radiolabeled ligand to the receptor, for its ability to reduce complex formation between the known ligand Radiolabelled and the receiver. Suitable radionuclides that can incorporated into compounds of the present invention include, but no limitation 3 H (also written as T), 11 C, 14 C, 18 F, 125 I, 82 Br, 123 I, 124 I, 125 I, 131 I, 75 Br, 76 Br, 15 O, 13 N, 35 S and 77 Br. Generally the most useful will be compounds that incorporate 3 H, 14 C, 125 I, 131 I, 35 S and 82 Br.

It is understood that a "radiolabeled compound" It is a compound that has at least one radionuclide incorporated. In some embodiments, the radionuclide is selected from the group that it consists of 3 H, 14 C, 125 I, 35 S and 82 Br. In In some embodiments, the radionuclide is 3 H or 14 C. In addition, it should be understood that all atoms represented in compounds known to be ligands of a coupled receptor a G protein of the invention may be the isotope that appears most commonly of said atoms or the radioisotope or isotope not radioactive more scarce.

Methods are well known in the art. synthetic to incorporate radioisotopes in organic compounds including those applicable to compounds known to be ligands of a G protein coupled receptor of the invention and include incorporating levels of tritium activity in molecules target, including: A. Catalytic Reduction with Tritium Gas - This procedure normally produces high specific activity products and requires precursors halogenated or unsaturated. B. Sodium Borohydride Reduction [&lt;3&gt; H) -This procedure is quite economical and requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters and the like. C. Reduction with Lithium Aluminum Hydride [3 H] - This procedure offers products to almost theoretical specific activities. It also requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters and the like. D. Marking by Exposure to Tritium Gas - This procedure involves expose precursors containing gas exchangeable protons tritium in the presence of a suitable catalyst. AND. N-Methylation using Methyl Iodide [3M - This procedure is commonly used to prepare O-methyl products or N-methyl (&lt;3&gt; H) by precursor treatment appropriate with high specific activity methyl iodide (3 H). This method generally allows high activity specific, such as about 80-87 Ci / mmol.

Synthetic methods to incorporate levels of 125 I activity in target molecules include: A. Reactions of Sandmeyer and the like - This procedure transforms an aryl or heteroaryl amine into a diazonium salt, such as a tetrafluoroborate salt and subsequently in a compound 115 I labeled using Na 125 I. It described a procedure represented by Zhu, D. -G. and collaborators in J. Org. Chem. 2002, 67, 943-948. B. Ortho - 125 Iodization of phenols - This procedure allows incorporation of125I in the ortho position of a phenol as described by Collier, TL et al. In J. Labelled Compd Radiopharm. 1999, 42, S264-S266. C. Exchange of aril and heteroaryl bromide with125I - Generally this method is a two stage process. The first step is the conversion of aryl or heteroaryl bromide in the corresponding tri-alkyltin intermediate using, for example, a reaction catalyzed by Pd [ie, Pd (Ph 3 P) 4] or through an aryl or heteroaryl lithium, in the presence of a halide of tri-alkyl tin or hexalkyl tin [for example, (CH 3) 3 SnSn (CH 3) 3]. He described a procedure represented by Bas, M. -D. and collaborators at J. Labelled Compd Radiopharm. 2001, 44, S280-S282.

The prior techniques are intended to be Illustrative and not limiting. They are well known to him specialist other techniques for the radiolabeling of a compound which is known to be a ligand of a G-protein coupled receptor of the invention.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 9

Receptor Binding Assay

A test compound can be evaluated by its ability to reduce complex formation between a compound which is known to be a ligand of a G-protein coupled receptor of the invention and the receiver. In certain embodiments, the ligand known is radiolabelled. The radiolabelled known ligand can be used in a screening test to identify / evaluate compounds. Generally speaking, a compound can be evaluated freshly synthesized or identified (i.e. test compound) for its ability to reduce the binding of the known ligand radiolabeled with the receiver, for its ability to reduce the complex formation between the radiolabelled known ligand and the receiver.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Test Protocol to Detect Complex between a Compound It is Known to be a Ligand of a G-Protein Coupled Receptor of the Invention and the Receiver

A. Receiver Preparation

293 cells were transiently transfected with 10 µg of an expression vector comprising a polynucleotide encoding a G protein coupled receptor of the invention using 60 µl of Lipofectamine (per 15 cm plate). Transiently transfected cells are cultured on the plate for 24 hours (75% confluence) with a change of medium and Remove with 10 ml / Hepes-EDTA buffer plate (Hepes 20 mM + 10 mM EDTA, pH 7.4). Then, the cells are centrifuged in a Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50 rotor). Subsequently, the sediment is resuspended in 20 mM Hepes + 1 mM EDTA, pH 7.4 and homogenized with a 50 ml Dounce homogenizer and centrifuged again. Then of removing the supernatant, the sediments are stored at -80 ° C until used in the binding assay. When used in the test, the membranes are thawed on ice for 20 minutes and then 10 ml of incubation buffer (Hepes 20 mM, 1 mM MgCl 2, 100 mM NaCl, pH 7.4). Then the membranes vortexed to resuspend the membrane sediment crude and homogenized with a Brinkmann homogenizer PT-3100 Polytron for 15 seconds in adjustment 6. The concentration of membrane protein is determined using the Bradford BRL protein assay.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

B. Union test

For total binding, a total volume is added 50 µl of appropriately diluted membranes (diluted in Assay buffer containing 50 mM Tris HCl (pH 7.4), MgCl2 10 mM and 1 mM EDTA; 5-50 µg of protein) to plates 96-well polypropylene microtiter, followed by adding 100 µl of assay buffer and 50 µl of a ligand known radiolabelled. For nonspecific binding, 50 are added µl of assay buffer instead of 100 µl, and 50 are added additional µ of said known 10 µM ligand that is not radiolabeled before 50 µl of said ligand are added known radiolabelled. Then, the plates are incubated at temperature ambient for 60-120 minutes. The reaction of binding is interrupted by filtering the test plates through of a Microplate Devices GF / C Unifilter filtration plate with a Brandell 96-well plate collector followed by washing with Cold 50 mM Tris HCl, pH 7.4 containing 0.9% NaCl. After the bottom of the filtration plate is sealed, 50 µl of Optiphase Supermix to each well, the top of the plates it is sealed and the plates are counted in a Trilux scintillation counter MicroBeta To determine if less complex is formed between said radiolabelled known ligand and said receptor in presence of a test compound, instead of adding 100 µl of assay buffer, 100 µl of said compound is added appropriately diluted assay to the appropriate wells, followed by addition of 50 µl of said radiolabelled known ligand.

A specific ligand binding level known radiolabeled in the presence of the minor test compound that a specific binding level of the radiolabelled known ligand in the absence of the test compound it is indicative that it is forming less amount of the complex between said known ligand radiolabeled and said receptor in the presence of the test compound than in the absence of the test compound.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 10

Expression of GPR119 in intestine

GPR119 mRNA expression in various Tissues were determined using an RNAse Protection Test (RPA).

Mouse tissue RNA was obtained in the market (Clontech). A protected 255 bp fragment of GPR119 was cloned from mouse in the cloning vector pCRII-TOPO (Invitrogen). The sequence of the 255 bp protected fragment was as follows (nucleotides that comprise the GPR119 coding region of mouse are underlined):

<figref>56</figref>

The full length probe size was of 356 bp. The plasmid was linearized with BamHI and gel purified. using the Sephaglass Bandprep Kit (Amersham). After the gel purification of the fragment, a ribosonde was generated by transcription <i>in vitro</i> with the use of T7 RNA polymerase (Ambion Maxiscript Kit). The probe was purified by Acrylamide gel electrophoresis and hybridized with 20 µg of Total RNA at 45 ° C overnight. The hybrids were digested with RNase the next day and were processed on an acrylamide gel at 5% to detect the results (Ambion, Kit RPA III). All the procedures for transcription <i>in vitro</i> and the RPA reactions were following the instructions of the maker.

The highest level of expression of GPR119 is found in pancreatic islets, although it was discovered that GPR119 was also expressed in colon and, to a lesser extent, in intestine thin. See Figure 3.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example eleven

Expression of gpr119 in the enteroendocrine cell line GLUTag

Northern blot analysis was used to determine the level of mRNA expression of GPR119 in GLUTag (subline <i>Fla;</i> see Example 12 below), HIT-T15 (a line of pancreatic beta cells from hamster; ATCC No. CRL-1777) and NCI-H716 (a line of human endocrine cells, ATCC No. CRL-251). GLUTag is a cell line mouse enteroendocrines secreting GLP-1 [Brubaker <i>et al</i>., Endocrinology (1998) 139: 4108-4114].

RNA was extracted from culture cells Tissues using Bee RNA (Tel-Test). They separated ten (10) mug of total RNA in a gel electrophoresis of 0.8% agarose and transferred onto a nylon membrane (Amersham) RNA transfer was hybridized with a cDNA probe of mouse GPR119 labeled with 32 P (see, for example, GPR119 Mouse, GenBank® Accession Number AY288423), followed by a new probing with a cDNA probe labeled with 32 P for mRNA mouse preproglucagon as a control. The hybridization signals are visualized by autoradiography.

It was discovered that GLUTag cells (subline<i>Fla;</i> see Example 12 below) express GPR119 and preproglucagon. See Figure 4.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 12

GPR119 agonist elevates intracellular AMPC in cells GLUTag

GLUTag is a cell line mouse enteroendocrines secreting GLP-1 [Brubaker <i>et al</i>., Endocrinology (1998) 139: 4108-4114]. The effect of an agonist of GPR119 on the level of intracellular cAMP in cells GLUTag enteroendocrines (subline <i>Fla</i>). Subline<i>Fro</i> of GLUTag was used as a negative control. The analysis of Northern transfer (<i>box</i>) using GPR119 cDNA from mouse as probe (see, for example, mouse GPR119, Accession No. of GenBank® AY288423) indicated that the subline <i>Fla</i> from GLUTag expresses GPR119 while the subline <i>Flo</i> from GLUTag no GPR119 expresses detectably.

GluTag cells were seeded (GLUTag-Fla and GLUTag-Fro) at one confluence of sim85% in a tissue culture plate of 15 cm with usual culture medium. The next day, the cells will scraped off with cold scraping buffer (20 mM HEPES, EDTA 10 mM, pH 7.4) and sedimented by centrifugation at 1000 rpm for 17 min at 4 ° C. The cell pellets were washed with Cold Membrane Wash Buffer (20 mM HEPES, 0.1 mM EDTA, pH 7.4) and centrifuged again as before. Sediments membrane resuspended in cold binding buffer (20 mm HEPES, 1 mM MgCl 2, 100 mM NaCl, pH 7.4) and homogenized twice using a Polytron ™ homogenizer (Model No. PT3100; Brinkman) at 7000 rpm for 10 seconds. The protein concentration by a Bradford Assay. He diluted cell membranes to a concentration of 0.2 mg / ml protein in Binding Buffer. (The concentration of final test was 10 µg / well).

The cyclase assay was performed with a kit of Adenilil Cyclase Flash Plate? (New England Nuclear, Cat. No. SMP004A). The wells of the Flash Plate? Contain a scintillation coating that also contains an antibody specific that cAMP recognizes. CAMP generated in the wells can quantified by direct competition for the union of cAMP indicator radioactive to cAMP antibody.

Details of the Cyclase assay as performed. CAMP patterns were prepared and Detection Buffer (comprising 1 µCi of [125I] -AMPc indicator (50 µl) in 11 ml of Buffer of Detection) and were maintained in accordance with the instructions of the maker. Fresh GPR119 agonist AR231453 was prepared and made serial dilutions in 50 µl of Buffer Reconstitution 2x freshly prepared (20 mM Phosphocreatine, Creatine Phosphokinase 20 units / 50 µL, 20 µM GTP, 0.2 mM ATP, IBMX 1 mM). Eight doses of GPR119 agonist were tested, from 10 µM up to 1.27 nM. The test was performed on a 96 Flash Plate wells. GPCR119 agonist and cAMP patterns were added first to the appropriate wells. The cell membranes are then added to the wells and the plate was incubated for 60 minutes at room temperature. Then 100 µl of The Detection Mixture containing &lt;3&gt; H-cAMP indicator to each well. The plates were incubated for two hours additional, after which a count of the samples in a Wallac MicroBeta scintillation counter. Later extrapolated cAMP / well values ​​from a curve cAMP pattern that was contained within each plate of test.

It was discovered that the GPCR119 agonist raises the level of intracellular cAMP in GLUTag-Fla cells that express GPR119, but not in GLUTag-Fro cells that Do not express GPR119. It was discovered that the GPR119 agonist raises the CAMP in GLUTag cells with an EC50 of approximately 4.3 nM. See Figure 5.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 13

The GPR119 agonist stimulates the secretion of GLP-1 in GLUTag cells

GLUTag-Fla cells were seeded (see Example 12, above) in 24-well plates the day one in complete culture medium (DMEM / 10% FBS). Day two on culture medium was replaced with a low glucose medium (DMEM / 3 mM Glucose / 10% FBS). On day three the cells were washed twice with PBS IX. GLUTag-Fla cells Washes were stimulated with GPR119 agonist (AR231453) to various concentrations or with forskolin (1 µM) as a positive control in DMEM without serum with 15 mM glucose for one hour at 37 ° C and CO2 at 5% in a tissue culture incubator. Then they were collected the supernatants and rinsed by centrifugation at 500 g and at 4 ° C for 5 minutes. The GLP-1 released at ELISA supernatant using reagents purchased from LINCO Research Laboratory [Glucagon-like Peptide ELISA Kit 1 (Active). Cat. No. EGLP-3SK].

It was discovered that the cells GLUTag-Fla secrete GLP-1 when stimulate with GPR119 agonist. See Figure 6.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

Example 14

Effect of GPR119 AR244061 agonist and inhibitors of DPP-IV in decreasing blood glucose level in an oral glucose tolerance test (oGTT) in mice

An oral tolerance test to the glucose (oGTT) in C57BL / 6J mice 7-8 weeks of Age as described in this document. To fasting mice overnight (n = 8 mice per treatment group) they were administered by means of oral probe vehicle, an agonist of GPR119 (AR244061, different from that used in Example 1), an inhibitor of DPP-IV (MK-0431, LAF237 or FE107542), or a combination of the GPR119 agonist and the inhibitor of DPP-IV GPR119 agonist AR244061 was administered at 10 mpk or 30 mpk (milligrams of compound per kilogram of weight bodily). Inhibitors were administered DPP-IV MK-0431 and LAF237 at 1 mpk and it administered the FE107542 at 10 mpk. An hour after compound dosage, a bolus of glucose was administered (2 grams / kg) orally and blood samples were collected from the glue to measure blood glucose at 0, 30, 60 and 120 minutes. The results obtained for MK-0431 are shown in Figure 7; The results obtained for LAF237 are shown in the Figure 8; and the results obtained for FE107542 are shown in Figure 9. For each treatment group, it was represented graphically the glycemic oscillation curve and is presented with the blood glucose concentration given in average values +/- typical error of the mean (ETM). The Area was calculated Under the Curve (AUC) of glycemic oscillations and described as AUC (% of vehicle control).

From the inspection of Figure 7, Figure 8 and Figure 9, it is evident that while at concentrations used both the GPR119 agonist (a different GPR119 agonist of the one used in Example 1) as the inhibitor of DPP-IV alone (for each of three different DPP-IV inhibitors) provided a measurable glycemic control, the agonist combination of GPR119 and the DPP-IV inhibitor provided a level of dose-dependent glycemic control above provided by the GPR119 agonist or inhibitor of DPP-IV alone.

Although the above specification shows the principles of the present invention, with examples provided For illustrative purposes, it will be understood that the practice of the invention includes all variations, adaptations or modifications usual, as included in the scope of the following claims.

<pre listing-type="other">\ vskip1.000000 \ baselineskip</pre>

References cited in the description

<i>This list of references cited by the Applicant is solely for the convenience of the reader. That list does not It is part of the European patent document. Although it has been great care in the collection of references, you can not exclude errors or omissions and the EPO rejects all responsibility to this respect</i>.

Patent documents cited in the description

<dl><dt>WO 04065380 A [0008] [0158]</dt><dd>US 2005059724 A [0225]</dd></dl>

<dl><dt>WO 04076413 A [0008] [0161]</dt><dd>US 2005059716 A [0225]</dd></dl>

<dl><dt>EP 1338651 A [0008] [0212]</dt><dd>US 2005043292 A [0225]</dd></dl>

<dl><dt>WO 0031258 A [0008]</dt><dd>US 2005038020 A [0225]</dd></dl>

<dl><dt>US 2004001267 W [0158] [0160]</dt><dd>US 2005032804 A [0225]</dd></dl>

<dl><dt>US 2004001267 A [0158]</dt><dd>US 2005004205 A [0225]</dd></dl>

<dl><dt>US 2004005555 W [0161] [0163] [0164] [0165]</dt><dd>? US 2004259903 A [0225]</dd></dl>

<dl><dt>{} \ hskip0,2cm [0166] [0167]</dt><dd>US 2004259902 A [0225]</dd></dl>

<dl><dt>US 2004005555 A [0161]</dt><dd>US 2004259883 A [0225]</dd></dl>

<dl><dt>US 2004022327 W [0168] [0170] [0171] [0172]</dt><dd>? US 2004254226 A [0225]</dd></dl>

<dl><dt>{} \ hskip0,2cm [0173] [0174] [0175] [0176] [0177] [0178] [0179]</dt><dd>US 2004242898 A [0225]</dd></dl>

<dl><dt>WO 05007647 A [0168] </dt><dd>US 2004229926 A [0225]</dd></dl>

<dl><dt>US 2004022327 A [0168]</dt><dd>US 2004180925 A [0225]</dd></dl>

<dl><dt>US 2004022417 W [0180] [0182] [0183] [0184]</dt><dd>? US 2004176406 A [0225]</dd></dl>

<dl><dt>{} \ hskip0,2cm [0185] [0186] [0187] [0188] [0189] [0190] [0191]</dt><dd>US 2004138214 A [0225]</dd></dl>

<dl><dt>{} \ hskip0,2cm [0192] [0193] [0194]</dt><dd>US 2004116328 A [0225]</dd></dl>

<dl><dt>WO 05007658 A [0180] </dt><dd>US 2004110817 A [0225]</dd></dl>

<dl><dt>US 2004022417 A [0180]</dt><dd>US 2004106656 A [0225]</dd></dl>

<dl><dt>US 20041022417 A [0195]</dt><dd>US 2004097510 A [0225]</dd></dl>

<dl><dt>US 577354 P [0196] [0196] [0198] [0199] </dt><dd>US 2004087587 A [0225]</dd></dl>

<dl><dt>GB 2004050046 A [0200] [0200] [0202] </dt><dd>US 2004082570 A [0225]</dd></dl>

<dl><dt>WO 2005061489 A [0200]</dt><dd>US 2004077645 A [0225]</dd></dl>

<dl><dt>WO 0302666 A [0213]</dt><dd>US 2004072892 A [0225]</dd></dl>

<dl><dt>WO 03026661 A [0213]</dt><dd>US 2004063935 A [0225]</dd></dl>

<dl><dt>JP 2004269468 B [0214] [0214]</dt><dd>US 2004034014 A [0225]</dd></dl>

<dl><dt>JP 2004269469 B [0215] [0215]</dt><dd>US 2003232788 A [0225]</dd></dl>

<dl><dt>US 6303661 B [0224] [0225] [0228]</dt><dd>US 2003225102 A [0225]</dd></dl>

<dl><dt>US 6869947 B [0225]</dt><dd>US 2003216450 A [0225]</dd></dl>

<dl><dt>US 6867205 B [0225]</dt><dd>US 2003216382 A [0225]</dd></dl>

<dl><dt>US 6861440 B [0225]</dt><dd>US 2003199528 A [0225]</dd></dl>

<dl><dt>US 6849622 B [0225]</dt><dd>US 2003195188 A [0225]</dd></dl>

<dl><dt>US 6812350 B [0225]</dt><dd>US 2003162820 A [0225]</dd></dl>

<dl><dt>US 6803357 B [0225]</dt><dd>US 2003149071 A [0225]</dd></dl>

<dl><dt>US 6800650 B [0225]</dt><dd>US 2003134802 A [0225]</dd></dl>

<dl><dt>US 6727261 B [0225]</dt><dd>US 2003130281 A [0225]</dd></dl>

<dl><dt>US 6716843 B [0225]</dt><dd>US 2003130199 A [0225]</dd></dl>

<dl><dt>US 6710040 B [0225]</dt><dd>US 2003125304 A [0225]</dd></dl>

<dl><dt>US 6706742 B [0225]</dt><dd>US 2003119750 A [0225]</dd></dl>

<dl><dt>US 6645995 B [0225]</dt><dd>US 2003119738 A [0225]</dd></dl>

<dl><dt>US 6617340 B [0225]</dt><dd>US 2003105077 A [0225]</dd></dl>

<dl><dt>US 6699871 B [0225] [0231]</dt><dd>US 2003100563 A [0225] [0231]</dd></dl>

<dl><dt>US 6573287 B [0225]</dt><dd>US 2003087950 A [0225]</dd></dl>

<dl><dt>US 6432969 B [0225]</dt><dd>US 2003078247 A [0225]</dd></dl>

<dl><dt>US 6395767 B [0225]</dt><dd>US 2002198205 A [0225]</dd></dl>

<dl><dt>US 6380398 B [0225]</dt><dd>US 2002183367 A [0225]</dd></dl>

<dl><dt>US 6242422 B [0225]</dt><dd>US 2002103384 A [0225]</dd></dl>

<dl><dt>US 6166063 A [0225] [0232]</dt><dd>US 2002049164 A [0225]</dd></dl>

<dl><dt>US 6100234 A [0225]</dt><dd>US 2002006899 A [0225]</dd></dl>

<dl><dt>US 6040145 A [0225]</dt><dd>WO 2005087235 A [0226]</dd></dl>

<dl><dt>WO 2005082348 A [0226]</dt><dd>WO 0450022 A [0226]</dd></dl>

<dl><dt>WO 2005082849 A [0226]</dt><dd>WO 0450658 A [0226]</dd></dl>

<dl><dt>WO 2005079795 A [0226]</dt><dd>WO 0448379 A [0226]</dd></dl>

<dl><dt>WO 2005075426 A [0226]</dt><dd>WO 0446106 A [0226]</dd></dl>

<dl><dt>WO 2005072530 A [0226]</dt><dd>WO 0443940 A [0226]</dd></dl>

<dl><dt>WO 2005063750 A [0226]</dt><dd>WO 0441820 A [0226]</dd></dl>

<dl><dt>WO 2005058849 A [0226]</dt><dd>WO 0441795 A [0226]</dd></dl>

<dl><dt>WO 2005049022 A [0226]</dt><dd>WO 0437169 A [0226]</dd></dl>

<dl><dt>WO 2005047297 A [0226]</dt><dd>WO 0437181 A [0226]</dd></dl>

<dl><dt>WO 2005044195 A [0226]</dt><dd>WO 0433455 A [0226]</dd></dl>

<dl><dt>WO 2005042488 A [0226]</dt><dd>WO 0432836 A [0226]</dd></dl>

<dl><dt>WO 2005040095 A [0226]</dt><dd>WO 0420407 A [0226]</dd></dl>

<dl><dt>WO 2005037828 A [0226]</dt><dd>WO 0418469 A [0226]</dd></dl>

<dl><dt>WO 2005037779 A [0226]</dt><dd>WO 0418468 A [0226]</dd></dl>

<dl><dt>WO 2005034940 A [0226]</dt><dd>WO 0418467 A [0226]</dd></dl>

<dl><dt>WO 2005033099 A [0226]</dt><dd>WO 0414860 A [0226]</dd></dl>

<dl><dt>WO 2005032590 A [0226]</dt><dd>WO 0409544 A [0226]</dd></dl>

<dl><dt>WO 2005030751 A [0226]</dt><dd>WO 0407468 A [0226]</dd></dl>

<dl><dt>WO 2005030127 A [0226]</dt><dd>WO 0407446 A [0226]</dd></dl>

<dl><dt>WO 2005026148 A [0226]</dt><dd>WO 0404661 A [0226]</dd></dl>

<dl><dt>WO 2005025554 A [0226]</dt><dd>WO 0400327 A [0226]</dd></dl>

<dl><dt>WO 2005023762 A [0226]</dt><dd>WO 03106456 A [0226]</dd></dl>

<dl><dt>WO 2005020920 A [0226]</dt><dd>WO 03104229 A [0226]</dd></dl>

<dl><dt>WO 0519168 A [0226]</dt><dd>WO 03101958 A [0226]</dd></dl>

<dl><dt>WO 0512312 A [0226]</dt><dd>WO 03101448 A [0226]</dd></dl>

<dl><dt>WO 0512308 A [0226]</dt><dd>WO 0399279 A [0226]</dd></dl>

<dl><dt>WO 0512249 A [0226]</dt><dd>WO 0395425 A [0226]</dd></dl>

<dl><dt>WO 0511581 A [0226]</dt><dd>WO 0384940 A [0226]</dd></dl>

<dl><dt>WO 0509956 A [0226]</dt><dd>WO 0382817 A [0226]</dd></dl>

<dl><dt>WO 0503135 A [0226]</dt><dd>WO 0380633 A [0226]</dd></dl>

<dl><dt>WO 0500848 A [0226]</dt><dd>WO 0374500 A [0226]</dd></dl>

<dl><dt>WO 0500846 A [0226]</dt><dd>WO 0372556 A [0226]</dd></dl>

<dl><dt>WO 04112701 A [0226]</dt><dd>WO 0372528 A [0226]</dd></dl>

<dl><dt>WO 04111051 A [0226]</dt><dd>WO 0368757 A [0226]</dd></dl>

<dl><dt>WO 04111041 A [0226]</dt><dd>WO 0368748 A [0226]</dd></dl>

<dl><dt>WO 04110436 A [0226]</dt><dd>WO 0357666 A [0226]</dd></dl>

<dl><dt>WO 04110375 A [0226]</dt><dd>WO 0357144 A [0226]</dd></dl>

<dl><dt>WO 04108730 A [0226]</dt><dd>WO 0355881 A [0226]</dd></dl>

<dl><dt>WO 04104216 A [0226]</dt><dd>WO 0345228 A [0226]</dd></dl>

<dl><dt>WO 04104215 A [0226]</dt><dd>WO 0340174 A [0226]</dd></dl>

<dl><dt>WO 04103993 A [0226]</dt><dd>WO 0338123 A [0226]</dd></dl>

<dl><dt>WO 04103276 A [0226]</dt><dd>WO 0337327 A [0226]</dd></dl>

<dl><dt>WO 0499134 A [0226]</dt><dd>WO 0335067 A [0226]</dd></dl>

<dl><dt>WO 0496806 A [0226]</dt><dd>WO 0335057 A [0226]</dd></dl>

<dl><dt>WO 0492128 A [0226]</dt><dd>WO 0324965 A [0226]</dd></dl>

<dl><dt>WO 0487650 A [0226]</dt><dd>WO 0324942 A [0226]</dd></dl>

<dl><dt>WO 0487053 A [0226]</dt><dd>WO 0322871 A [0226]</dd></dl>

<dl><dt>WO 0485661 A [0226]</dt><dd>WO 0315775 A [0226]</dd></dl>

<dl><dt>WO 0485378 A [0226]</dt><dd>WO 0304498 A [0226] [0231]</dd></dl>

<dl><dt>WO 0476434 A [0226]</dt><dd>WO 0304496 A [0226]</dd></dl>

<dl><dt>WO 0476433 A [0226]</dt><dd>WO 0302530 A [0226]</dd></dl>

<dl><dt>WO 0471454 A [0226]</dt><dd>WO 0302596 A [0226]</dd></dl>

<dl><dt>WO 0469162 A [0226]</dt><dd>WO 0302595 A [0226]</dd></dl>

<dl><dt>WO 0467509 A [0226]</dt><dd>WO 0302593 A [0226]</dd></dl>

<dl><dt>WO 0464778 A [0226]</dt><dd>WO 0302553 A [0226]</dd></dl>

<dl><dt>WO 0458266 A [0226]</dt><dd>WO 0302531 A [0226]</dd></dl>

<dl><dt>WO 0452362 A [0226]</dt><dd>WO 0300181 A [0226]</dd></dl>

<dl><dt>WO 0452850 A [0226]</dt><dd>WO 0300180 A [0226]</dd></dl>

&lt;110&gt; Arena Pharmaceuticals, Inc.

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;120&gt; Terapia de combinación para el tratamiento de la diabetes y afecciones relacionadas con la misma y para el tratamiento de afecciones que se mejoran por aumento del nivel de GLP-1 en sangre

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;130&gt; WJW/FP6442545

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;140&gt; EP

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;141&gt; 09-01-2006

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; EP 06717678.4

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 09-01-2006

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; PCT/US2006/000510

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 09-01-2006

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; US 60/643.086

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 10-01-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; US 60/683.172

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 19-05-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; US 60/726.880

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 14-10-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;160&gt; 5

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;170&gt; PatentIn versión 3.2

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 1

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 1008

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; <i>Homo sapien</i>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 1

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>57</figref>

<pre listing-type="other">\hskip0,8cm</pre><figref>570</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 2

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 335

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; PRT

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; <i>Homo sapien</i>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 2

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>58</figref>

<pre listing-type="other">\hskip0,8cm</pre><figref>59</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 3

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 22

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Cebador

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 3

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

<pre listing-type="other">\hskip-.1em\dddseqskip</pre>gtcctgccac ttcgagacat gg <pre listing-type="other">\hfill</pre> 22

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 4

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 23

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Cebador

<pre listing-type="other">\newpage</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 4

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

<pre listing-type="other">\hskip-.1em\dddseqskip</pre>gaaacttctc tgcccttacc gtc <pre listing-type="other">\hfill</pre> 23

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 5

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 255

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Sonda

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 5

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>60</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

LISTADO DE SECUENCIAS

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;110&gt; Arena Pharmaceuticals, Inc.

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;120&gt; Terapia de combinación para el tratamiento de la diabetes y afecciones relacionadas con la misma y para el tratamiento de afecciones que se mejoran por aumento del nivel de GLP-1 en sangre

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;130&gt; WJW/FP6442545

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;140&gt; EP

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;141&gt; 09-01-2006

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; EP 06717678.4

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 09-01-2006

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; PCT/US2006/000510

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 09-01-2006

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; US 60/643.086

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 10-01-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; US 60/683.172

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 19-05-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; US 60/726.880

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 14-10-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;160&gt; 5

<pre listing-type="other">\newpage</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;170&gt; PatentIn versión 3.2

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 1

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 1008

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; <i>Homo sapien</i>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 1

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>61</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 2

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 335

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; PRT

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; <i>Homo sapien</i>

<pre listing-type="other">\newpage</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 2

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>62</figref>

<pre listing-type="other">\hskip0,8cm</pre><figref>63</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 3

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 22

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Cebador

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 3

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

<pre listing-type="other">\hskip-.1em\dddseqskip</pre>gtcctgccac ttcgagacat gg <pre listing-type="other">\hfill</pre> 22

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 4

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 23

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Cebador

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 4

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

<pre listing-type="other">\hskip-.1em\dddseqskip</pre>gaaacttctc tgcccttacc gtc <pre listing-type="other">\hfill</pre> 23

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 5

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 255

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Sonda

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 5

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>64</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

LISTADO DE SECUENCIAS

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;110&gt; Arena Pharmaceuticals, Inc.

<pre listing-type="other">\hskip1cm</pre> Chu, zhi-Liang

<pre listing-type="other">\hskip1cm</pre> Leornard, James

<pre listing-type="other">\hskip1cm</pre> Al-Shamma, Hussien

<pre listing-type="other">\hskip1cm</pre> Jones, Robert M.

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;120&gt; TERAPIA DE COMBINACIÓN PARA EL TRATAMIENTO DE LA DIABETES Y AFECCIONES RELACIONADAS CON LA MISMA Y PARA EL TRATAMIENTO DE AFECCIONES QUE SE MEJORAN POR AUMENTO DEL NIVEL DE GLP-1 EN SANGRE

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;130&gt; 107.WO1

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; 60/643.086

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 10-01-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; 60/683.172

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 19-05-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;150&gt; 60/726.880

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;151&gt; 14-10-2005

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;160&gt; 5

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;170&gt; PatentIn versión 3.2

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 1

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 1008

<pre listing-type="other">\newpage</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; <i>Homo sapien</i>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 1

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>65</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 2

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 335

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; PRT

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; <i>Homo sapien</i>

<pre listing-type="other">\newpage</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 2

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>66</figref>

<pre listing-type="other">\hskip0,8cm</pre><figref>67</figref>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 3

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 22

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Cebador

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 3

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

<pre listing-type="other">\hskip-.1em\dddseqskip</pre>gtcctgccac ttcgagacat gg <pre listing-type="other">\hfill</pre> 22

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 4

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 23

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Cebador

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 4

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

<pre listing-type="other">\hskip-.1em\dddseqskip</pre>gaaacttctc tgcccttacc gtc <pre listing-type="other">\hfill</pre> 23

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;210&gt; 5

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;211&gt; 255

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;212&gt; ADN

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;213&gt; Artificial

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;220&gt;

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;223&gt; Sonda

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip0.400000\baselineskip</pre>

&lt;400&gt; 5

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\vskip1.000000\baselineskip</pre>

<pre listing-type="other">\hskip0,8cm</pre><figref>68</figref>